tranexamic acid has been researched along with Hemorrhage in 470 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Hemorrhage: Bleeding or escape of blood from a vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 9.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| "Screening for the risk of thromboembolism (TE) due to tranexamic acid (TXA) in patients with severe traumatic injury has not been performed in randomized clinical trials." | 9.51 | The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial ( Bochicchio, G; Bochicchio, K; Cap, AP; Levy, JH; Pusateri, AE; Schuerer, D; Shea, SM; Spinella, PC; Staudt, A; Thomas, KA, 2022) |
| "Because no medication has been approved for coagulation support in trauma, the current study was aimed to evaluate the effectiveness of intravenous injection of Tranexamic acid (TXA) in patients with acute traumatic bleeding." | 9.41 | The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial. ( Alimohamadi, Y; Khaleghian, M; Negahi, A; Teimoury, T; Vaziri, M, 2021) |
| "There is moderate-certainty evidence to support the beneficial value of topical or intravenous tranexamic acid during endoscopic sinus surgery with respect to surgical field bleeding score." | 9.41 | Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery. ( Avdeeva, K; Fokkens, W; Gan, KL; Lourijsen, E; Pundir, V, 2023) |
| "To explore clinical effects of tranexamic acid on postoperative intra-articular hemorrhage after shoulder arthroscopy." | 9.34 | [Clinical study on the control of intra-articular hemorrhage by tranexamic acid after shoulder arthroscopy]. ( Gao, HL; He, Y; Shi, Q; Xiao, LB; Zhai, WT; Zhang, JC, 2020) |
| "This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders." | 9.30 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019) |
| "The CRASH-2 trial showed that tranexamic acid (TXA) administration reduces mortality in bleeding trauma patients." | 9.24 | Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms. ( Edwards, P; Joshi, M; Ker, K; Mahmood, A; Prieto, D; Roberts, I; Shakur, H, 2017) |
| "To investigate the mechanism of action of tranexamic acid (TXA) in bleeding trauma patients, we examined the timing of its effect on mortality." | 9.19 | Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. ( Manno, D; Prieto-Merino, D; Roberts, I, 2014) |
| " The CRASH-2 trial aimed to determine the effect of the early administration of tranexamic acid on death and transfusion requirement in bleeding trauma patients." | 9.17 | The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. ( Balogun, E; Barnetson, L; Cairns, J; Coats, T; Cook, L; Guerriero, C; Hunt, B; Kawahara, T; Perel, P; Prieto-Merino, D; Ramos, M; Roberts, I; Shakur, H, 2013) |
| "To examine whether the effect of tranexamic acid on the risk of death and thrombotic events in patients with traumatic bleeding varies according to baseline risk of death." | 9.16 | Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. ( Brohi, K; Coats, T; Hunt, BJ; Lecky, F; Perel, P; Prieto-Merino, D; Roberts, I; Shakur, H; Willett, K, 2012) |
| " 20,211 adult trauma patients with, or at risk of, significant bleeding were randomly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h) or placebo." | 9.15 | The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. ( Afolabi, A; Brohi, K; Coats, T; Dewan, Y; Gando, S; Guyatt, G; Hunt, BJ; Morales, C; Perel, P; Prieto-Merino, D; Roberts, I; Shakur, H; Woolley, T, 2011) |
| "To assess the cost effectiveness of giving tranexamic acid (TXA) to bleeding trauma patients in low, middle and high income settings." | 9.15 | Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. ( Cairns, J; Guerriero, C; Perel, P; Roberts, I; Shakur, H, 2011) |
| "Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth." | 9.12 | Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. ( Murao, S; Nakata, H; Roberts, I; Yamakawa, K, 2021) |
| "The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis." | 9.12 | [Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?] ( Möhnle, P; Pekrul, I; Schachtner, T; Zwißler, B, 2021) |
| "In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study." | 9.08 | A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. ( Ben-Bassat, I; Blumenthal, R; Chetrit, A; Eldor, A; Katz, Y; Ramot, B; Shpilberg, O; Sofer, O, 1995) |
| "A controlled, randomized, double-blind study was performed to assess the effect of the oral antifibrinolytic agent tranexamic acid in patients with amegakaryocytic thrombocytopenia as regards their need for platelet transfusions and the number of bleeding episodes experienced." | 9.07 | Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. ( Alling, D; Fricke, W; Griffith, P; Kimball, J; Klein, H, 1991) |
| "Early administration of the antifibrinolytic drug tranexamic acid reduces death from bleeding in trauma and postpartum haemorrhage." | 9.05 | Effect of tranexamic acid by baseline risk of death in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients. ( Ageron, FX; Coats, TJ; Gayet-Ageron, A; Ker, K; Roberts, I; Shakur-Still, H, 2020) |
| "The publication of the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2 (CRASH-2) study and its intense dissemination prompted a renaissance for the use of the antifibrinolytic agent tranexamic acid (TXA) in acute trauma hemorrhage." | 9.01 | Tranexamic Acid for Acute Hemorrhage: A Narrative Review of Landmark Studies and a Critical Reappraisal of Its Use Over the Last Decade. ( Lier, H; Maegele, M; Shander, A, 2019) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 8.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| "There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding." | 8.91 | The current place of tranexamic acid in the management of bleeding. ( Hunt, BJ, 2015) |
| "Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and an increased risk remains a theoretical concern." | 8.89 | Topical application of tranexamic acid for the reduction of bleeding. ( Beecher, D; Ker, K; Roberts, I, 2013) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders." | 8.89 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013) |
| "Tranexamic acid, an antifibrinolytic agent, reduces postoperative transfusion requirements but carries a poorly documented risk of thrombosis." | 8.89 | Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality. ( , 2013) |
| "The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage." | 8.87 | Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011) |
| "To review the real-world management of rivaroxaban-associated major bleeding across the public hospitals of New Zealand's largest city." | 8.31 | Real-world decision-making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience. ( Eaddy, N; Grainger, BT; Merriman, E; Ockelford, P; Royle, G; Young, L, 2023) |
| " The seminal CRASH-2 trial demonstrated a reduction in overall mortality following early tranexamic acid (TXA) administration to bleeding trauma patients." | 8.31 | Estimated Cost-Effectiveness of Implementing a Statewide Tranexamic Acid Protocol for the Management of Suspected Hemorrhage in the Prehospital Setting. ( Houston, S; Hubble, MW; Renkiewicz, GK; Schiro, S; Van Vleet, L, 2023) |
| "The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders." | 8.31 | Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023) |
| "We conducted a secondary analysis of the MAssive Transfusion in Children (MATIC), a prospectively collected database of children with life-threatening hemorrhage (LTH), and evaluated for risk of adverse events with either antifibrinolytic treatment, epsilon aminocaproic acid (EACA) or tranexamic acid (TXA)." | 8.31 | Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. ( Josephson, CD; Kolodziej, JH; Leeper, CM; Leonard, JC; Spinella, PC; Zenati, MS, 2023) |
| "To evaluate the association of treatment with nebulized tranexamic acid (TXA) with rates of operative intervention in post-tonsillectomy hemorrhage (PTH)." | 8.31 | Treatment of post-tonsillectomy hemorrhage with nebulized tranexamic acid: A retrospective study. ( Elghouche, AN; Hasnain, F; Matt, BH; Shay, EO; Shin, TJ; Ye, MJ, 2023) |
| "This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO)." | 8.31 | Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation. ( Jakowenko, ND; Kalvelage, EL; Macielak, RJ; Nabzdyk, CGS; Nei, SD; Seelhammer, TG; Wieruszewski, PM, 2023) |
| " We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA)." | 8.12 | Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report. ( Angelidis, IK; Budd, AN; Malsin, ES; Patel, S; Pawale, A; Smith, S, 2022) |
| "Intravenous tranexamic acid (TXA) reduces bleeding deaths after injury and childbirth." | 8.02 | Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial. ( Davenport, R; Frimley, L; Gilliam, C; Grassin-Delyle, S; Jarman, H; Lamy, E; McGuinness, W; Moss, P; Picetti, R; Pott, J; Prowse, D; Pynn, H; Roberts, I; Shakur-Still, H; Tai, N; Thayne, A; Urien, S, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic used for prophylaxis and treatment of acute bleeding." | 8.02 | Impact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding. ( Farina, N; Franz, ND; Machado-Aranda, D; Miller, JT, 2021) |
| "Evaluate nebulized tranexamic acid (TXA) as a treatment to reduce the need for an operation to control a post-tonsillectomy hemorrhage (PTH)." | 8.02 | Post-tonsillectomy hemorrhage control with nebulized tranexamic acid: A retrospective cohort study. ( Earley, MA; Erwin, DZ; Goldstein, NA; Heichel, PD; McEvoy, TP; Meyer, AD; Wright, LM, 2021) |
| "Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products." | 7.96 | Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ( Beyer, CA; Caples, CM; DeSoucy, ES; Grayson, JK; Hoareau, GL; Johnson, MA; Kashtan, HW; Spruce, MW, 2020) |
| "Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding." | 7.96 | Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020) |
| "Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 7.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
| " Tranexamic Acid (TXA) is used as an anti-fibrinolytic agent to reduce surgical bleeding if administered prior to or during surgery, and to improve survival in trauma if given early after trauma." | 7.91 | Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage. ( Benov, A; Cap, AP; Darlington, DN; Keesee, JD; Liu, B; Wu, X, 2019) |
| "Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death." | 7.91 | Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. ( Brown, JB; Kutcher, ME; Myers, SP; Neal, MD; Peitzman, AB; Rosengart, MR; Sperry, JL, 2019) |
| "To describe the use of tranexamic acid (TXA) in trauma care in England and Wales since the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage (CRASH-2) trial results were published in 2010." | 7.91 | Implementation of tranexamic acid for bleeding trauma patients: a longitudinal and cross-sectional study. ( Coats, TJ; Fragoso-Iñiguez, M; Roberts, I, 2019) |
| " The aim of this study is to determine the effect of tranexamic acid, an antifibrinolytic agent, on the anticoagulant activity and bleeding by edoxaban in rats." | 7.88 | Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban. ( Furugohri, T; Honda, Y; Morishima, Y, 2018) |
| "The current study aimed to evaluate the efficacy of three nonspecific haemostatic drugs - recombinant activated factor VII (rFVIIa), tranexamic acid and desmopressin (DDAVP) - to limit blood loss after administration of prasugrel in a rabbit model of bleeding while also evaluating any prothrombotic effects." | 7.88 | Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model. ( Bonhomme, F; Fontana, P; Godier, A; Lecompte, T; Samama, CM, 2018) |
| "We describe the case of a bleeding trauma patient who received tranexamic acid (TXA) during air transport who subsequently developed multiple intra-cardiac thrombi." | 7.88 | Left atrial thrombi following tranexamic acid in a bleeding trauma patient-A word of caution. ( Carroll, ND; Eastridge, BJ; Restrepo, CS; Stasik, CN, 2018) |
| "The California Prehospital Antifibrinolytic Therapy (Cal-PAT) study seeks to assess the safety and impact on patient mortality of tranexamic acid (TXA) administration in cases of trauma-induced hemorrhagic shock." | 7.85 | Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study. ( Benson, P; Borger, R; Culhane, JT; Dong, F; Jabourian, A; Jabourian, N; Kissel, S; Kwong, E; Ludi, D; Mistry, J; Neeki, MM; O'Bosky, KR; Pennington, TW; Pitts, R; Powell, J; Schulz-Costello, K; Seiler, K; Sporer, K; Surrusco, MS; Toy, J; Vaezazizi, R; Van Stralen, D; Vara, R; Wong, D; Yoshida-McMath, C, 2017) |
| " Several reports show a successful therapeutic use of the antifibrinolytic agent tranexamic acid in palliative care patients having hemorrhages." | 7.85 | Bleeding Control in Palliative Care Patients With the Help of Tranexamic Acid. ( Bardenheuer, HJ; Frankenhauser, S; Geist, MJP; Kessler, J, 2017) |
| " We loaded these microparticles with thrombin and tranexamic acid and tested their efficacy in a swine arterial bleeding model without wound compression." | 7.83 | Self-Propelled Dressings Containing Thrombin and Tranexamic Acid Improve Short-Term Survival in a Swine Model of Lethal Junctional Hemorrhage. ( Baylis, JR; Chien, D; Kastrup, CJ; Liggins, RT; Lim, EB; Simonson, E; St John, AE; Statz, ML; Stern, SA; Wang, X; White, NJ, 2016) |
| "To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 7.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
| " Our purposes were to study the efficacy of tranexamic acid (TXA) and prothrombin complex concentrate (PCC) on a traumatic coagulopathy with a severe native metabolic acidosis and compare the efficacy of PCC versus fresh frozen plasma (FFP) to reverse a dilutional coagulopathy." | 7.79 | The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis. ( Eckert, M; Izenberg, S; Martin, MJ; McVay, D; Nelson, D; Porta, CR; Salgar, S, 2013) |
| "We examined the effect of local administration of tranexamic acid( TA) on reducing aspirin-induced bleeding in off-pump coronary artery bypass grafting(CABG)." | 7.79 | [Can local administration of tranexamic acid reduce aspirin-induced bleeding in off-pump coronary artery bypass grafting( CABG) ?]. ( Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y, 2013) |
| "A case is presented in which topical tranexamic acid was used to stop local bleeding from a nipple following piercing in a young man with haemophilia." | 7.79 | Case report: use of topical tranexamic acid to stop localised bleeding. ( Chitnis, J; Noble, S, 2013) |
| "The early administration of tranexamic acid (TXA) to bleeding trauma patients reduces all-cause mortality without increasing the risk of vascular occlusive events." | 7.78 | Tranexamic acid: less bleeding and less thrombosis? ( Godier, A; Hunt, BJ; Roberts, I, 2012) |
| " In the present case study, a new technique, using intratumoral injection of tranexamic acid to control significant bleeding during bronchoscopic biopsy, is described." | 7.77 | Bronchoscopic intratumoral injection of tranexamic acid: a new technique for control of biopsy-induced bleeding. ( Zamani, A, 2011) |
| "Tranexamic acid had no effect on the number of rebleeding events, bled volume, or mortality." | 7.73 | Tranexamic acid does not prevent rebleeding in an uncontrolled hemorrhage porcine model. ( Drobin, D; Hahn, RG; Hedin, A; Heinius, G; Piros, D; Sjostrand, F, 2005) |
| "Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders." | 7.71 | Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. ( Cordingley, FT; Leahy, MF; Taparia, M, 2002) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 7.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "Complete inhibition of vitreous fibrinolytic activity with 4-amino-methylcyclohexane carbonic acid was associated with significantly delayed resolution of vitreous hemorrhages in rabbits." | 7.65 | The effect of fibrinolytic inhibition in the resolution of experimental vitreous hemorrhage. ( Edgar, W; Forbes, CD; Forrester, JV; Prentice, CR; Williamson, J, 1977) |
| "Tranexamic acid (TXA) is a well-studied, widely used intravenous hemostatic; however, the potential benefit during resection of ACTH-secreting pituitary adenoma is unstudied." | 7.01 | Perioperative Tranexamic Acid for ACTH-Secreting Pituitary Adenomas: Implementation Protocol Results and Trial Prospectus. ( Carlstrom, LP; Choby, G; Cohen, SC; Graffeo, CS; Perry, A; Van Gompel, JJ, 2021) |
| "In trauma patients with severe injury, 4 g intravenous bolus dosing of TXA has minimal immunomodulatory effects with respect to leukocyte phenotypes and circulating cytokine levels." | 6.94 | The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. ( Baty, J; Bochicchio, GV; Bochicchio, K; Cap, AP; Coleoglou Centeno, AA; Fuchs, A; Horn, CB; Levy, JH; Meledeo, MA; Pusateri, AE; Reese, S; Schuerer, D; Shea, SM; Spinella, PC; Thomas, KA; Turnbull, IR, 2020) |
| "Bleeding is the leading cause of maternal mortality in the world." | 6.82 | Tranexamic acid for prevention of bleeding in cesarean delivery: An overview of systematic reviews. ( Boet, S; Burns, JK; Deng, MX; Edwards, W; Etherington, C; Hurskainen, T; Martin Calderon, L; Moher, D, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that was shown to increase survival in trauma patients, but the mechanisms remain unclear." | 6.82 | Double-blinded, placebo-controlled study of early tranexamic acid treatment in swine uncontrolled hemorrhage model. ( Aden, JK; Cap, AP; de Guzman, R; Dubick, MA; Hanson, MA; Polykratis, IA; Prince, MD; Sondeen, JL, 2016) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 6.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "The trial included 20,127 trauma patients with, or at risk of, significant bleeding, within 8 hours of injury." | 6.78 | Development and validation of a prognostic model to predict death in patients with traumatic bleeding, and evaluation of the effect of tranexamic acid on mortality according to baseline risk: a secondary analysis of a randomised controlled trial. ( Perel, P; Prieto-Merino, D; Roberts, I; Shakur, H, 2013) |
| " (3) The appropriate, empirically established, dosage and administration patterns of TEA for CDH repair during ECMO seem to be one bolus of 4 mg/kg TEA intravenously 30 minutes before the anticipated CDH repair and a continuous infusion of 1 mg/kg/h TEA during the 24 hours after CDH repair." | 6.68 | Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. ( de Haan, AF; Festen, C; Geven, WB; van der Staak, FH, 1997) |
| "Hemorrhage is responsible for 91% of preventable prehospital deaths in combat." | 5.91 | Ruggedized Self-Propelling Hemostatic Gauze Delivers Low Dose of Thrombin and Systemic Tranexamic Acid and Achieves High Survival in Swine With Junctional Hemorrhage. ( Ali-Mohamad, N; Baylis, JR; Beckett, A; Cau, MF; Kastrup, CJ; Khavari, A; Naveed, A; Peng, H; Peng, N; Ringgold, K; Semple, H; Sherwood, C; Tenn, C; Wang, X; White, NJ; Zhang Gao, H; Zhang, Y, 2023) |
| "These interim data suggest that recombinant VWF is not superior to tranexamic acid in reducing heavy menstrual bleeding in patients with mild or moderate von Willebrand disease." | 5.69 | Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial. ( Althouse, AD; Angelini, D; Bellissimo, D; Feldman, R; Humphreys, G; Hwang, N; Ivanco, D; Koerbel, G; Kraut, E; Kulkarni, R; Lasky, J; Leavitt, AD; Machin, N; Malec, L; Merricks, EP; Meyer, M; Nance, D; Nichols, TC; Philipp, C; Pruthi, R; Ragni, MV; Rothenberger, SD; Seaman, C; Sidonio, R; Smith, KJ; Vehec, D; Wheeler, AP; Xavier, F, 2023) |
| "Abnormal bleeding is sometimes observed in patients with immunoglobulin light chain (AL) amyloidosis." | 5.56 | Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid. ( Arahata, M; Asakura, H; Ichinose, A; Kadohira, Y; Morishita, E; Takamatsu, H; Yamada, S, 2020) |
| " Tranexamic acid (TXA) is a lysine analogue frequently used in the setting of significant trauma with hemorrhage." | 5.51 | Effect of age on the efficacy of tranexamic acid: An analysis of heterogeneity of treatment effect within the CRASH-2 dataset. ( Manoukian, MAC; Nishijima, DK; Tancredi, DJ, 2022) |
| "Among patients undergoing noncardiac surgery, the incidence of the composite bleeding outcome was significantly lower with tranexamic acid than with placebo." | 5.51 | Tranexamic Acid in Patients Undergoing Noncardiac Surgery. ( Aguado, HJ; Alfonsi, P; Amir, M; Astrakov, SV; Balasubramanian, K; Bangdiwala, SI; Belley-Côté, EP; Bhatt, K; Borges, FK; Cafaro, T; Chan, MTV; Conen, D; Copland, I; de Nadal, M; Devereaux, PJ; Duceppe, E; Efremov, S; Eikelboom, J; Fleischmann, E; Garg, AX; Gross, PL; Guyatt, G; Kleinlugtenbelt, YV; Lamy, A; Landoni, G; Leslie, K; Likhvantsev, VV; Lomivorotov, V; Marcucci, M; Martínez-Zapata, MJ; McGillion, MH; McIntyre, W; Meyhoff, CS; Ofori, SN; Painter, TW; Paniagua, P; Parlow, JL; Patel, A; Polanczyk, CA; Prystajecky, M; Rao, M; Richards, T; Roshanov, PS; Ruetzler, K; Schmartz, D; Sessler, DI; Short, TG; Spence, J; Stillo, D; Szczeklik, W; Tandon, V; Torres, D; Turan, A; VanHelder, T; Vincent, J; Wang, CY; Wang, MK; Whitlock, RP; Wittmann, M; Wu, WKK; Xavier, D; Yusuf, S, 2022) |
| "Screening for the risk of thromboembolism (TE) due to tranexamic acid (TXA) in patients with severe traumatic injury has not been performed in randomized clinical trials." | 5.51 | The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial ( Bochicchio, G; Bochicchio, K; Cap, AP; Levy, JH; Pusateri, AE; Schuerer, D; Shea, SM; Spinella, PC; Staudt, A; Thomas, KA, 2022) |
| "The TXA-loaded trauma-targeted nanovesicles (T-tNVs) were evaluated in vitro in rat blood, and then in vivo in a liver trauma model in rats." | 5.51 | Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model. ( Banerjee, A; Girish, A; Hickman, DA; Huang, S; Luc, N; Ma, Y; Miyazawa, K; Sekhon, UDS; Sen Gupta, A; Sun, M, 2019) |
| "The clinical significance of immune thrombocytopenia (ITP) is mainly reflected by bleeding and/or bleeding risks, which, in some cases, cannot be adequately controlled by standard therapy." | 5.46 | Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. ( Mayer, B; Salama, A, 2017) |
| "Sprague-Dawley rats were subjected to polytrauma (laparotomy, and trauma to intestines, liver, right leg skeletal muscle, and right femur fracture), then bled 40% of their blood volume." | 5.46 | Tranexamic Acid Attenuates The Loss of Lung Barrier Function in a Rat Model of Polytrauma And Hemorrhage With Resuscitation. ( Cap, AP; Darlington, DN; Dubick, MA; Schwacha, MG; Wu, X, 2017) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 5.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid." | 5.42 | Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015) |
| "Because no medication has been approved for coagulation support in trauma, the current study was aimed to evaluate the effectiveness of intravenous injection of Tranexamic acid (TXA) in patients with acute traumatic bleeding." | 5.41 | The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial. ( Alimohamadi, Y; Khaleghian, M; Negahi, A; Teimoury, T; Vaziri, M, 2021) |
| "There is moderate-certainty evidence to support the beneficial value of topical or intravenous tranexamic acid during endoscopic sinus surgery with respect to surgical field bleeding score." | 5.41 | Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery. ( Avdeeva, K; Fokkens, W; Gan, KL; Lourijsen, E; Pundir, V, 2023) |
| " Tranexamic acid (TXA) prevents bleeding and has been shown to reduce trauma mortality." | 5.41 | Factors that influence the administration of tranexamic acid (TXA) to trauma patients in prehospital settings: a systematic review. ( Bedson, A; Benger, JR; Briscoe, S; Goodwin, L; Kirby, K; Nicholson, H; Robinson, M; Scotney, N; Taylor, H; Thompson Coon, J; Voss, S, 2023) |
| " Prophylaxis (Desmopressin, clotting factor concentrates or tranexamic acid) to prevent bleeding was described in 100% (30/30) of EA procedures and in 4% (24/661) of hysterectomies." | 5.41 | Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review. ( Bongers, MY; Eising, HP; Leemans, JC; Punt, MC, 2023) |
| "Tranexamic acid (TEA) was injected through a 22-gauge Wang cytology needle into the lesion in nominal doses of 250-500 mg." | 5.40 | Bronchoscopic intratumoral injection of tranexamic acid to prevent excessive bleeding during multiple forceps biopsies of lesions with a high risk of bleeding: a prospective case series. ( Zamani, A, 2014) |
| "Tranexamic acid is an antifibrinolytic drug." | 5.39 | Tranexamic acid and thrombosis. ( , 2013) |
| "To explore clinical effects of tranexamic acid on postoperative intra-articular hemorrhage after shoulder arthroscopy." | 5.34 | [Clinical study on the control of intra-articular hemorrhage by tranexamic acid after shoulder arthroscopy]. ( Gao, HL; He, Y; Shi, Q; Xiao, LB; Zhai, WT; Zhang, JC, 2020) |
| "This trial will assess the safety and efficacy of using prophylactic tranexamic acid during a period of intensive chemotherapy and associated thrombocytopenia in people with haematological disorders." | 5.30 | The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri ( Curnow, E; Dyer, C; Estcourt, LJ; McQuilten, Z; Powter, G; Stanworth, SJ; Wood, EM, 2019) |
| " Although four-factor prothrombin complex concentrate (4F-PCC) and tranexamic acid (TXA) are sometimes used to manage serious bleeding, their efficacy is unknown." | 5.27 | Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. ( Ariyawansa, J; Levy, JH; Marcsisin, VS; Moore, KT; Neal, MD; Schneider, D; Weitz, JI, 2018) |
| " The antifibrinolytic drug tranexamic acid (TXA) improves survival in adults with traumatic hemorrhage, however, the drug has not been evaluated in a clinical trial in severely injured children." | 5.27 | Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial. ( Adelson, PD; Barnhard, SE; Bobinski, M; Ghetti, S; Hewes, HA; Holmes, JF; Kuppermann, N; Michael Dean, J; Myers, SR; Nishijima, DK; Roberts, I; Schalick, WO; Stanley, RM; Tran, NK; Tzimenatos, LS; VanBuren, J, 2018) |
| "Tranexamic acid reduces the risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to improved outcomes." | 5.24 | Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. ( Bussières, JS; Byrne, K; Chan, MT; Cooper, DJ; Forbes, A; Jayarajah, M; Landoni, G; Marasco, S; McGuinness, S; McNeil, J; Myles, PS; Painter, T; Silbert, B; Smith, JA; Wallace, S, 2017) |
| "The CRASH-2 trial showed that tranexamic acid (TXA) administration reduces mortality in bleeding trauma patients." | 5.24 | Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms. ( Edwards, P; Joshi, M; Ker, K; Mahmood, A; Prieto, D; Roberts, I; Shakur, H, 2017) |
| "Tranexamic acid is widely available and used off-label in patients with bleeding traumatic injury, although the literature does not consistently agree on its efficacy and safety." | 5.22 | Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis. ( Hess, S; Karl, V; Maegele, M; Mathes, T; Thorn, S, 2022) |
| "Urgent treatment with tranexamic acid (TXA) reduces bleeding deaths but there is disagreement about which patients should be treated." | 5.22 | Effects of tranexamic acid treatment in severely and non-severely injured trauma patients. ( Ageron, FX; Roberts, I; Shakur-Still, H, 2022) |
| "To investigate the mechanism of action of tranexamic acid (TXA) in bleeding trauma patients, we examined the timing of its effect on mortality." | 5.19 | Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial. ( Manno, D; Prieto-Merino, D; Roberts, I, 2014) |
| " The CRASH-2 trial aimed to determine the effect of the early administration of tranexamic acid on death and transfusion requirement in bleeding trauma patients." | 5.17 | The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. ( Balogun, E; Barnetson, L; Cairns, J; Coats, T; Cook, L; Guerriero, C; Hunt, B; Kawahara, T; Perel, P; Prieto-Merino, D; Ramos, M; Roberts, I; Shakur, H, 2013) |
| "There was no statistically significant reduction in bleeding volume with the use of tranexamic acid (mean ± standard deviation, 135." | 5.16 | Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. ( Brum, MR; Castro, SF; Lima, LH; Lubianca Neto, JF; Machado, GM; Miura, MS, 2012) |
| "To examine whether the effect of tranexamic acid on the risk of death and thrombotic events in patients with traumatic bleeding varies according to baseline risk of death." | 5.16 | Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial. ( Brohi, K; Coats, T; Hunt, BJ; Lecky, F; Perel, P; Prieto-Merino, D; Roberts, I; Shakur, H; Willett, K, 2012) |
| " 20,211 adult trauma patients with, or at risk of, significant bleeding were randomly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h) or placebo." | 5.15 | The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. ( Afolabi, A; Brohi, K; Coats, T; Dewan, Y; Gando, S; Guyatt, G; Hunt, BJ; Morales, C; Perel, P; Prieto-Merino, D; Roberts, I; Shakur, H; Woolley, T, 2011) |
| "To assess the cost effectiveness of giving tranexamic acid (TXA) to bleeding trauma patients in low, middle and high income settings." | 5.15 | Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. ( Cairns, J; Guerriero, C; Perel, P; Roberts, I; Shakur, H, 2011) |
| "Tranexamic acid can reduce bleeding in patients undergoing elective surgery." | 5.14 | Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. ( Bautista, R; Caballero, J; Coats, T; Dewan, Y; El-Sayed, H; Gogichaishvili, T; Gupta, S; Herrera, J; Hunt, B; Iribhogbe, P; Izurieta, M; Khamis, H; Komolafe, E; Marrero, MA; Mejía-Mantilla, J; Miranda, J; Morales, C; Olaomi, O; Olldashi, F; Perel, P; Peto, R; Ramana, PV; Ravi, RR; Roberts, I; Shakur, H; Yutthakasemsunt, S, 2010) |
| "Tranexamic acid can reduce bleeding in patients undergoing elective surgery." | 5.14 | Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial. ( McDonald, AH; Strachan, GG; Williams, EW; Williams-Johnson, JA, 2010) |
| "Tranexamic acid (TXA) reduces surgical bleeding and reduces death from bleeding after trauma and childbirth." | 5.12 | Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis. ( Murao, S; Nakata, H; Roberts, I; Yamakawa, K, 2021) |
| "Tranexamic acid (TXA) is one of the measures indicated to reduce bleeding and the need for volume replacement." | 5.12 | Tranexamic acid in Neurosurgery: a controversy indication-review. ( Costa E Silva, LT; da Silva Brito, J; de Faria, JL; de Souza, NB; Figueiredo, EG; Kilesse, CTSM; Pereira, CU; Rabelo, NN, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug associated with improved survival among trauma patients with hemorrhage." | 5.12 | The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis. ( Almuwallad, A; Cole, E; Davenport, R; Perkins, Z; Ross, J, 2021) |
| "The use of tranexamic acid (TXA) is established in the treatment of bleeding, especially of bleeding due to hyperfibrinolysis." | 5.12 | [Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?] ( Möhnle, P; Pekrul, I; Schachtner, T; Zwißler, B, 2021) |
| " Systematic review and meta-analysis to determine the bleeding rates associated with tranexamic acid, desmopressin, platelet transfusion, plasma transfusion and recombinant activated factor VII, for patients with unclassified bleeding disorders undergoing surgery, childbirth or with menorrhagia." | 5.12 | Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies. ( Desborough, MJR; Doree, C; Lowe, GC; Obaji, S; Thomas, W, 2021) |
| "Tranexamic acid is an efficacious and safe pharmacological-based blood conservation technique in the management of clinically significant hemorrhage." | 5.12 | Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery. ( George, RB; Hanley, CM; Jerath, A; Saliba, C; Wong, J; Yee, DA, 2021) |
| "In order to determine the efficacy of the antifibrinolytic agent tranexamic acid (TA) in reducing bleeding and platelet transfusions during the treatment of acute myeloid leukemia (AML), we conducted a randomized placebo-controlled double-blind study." | 5.08 | A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. ( Ben-Bassat, I; Blumenthal, R; Chetrit, A; Eldor, A; Katz, Y; Ramot, B; Shpilberg, O; Sofer, O, 1995) |
| "The contribution of fibrinolysis to postoperative bleeding after cardiopulmonary bypass led to routine use of tranexamic acid, a potent antifibrinolytic drug, for a period of time." | 5.07 | Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. ( Abdelnoor, M; Am Holen, E; Ovrum, E; Oystese, R; Ringdal, ML, 1993) |
| "A controlled, randomized, double-blind study was performed to assess the effect of the oral antifibrinolytic agent tranexamic acid in patients with amegakaryocytic thrombocytopenia as regards their need for platelet transfusions and the number of bleeding episodes experienced." | 5.07 | Lack of efficacy of tranexamic acid in thrombocytopenic bleeding. ( Alling, D; Fricke, W; Griffith, P; Kimball, J; Klein, H, 1991) |
| "Thirty one diabetic patients were prospectively randomized for treatment with or without tranexamic acid during vitrectomy for proliferative diabetic retinopathy." | 5.06 | Effect of tranexamic acid on postvitrectomy haemorrhage in diabetic patients. ( Immonen, I; Laatikainen, L; Summanen, P, 1987) |
| "Tranexamic acid (TA) is an antifibrinolytic agent, increasingly recognized as being of utility for a wide variety of skin diseases." | 5.05 | The emerging importance of tranexamic acid in dermatology. ( Al-Niaimi, F; Ali, FR; Forbat, E, 2020) |
| "Early administration of the antifibrinolytic drug tranexamic acid reduces death from bleeding in trauma and postpartum haemorrhage." | 5.05 | Effect of tranexamic acid by baseline risk of death in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients. ( Ageron, FX; Coats, TJ; Gayet-Ageron, A; Ker, K; Roberts, I; Shakur-Still, H, 2020) |
| "The publication of the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage-2 (CRASH-2) study and its intense dissemination prompted a renaissance for the use of the antifibrinolytic agent tranexamic acid (TXA) in acute trauma hemorrhage." | 5.01 | Tranexamic Acid for Acute Hemorrhage: A Narrative Review of Landmark Studies and a Critical Reappraisal of Its Use Over the Last Decade. ( Lier, H; Maegele, M; Shander, A, 2019) |
| "Antifibrinolytic agent tranexamic acid (TXA) has a potential clinical benefit for in-hospital patients with severe bleeding but its effectiveness in pre-hospital settings remains unclear." | 4.98 | Efficacy of prehospital administration of tranexamic acid in trauma patients: A meta-analysis of the randomized controlled trials. ( Al-Thani, H; Asim, M; El-Menyar, A; Latifi, R; Sathian, B, 2018) |
| "Following results from the CRASH-2 trial, tranexamic acid (TXA) gained considerable interest for the treatment of hemorrhage in trauma patients." | 4.95 | Tranexamic Acid Update in Trauma. ( Bochicchio, GV; Ramirez, RJ; Spinella, PC, 2017) |
| " There have been many changes in the management of massive hemorrhage, for example, the administration of the tranexamic acid and the use of balanced transfusion ratio." | 4.93 | [Management of bleeding and coagulopathy following major trauma]. ( Etxaniz, A; Pita, E, 2016) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in people with haematological disorders." | 4.93 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders. ( Brunskill, SJ; Desborough, M; Doree, C; Estcourt, LJ; Hopewell, S; Murphy, MF; Stanworth, SJ, 2016) |
| " A recent example of self-propelling particles is highlighted, where propulsion enhanced the efficacy of a formulation of thrombin and tranexamic acid in treating bleeding in two murine models of hemorrhage and a porcine model of fatal, non-compressible hemorrhage." | 4.93 | Halting hemorrhage with self-propelling particles and local drug delivery. ( Baylis, JR; Chan, KY; Kastrup, CJ, 2016) |
| "There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding." | 4.91 | The current place of tranexamic acid in the management of bleeding. ( Hunt, BJ, 2015) |
| " The aim of this study was to review the literature on the use of lysine analogs to prevent bleeding and blood transfusion during pelvic surgery." | 4.90 | The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis. ( Beck, A; Breau, RH; Buenaventura, C; Cagiannos, I; Cowan, J; Fergusson, DA; Knoll, G; Kokolo, MB; Momoli, F; Morash, C; Niznick, N; Punjani, N; Ruzicka, M; Schachkina, S; Tinmouth, A; Xie, HY, 2014) |
| "None of the patients experienced further bleeding following the commencement of tranexamic acid treatment, and no adverse effect was noted." | 4.89 | Treatment of bleeding upper aerodigestive tract tumor-a novel approach with antifibrinolytic agent: case series and literature review. ( Clark, JR; Elliott, M; Huang, J; Low, TH; Reid, C, 2013) |
| "Intravenous tranexamic acid reduces bleeding in surgery, however, its effect on the risk of thromboembolic events is uncertain and an increased risk remains a theoretical concern." | 4.89 | Topical application of tranexamic acid for the reduction of bleeding. ( Beecher, D; Ker, K; Roberts, I, 2013) |
| "To determine the efficacy and safety of antifibrinolytics (lysine analogues) in preventing bleeding in patients with haematological disorders." | 4.89 | Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. ( Brunskill, SJ; Doree, C; Estcourt, LJ; Murphy, MF; Stanworth, S; Trivella, M; Wardrop, D, 2013) |
| "Tranexamic acid, an antifibrinolytic agent, reduces postoperative transfusion requirements but carries a poorly documented risk of thrombosis." | 4.89 | Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality. ( , 2013) |
| " One such protocol governs the use of tranexamic acid (TXA), which is used to control bleeding." | 4.89 | Tranexamic acid in patients with major injuries and blood loss. ( Livingstone, C, 2013) |
| "Tranexamic acid safely reduces mortality in bleeding trauma patients without increasing the risk of adverse events." | 4.88 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, T; Ker, K; Roberts, I; Shakur, H, 2012) |
| "Analysis of these reviews yielded meanfuling observations: (1) The effectiveness of most ordinary treatments in TBI is inconclusive except that corticosteroids are likely to be ineffective or harmful, and tranexamic acid, nimodipine and progesterone show a promising effect in bleeding trauma, traumatic subarachnoid hemorrhage, TBI or severe TBI." | 4.88 | Is management of acute traumatic brain injury effective? A literature review of published Cochrane Systematic Reviews. ( Gao, GY; Jiang, JY; Lei, J, 2012) |
| "In view of this efficacy and safety of this relatively cheap and simple drug, it may be recommended to put tranexamic acid in the first (maybe even prehospital) line of management of patients with severe traumatic hemorrhage." | 4.88 | Should antifibrinolytics be given in all patients with trauma? ( Levi, M, 2012) |
| "We sought trials or observational studies of ≥20 adults involving any antifibrinolytic drug (TXA, epsilonaminocaproic acid (EACA) or aprotinin) for spontaneous (non-traumatic, non-surgical/iatrogenic), non-heamophiliac bleeding." | 4.88 | The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials. ( Al-Shahi Salman, R; Ross, J, 2012) |
| "The aim of this study is critically to review the available evidence regarding the use, efficacy and safety of tranexamic acid in the management of hemorrhage during pregnancy and for prevention and treatment of postpartum hemorrhage." | 4.87 | Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. ( Kadir, RA; Peitsidis, P, 2011) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "To review the real-world management of rivaroxaban-associated major bleeding across the public hospitals of New Zealand's largest city." | 4.31 | Real-world decision-making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience. ( Eaddy, N; Grainger, BT; Merriman, E; Ockelford, P; Royle, G; Young, L, 2023) |
| " The seminal CRASH-2 trial demonstrated a reduction in overall mortality following early tranexamic acid (TXA) administration to bleeding trauma patients." | 4.31 | Estimated Cost-Effectiveness of Implementing a Statewide Tranexamic Acid Protocol for the Management of Suspected Hemorrhage in the Prehospital Setting. ( Houston, S; Hubble, MW; Renkiewicz, GK; Schiro, S; Van Vleet, L, 2023) |
| "The American Trial Using Tranexamic Acid (TXA) in Thrombocytopenia (A-TREAT, NCT02578901) demonstrated no superiority of TXA over placebo in preventing World Health Organization (WHO) grade 2 or higher bleeding in patients with severe thrombocytopenia requiring supportive platelet transfusion following myeloablative therapy for hematologic disorders." | 4.31 | Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia. ( Brown, SP; de Laat, B; El Kassar, N; Gernsheimer, TB; Herren, H; Holle, LA; Ilich, A; Key, NS; Lucas, AT; May, S; Triulzi, DJ; Wolberg, AS, 2023) |
| "We present a case of cardiopulmonary arrest secondary to rivaroxaban related oropharyngeal hemorrhage, which required rapid intravenous (IV) push administration of 4-factor prothrombin complex concentrate (4F-PCC)." | 4.31 | Rapid administration of Kcentra® during cardiopulmonary arrest. ( Cocchio, C; Gagnon, Z; White, K, 2023) |
| "We conducted a secondary analysis of the MAssive Transfusion in Children (MATIC), a prospectively collected database of children with life-threatening hemorrhage (LTH), and evaluated for risk of adverse events with either antifibrinolytic treatment, epsilon aminocaproic acid (EACA) or tranexamic acid (TXA)." | 4.31 | Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. ( Josephson, CD; Kolodziej, JH; Leeper, CM; Leonard, JC; Spinella, PC; Zenati, MS, 2023) |
| "Several studies have demonstrated the clinical utility of tranexamic acid (TXA) for use in trauma patients presenting with significant hemorrhage." | 4.31 | EFFECTS OF TRANEXAMIC ACID ON NEUROPATHOLOGY, ELECTROENCEPHALOGRAPHY, AND CEREBRAL FIBRIN DEPOSITION IN A RAT MODEL OF POLYTRAUMA WITH CONCOMITANT PENETRATING TRAUMATIC BRAIN INJURY. ( Bailey, ZS; Cao, Y; Cardiff, K; Gilsdorf, J; Houchins, M; Lu, XC; Scultetus, A; Shear, D; Wang, P; Yang, X, 2023) |
| "To evaluate the association of treatment with nebulized tranexamic acid (TXA) with rates of operative intervention in post-tonsillectomy hemorrhage (PTH)." | 4.31 | Treatment of post-tonsillectomy hemorrhage with nebulized tranexamic acid: A retrospective study. ( Elghouche, AN; Hasnain, F; Matt, BH; Shay, EO; Shin, TJ; Ye, MJ, 2023) |
| "This study described the outcomes of patients receiving topical, nebulized, endobronchial, or systemic tranexamic acid (TXA) for bleeding events while on extracorporeal membrane oxygenation (ECMO)." | 4.31 | Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation. ( Jakowenko, ND; Kalvelage, EL; Macielak, RJ; Nabzdyk, CGS; Nei, SD; Seelhammer, TG; Wieruszewski, PM, 2023) |
| " Based on current evidence the elements of an evolving strategy in transfusion management and bleeding control are exposed to use of tranexamic acid, combination and ratios of blood products, use of fluids and viscoelastic testing, etc." | 4.12 | Massive transfusion in trauma: an evolving paradigm. ( Bouzat, P; Gauss, T; Moyer, JD, 2022) |
| "Children were compared according to receipt of antifibrinolytic medication (tranexamic acid or aminocaproic acid) during the bleeding event." | 4.12 | Use of Antifibrinolytics in Pediatric Life-Threatening Hemorrhage: A Prospective Observational Multicenter Study. ( Gaines, BA; Josephson, CD; Leeper, CM; Leonard, JC; Luther, JF; Spinella, PC; Wisniewski, SR, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug used to prevent bleeding." | 4.12 | Barriers and facilitators to the administration of prehospital tranexamic acid: a paramedic interview study using the theoretical domains framework. ( Bedson, A; Benger, J; Black, S; Goodwin, L; Kirby, K; Nicholson, H; Robinson, M; Taylor, H; Voss, S, 2022) |
| "Tranexamic acid (TXA) has become a widely used antifibrinolytic drug for reducing bleeding in surgery." | 4.12 | Safety and efficacy of intravenous or topical tranexamic acid administration in surgery: a protocol for a systematic review and network meta-analysis. ( Han, R; Liang, F; Wang, X; Yu, Y, 2022) |
| "The use of a standardized protocol increased the use of tranexamic acid, with a nonstatistically significant reduction in procedural bleeding rate." | 4.12 | Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders. ( Bourassa, M; Champagne, PA; Cloutier, S; Demers, C; Desjardins, MP; Néron, H; Pelland-Marcotte, MC; Singbo, NU, 2022) |
| " We describe a case of a patient supported by a right ventricular assist device with an oxygenator and a left ventricular assist device who developed pulmonary hemorrhage that was successfully treated with nebulized tranexamic acid (TXA)." | 4.12 | Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report. ( Angelidis, IK; Budd, AN; Malsin, ES; Patel, S; Pawale, A; Smith, S, 2022) |
| "This series demonstrates successful bleeding management with nebulized tranexamic acid, reducing the frequency of ECMO circuit changes, time off of anticoagulation and blood loss." | 4.12 | A role for nebulized tranexamic acid in veno-venous ECMO patients. ( Ahmed, S; Cabanilla, MG; Villalobos, NE, 2022) |
| "Intravenous tranexamic acid (TXA) reduces bleeding deaths after injury and childbirth." | 4.02 | Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial. ( Davenport, R; Frimley, L; Gilliam, C; Grassin-Delyle, S; Jarman, H; Lamy, E; McGuinness, W; Moss, P; Picetti, R; Pott, J; Prowse, D; Pynn, H; Roberts, I; Shakur-Still, H; Tai, N; Thayne, A; Urien, S, 2021) |
| "Tranexamic acid (TXA) is an antifibrinolytic used for prophylaxis and treatment of acute bleeding." | 4.02 | Impact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding. ( Farina, N; Franz, ND; Machado-Aranda, D; Miller, JT, 2021) |
| "Tranexamic acid reduces surgical blood loss and reduces deaths from bleeding in trauma patients." | 4.02 | Validation of the BATT score for prehospital risk stratification of traumatic haemorrhagic death: usefulness for tranexamic acid treatment criteria. ( Ageron, FX; Coats, TJ; Darioli, V; Roberts, I, 2021) |
| "Tranexamic acid is a cheap and easy to use drug for the treatment and prevention of bleeding." | 4.02 | [Tranexamic acid: widely applicable, few risks]. ( Meijer, K; Stein-Wit, MA, 2021) |
| "Evaluate nebulized tranexamic acid (TXA) as a treatment to reduce the need for an operation to control a post-tonsillectomy hemorrhage (PTH)." | 4.02 | Post-tonsillectomy hemorrhage control with nebulized tranexamic acid: A retrospective cohort study. ( Earley, MA; Erwin, DZ; Goldstein, NA; Heichel, PD; McEvoy, TP; Meyer, AD; Wright, LM, 2021) |
| "Tranexamic acid (TXA) improves survival in traumatic hemorrhage, but difficulty obtaining intravenous (IV) access may limit its use in austere environments, given its incompatibility with blood products." | 3.96 | Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage. ( Beyer, CA; Caples, CM; DeSoucy, ES; Grayson, JK; Hoareau, GL; Johnson, MA; Kashtan, HW; Spruce, MW, 2020) |
| "Forty-six patients receiving endobronchial ε-aminocaproic acid for the treatment or prevention of pulmonary bleeding." | 3.96 | Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series. ( Oromendia, C; Rajwani, K; Ramos, LG; Sanso, LM; Simon, RP, 2020) |
| " The final list of performance indicators was as follows: (a) rationale for transfusion documented in the notes; (b) rationale for transfusion in line with Thames Valley Air Ambulance blood transfusion guideline; (c) aggressive management of hypothermia; (d) tranexamic acid administered within an hour of injury; (e) evidence of bleeding in hospital; (f) monitoring of adverse effects of blood transfusion; (g) overall-was the use of blood justified; and (h) no units wasted this month." | 3.96 | Developing clinical performance indicators for pre-hospital blood transfusion: The Thames Valley Air Ambulance approach. ( Curry, N; Dearman, J; Lewis, P; Poole, K; Raitt, J; Surendra Kumar, D, 2020) |
| "The CRASH-2 trial demonstrated that tranexamic acid (TXA) in adults with significant traumatic hemorrhage safely reduces mortality." | 3.96 | Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era. ( Benipal, S; Erramouspe, PJ; Galante, JM; García-Pintos, MF; Manoukian, MAC; Nishijima, D; Santamarina, JL; Shawagga, HG; Vo, LL, 2020) |
| "Tranexamic acid reduces blood loss in patients with bleeding diatheses and is used in a number of gynaecologic and non-gynaecologic conditions CASE: We discuss the case of a 27-year-old woman with type 1 von Willebrand disease, who presented with a two-year history of severe mittelschmerz secondary to recurrent hemorrhagic cysts." | 3.96 | Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts. ( Balayla, J; Gil, Y; Lasry, A, 2020) |
| "Tranexamic acid (TXA) is a synthetic derivative of the amino acid lysine that inhibits fibrinolysis by blocking lysine-binding sites on plasminogen, which contribute to reduced bleeding, the need for transfusion and mortality." | 3.96 | Safety of tranexamic acid in thrombotic adverse events and seizure in patients with haemorrhage: a protocol for a systematic review and meta-analysis. ( Murao, S; Nakata, H; Yamakawa, K, 2020) |
| " Tranexamic Acid (TXA) is used as an anti-fibrinolytic agent to reduce surgical bleeding if administered prior to or during surgery, and to improve survival in trauma if given early after trauma." | 3.91 | Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage. ( Benov, A; Cap, AP; Darlington, DN; Keesee, JD; Liu, B; Wu, X, 2019) |
| "Tranexamic acid (TXA) has been shown to decrease mortality in adult trauma patients with or at significant risk of hemorrhage when administered within 3 h of injury." | 3.91 | Evaluation of tranexamic acid in trauma patients: A retrospective quantitative analysis. ( Burgess, S; Ng, M; Perrott, J, 2019) |
| "Tranexamic acid (TXA) is used as a hemostatic adjunct for hemorrhage control in the injured patient and reduces early preventable death." | 3.91 | Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism. ( Brown, JB; Kutcher, ME; Myers, SP; Neal, MD; Peitzman, AB; Rosengart, MR; Sperry, JL, 2019) |
| "To describe the use of tranexamic acid (TXA) in trauma care in England and Wales since the Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage (CRASH-2) trial results were published in 2010." | 3.91 | Implementation of tranexamic acid for bleeding trauma patients: a longitudinal and cross-sectional study. ( Coats, TJ; Fragoso-Iñiguez, M; Roberts, I, 2019) |
| " Tranexamic acid (TXA) blocks both the tPA-dependent generation of plasmin on blood clots as well as active plasmin binding to polymerized fibrin, and is commonly administered for bleeding in trauma to limit fibrinolysis." | 3.91 | Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner. ( Barrett, CD; Chapman, MP; Kong, YW; Lim, D; Moore, EE; Moore, HB; Sriram, G; Yaffe, MB, 2019) |
| " Bleeding prophylaxis included combinations of plasma-derived factor (VWD) or recombinant factor (haemophilia A and haemophilia B), desmopressin and/or tranexamic acid." | 3.91 | Low endoscopy bleeding risk in patients with congenital bleeding disorders. ( Barkun, A; Bessissow, T; Bienz, M; Kherad, O; Laflèche, T; Restellini, S; Tomaszewski, M; Warner, M, 2019) |
| " Administering tranexamic acid (TXA), an antifibrinolytic agent, is one strategy to reduce bleeding; however, it must be given soon after injury to be effective and minimize adverse effects." | 3.91 | Topical tranexamic acid inhibits fibrinolysis more effectively when formulated with self-propelling particles. ( Baylis, JR; Cau, M; Gusti, V; Kastrup, CJ; Kazerooni, A; Lee, MM; Liggins, RT; Simonson, E; St John, AE; Statz, ML; Wang, X; White, NJ; Yoon, JSJ, 2019) |
| "Tranexamic acid (TXA) reduces bleeding and mortality." | 3.91 | Prehospital tranexamic acid shortens the interval to administration by half in Major Trauma Networks: a service evaluation. ( Bagga, R; Buxton, WP; Duffield, CAB; Marsden, MER; Rossetto, A; Steynberg, S; Tai, NRM; Woolley, TGD, 2019) |
| " We are planning a multicenter, randomized clinical trial evaluating tranexamic acid in children with hemorrhage." | 3.91 | Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process. ( Galante, JM; Hewes, HA; Kuppermann, N; Meyers, SR; Nishijima, DK; Nuno, MA; Stanley, RM; Stephenson, JT; Thompson, KM; Trappey, AF, 2019) |
| " Tranexamic acid administration was an independent risk factor for venous thromboembolism (odds ratio, 2." | 3.88 | Evaluation of Military Use of Tranexamic Acid and Associated Thromboembolic Events. ( Bradley, MJ; Elster, EA; Johnston, LR; Rodriguez, CJ, 2018) |
| "To ascertain whether tranexamic acid reduces the blood loss and transfusion rate and volumes; increase the prevalence of deep vein thrombosis (DVT); and investigate factors associated with DVT in patients undergoing primary bilateral total knee arthroplasties (TKAs) without use of chemical thromboprophylaxis." | 3.88 | Does tranexamic acid increase the risk of thromboembolism after bilateral simultaneous total knee arthroplasties in Asian Population? ( Kim, JS; Kim, YH; Park, JW; Seo, DH, 2018) |
| " The aim of this study is to determine the effect of tranexamic acid, an antifibrinolytic agent, on the anticoagulant activity and bleeding by edoxaban in rats." | 3.88 | Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban. ( Furugohri, T; Honda, Y; Morishima, Y, 2018) |
| "The current study aimed to evaluate the efficacy of three nonspecific haemostatic drugs - recombinant activated factor VII (rFVIIa), tranexamic acid and desmopressin (DDAVP) - to limit blood loss after administration of prasugrel in a rabbit model of bleeding while also evaluating any prothrombotic effects." | 3.88 | Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model. ( Bonhomme, F; Fontana, P; Godier, A; Lecompte, T; Samama, CM, 2018) |
| "We describe the case of a bleeding trauma patient who received tranexamic acid (TXA) during air transport who subsequently developed multiple intra-cardiac thrombi." | 3.88 | Left atrial thrombi following tranexamic acid in a bleeding trauma patient-A word of caution. ( Carroll, ND; Eastridge, BJ; Restrepo, CS; Stasik, CN, 2018) |
| "Tranexamic acid was associated with increased 6-hour survival but does not improve long-term outcomes in severely injured trauma patients with hemorrhage who develop hyperfibrinolysis." | 3.88 | Severely injured trauma patients with admission hyperfibrinolysis: Is there a role of tranexamic acid? Findings from the PROPPR trial. ( Bulger, EM; Holcomb, JB; Jehan, F; Joseph, B; Khan, M; OʼKeeffe, T; Schreiber, MA; Wade, CE, 2018) |
| "Tranexamic acid (TXA) is increasingly used during major surgery with the goal to reduce excessive bleeding, transfusion requirements, and reexploration." | 3.85 | Tranexamic acid leads to paradoxical coagulation changes during cardiac surgery: a pilot rotational thromboelastometry study. ( Dobson, GP; Letson, HL; Sharma, R; Smith, S, 2017) |
| "The California Prehospital Antifibrinolytic Therapy (Cal-PAT) study seeks to assess the safety and impact on patient mortality of tranexamic acid (TXA) administration in cases of trauma-induced hemorrhagic shock." | 3.85 | Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study. ( Benson, P; Borger, R; Culhane, JT; Dong, F; Jabourian, A; Jabourian, N; Kissel, S; Kwong, E; Ludi, D; Mistry, J; Neeki, MM; O'Bosky, KR; Pennington, TW; Pitts, R; Powell, J; Schulz-Costello, K; Seiler, K; Sporer, K; Surrusco, MS; Toy, J; Vaezazizi, R; Van Stralen, D; Vara, R; Wong, D; Yoshida-McMath, C, 2017) |
| " Several reports show a successful therapeutic use of the antifibrinolytic agent tranexamic acid in palliative care patients having hemorrhages." | 3.85 | Bleeding Control in Palliative Care Patients With the Help of Tranexamic Acid. ( Bardenheuer, HJ; Frankenhauser, S; Geist, MJP; Kessler, J, 2017) |
| " The aim of this study was to investigate the combined effect of transfusion ratios, tranexamic acid and products containing fibrinogen on the outcome of injured patients with bleeding." | 3.85 | Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy. ( Baksaas-Aasen, K; Balvers, K; Brohi, K; Eaglestone, S; Gaarder, C; Goslings, JC; Johansson, PI; Juffermans, NP; Maegele, M; Ostrowski, SR; Stanworth, S; Stensballe, J; van Dieren, S, 2017) |
| "Management of ticagrelor-induced bleeding is challenging as platelet transfusion is ineffective." | 3.85 | Ticagrelor reversal: ( Bachelot-Loza, C; Calmette, L; Gaussem, P; Godier, A; Gouin-Thibault, I; Le Bonniec, B; Martin, AC; Zlotnik, D, 2017) |
| " The current European Management of Major Bleeding and Coagulopathy Following Trauma guidelines, published in 2013, recommend that tranexamic acid (TXA) be administered as early as possible to inhibit hyperfibrinolysis (grade of recommendation (GoR 1A))." | 3.85 | [Tranexamic acid in the German emergency medical service : A national survey]. ( Balzer, F; Casu, S; Greb, I; Henkelmann, A; Kaufner, L; von Heymann, C; Weber, CF; Zacharowski, K; Zickenrott, V, 2017) |
| "A reduction in mortality with the early use of tranexamic acid has been demonstrated in severely injured patients who are bleeding." | 3.85 | Effectiveness of early administration of tranexamic acid in patients with severe trauma. ( Hagiwara, A; Kushimoto, S; Matsui, H; Murata, K; Otomo, Y; Shiraishi, A, 2017) |
| " In postpartal period an excellent control of bleeding was obtained by regularly administering FVIII concentrate for several days as well by concomitant use of tranexamic acid and oral contraceptive pills in the next 6 weeks." | 3.85 | Pregnancy and delivery in a woman with severe haemophilia A. ( Antic, DA; Bodrozic, JN; Djunic, IS; Lekovic, DR; Miljic, PS; Mitrovic, MM; Petronijevic, MA; Petronijevic-Vrzic, SM, 2017) |
| "Administration of tranexamic acid (TXA) to bleeding trauma patients who are within 3 hours of injury has been shown to safely reduce mortality in bleeding trauma patients." | 3.83 | Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed. ( Roberts, I, 2016) |
| " We sought to determine if its reintroduction was still pertinent given the widespread administration of tranexamic acid, another antifibrinolytic shown to reduce bleeding and transfusions." | 3.83 | Major transfusions remain frequent despite the generalized use of tranexamic acid: an audit of 3322 patients undergoing cardiac surgery. ( Hardy, JF; Noiseux, N; Prieto, I; Stevens, LM, 2016) |
| " We loaded these microparticles with thrombin and tranexamic acid and tested their efficacy in a swine arterial bleeding model without wound compression." | 3.83 | Self-Propelled Dressings Containing Thrombin and Tranexamic Acid Improve Short-Term Survival in a Swine Model of Lethal Junctional Hemorrhage. ( Baylis, JR; Chien, D; Kastrup, CJ; Liggins, RT; Lim, EB; Simonson, E; St John, AE; Statz, ML; Stern, SA; Wang, X; White, NJ, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic agent that is listed as an essential medication by the World Health Organization for traumatic hemorrhage." | 3.83 | Tranexamic Acid Use in United States Trauma Centers: A National Survey. ( Huang, EC; Jawa, RS; Mccormack, JE; Rutigliano, DN; Singer, A; Vosswinkel, JA, 2016) |
| "To study the prophylactic effects of tranexamic acid (TXA) for reduction of bleeding episodes in patients with VWD and GT in non-invasive conditions." | 3.83 | Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial. ( Bagheri, B; Eghbali, A; Melikof, L; Taherahmadi, H, 2016) |
| "Based upon the results of CRASH-2, early administration of antifibrinolytic tranexamic acid (TXA) is recommended in bleeding trauma patients or trauma patients presumed to bleed." | 3.83 | [Uncritical use of tranexamic acid in trauma patients : Do no further harm!] ( Maegele, M, 2016) |
| " In the present study we evaluated the hemostatic effects of tranexamic acid (TXA) to decrease bleeding tendency and transfusion requirements in high-risk patients following transapical aortic valve implantation (TA-AVI)." | 3.81 | Prophylactic intraoperative tranexamic acid administration and postoperative blood loss after transapical aortic valve implantation. ( Choi, YH; Deppe, AC; Kuhn, E; Madershahian, N; Pfister, R; Rudolph, T; Scherner, M; Slottosch, I; Wahlers, T, 2015) |
| " The CRASH-2 trial demonstrated that early administration of tranexamic acid, ideally within 3 hours, can reduce mortality from trauma-associated bleeding by up to 32%." | 3.81 | Time since injury is the major factor in preventing tranexamic acid use in the trauma setting: An observational cohort study from a major trauma centre in a middle-income country. ( Chowdhury, S; Edu, S; Navsaria, PH; Nicol, AJ; Thurston, B, 2015) |
| "Accumulating evidence established the benefit of tranexamic acid (TXA) for traumatic bleeding in the hospital setting." | 3.80 | Tranexamic acid at the point of injury: the Israeli combined civilian and military experience. ( Abramovich, A; Benov, A; Gendler, S; Glassberg, E; Nadler, R; Strugo, R, 2014) |
| " Our purposes were to study the efficacy of tranexamic acid (TXA) and prothrombin complex concentrate (PCC) on a traumatic coagulopathy with a severe native metabolic acidosis and compare the efficacy of PCC versus fresh frozen plasma (FFP) to reverse a dilutional coagulopathy." | 3.79 | The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis. ( Eckert, M; Izenberg, S; Martin, MJ; McVay, D; Nelson, D; Porta, CR; Salgar, S, 2013) |
| "We examined the effect of local administration of tranexamic acid( TA) on reducing aspirin-induced bleeding in off-pump coronary artery bypass grafting(CABG)." | 3.79 | [Can local administration of tranexamic acid reduce aspirin-induced bleeding in off-pump coronary artery bypass grafting( CABG) ?]. ( Aoki, M; Baba, H; Goto, Y; Ogawa, S; Okawa, Y, 2013) |
| "A case is presented in which topical tranexamic acid was used to stop local bleeding from a nipple following piercing in a young man with haemophilia." | 3.79 | Case report: use of topical tranexamic acid to stop localised bleeding. ( Chitnis, J; Noble, S, 2013) |
| "To assess whether Haemocomplettan(®) (fibrinogen concentrate) or Fibrogammin(®) (Factor XIII concentrate) can be used to manage bleeding complications of antithrombotic treatment, we examined a normal plasma pool spiked with AR-H067637 (thrombin inhibitor) or rivaroxaban (activated factor X-inhibitor), to which one of the concentrates was added." | 3.79 | A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor. ( Blombäck, M; Cao, H; He, S; Hultenby, K; Johnsson, H; Zabczyk, M, 2013) |
| "The early administration of tranexamic acid (TXA) to bleeding trauma patients reduces all-cause mortality without increasing the risk of vascular occlusive events." | 3.78 | Tranexamic acid: less bleeding and less thrombosis? ( Godier, A; Hunt, BJ; Roberts, I, 2012) |
| " In the present case study, a new technique, using intratumoral injection of tranexamic acid to control significant bleeding during bronchoscopic biopsy, is described." | 3.77 | Bronchoscopic intratumoral injection of tranexamic acid: a new technique for control of biopsy-induced bleeding. ( Zamani, A, 2011) |
| " This series of studies tested whether these drugs (aprotinin, desmopressin, tranexamic acid, epsilon-aminocaproic acid) could reduce bleeding due to traumatic injuries in two models of uncontrolled hemorrhage in rats." | 3.73 | Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage. ( Cortez, DS; Dick, EJ; Pusateri, AE; Ryan, KL, 2006) |
| "Tranexamic acid (an antifibrinolytic agent) is of proven benefit in the treatment of bleeding in patients with congenital and acquired coagulation disorders." | 3.71 | Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. ( Cordingley, FT; Leahy, MF; Taparia, M, 2002) |
| "Tranexamic acid (AMCA) is an inhibitor of fibrinolysis used to treat fibrinolytic bleeding (e." | 3.68 | Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications. ( Astedt, B; Lindoff, C; Rybo, G, 1993) |
| "Complete inhibition of vitreous fibrinolytic activity with 4-amino-methylcyclohexane carbonic acid was associated with significantly delayed resolution of vitreous hemorrhages in rabbits." | 3.65 | The effect of fibrinolytic inhibition in the resolution of experimental vitreous hemorrhage. ( Edgar, W; Forbes, CD; Forrester, JV; Prentice, CR; Williamson, J, 1977) |
| "Among patients with hematologic malignancy undergoing chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment with TXA compared with placebo did not significantly reduce the risk of WHO grade ≥2 bleeding." | 3.11 | Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. ( Boyiadzis, M; Brown, SP; El Kassar, N; Emerson, S; Gernsheimer, TB; Herren, H; Key, NS; May, S; Pagano, MB; Poston, JN; Reeves, BN; Selukar, S; Triulzi, DJ, 2022) |
| "To compare the efficacy and adverse events of high-dose vs low-dose tranexamic acid in patients undergoing cardiac surgery with cardiopulmonary bypass." | 3.11 | Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. ( Cheng, Z; Feng, W; Liu, S; Pan, W; Shi, J; Sun, H; Wang, W; Wang, Y; Zheng, Z; Zhou, C, 2022) |
| " Individual conclusions regarding optimal dosing of TXA can be made within each injury group." | 3.01 | The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children. ( Casper, TC; Dean, JM; Kuppermann, N; Lewis, RJ; McGlothlin, A; Nishijima, DK; VanBuren, JM, 2021) |
| "Tranexamic acid (TXA) is a standard component of Tactical Combat Casualty Care." | 3.01 | A Systematic Review of Tranexamic Acid-Associated Venous Thromboembolic Events in Combat Casualties and Considerations for Prolonged Field Care. ( Ho, JW; Keeney-Bonthrone, TP; Lozano, R; Ruf, AC; Russo, RM; Strayve, D; Zakaluzny, SA, 2023) |
| "Hemorrhage and trauma-induced coagulopathy cause significant morbidity and mortality in trauma patients." | 3.01 | Alternative blood products in trauma. ( Jan, KM; Mohapatra, S; Moon, TS, 2023) |
| " The ongoing trials create six new comparisons: tranexamic acid (tablet + injection) versus placebo; intravenous tranexamic acid versus oral tranexamic acid; topical tranexamic acid versus oral tranexamic acid; different intravenous tranexamic acid dosing regimes; topical tranexamic acid versus topical fibrin glue; and fibrinogen (injection) versus placebo." | 3.01 | Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures. ( Brunskill, SJ; Champaneria, R; Dorée, C; Estcourt, LJ; Geneen, LJ; Gibbs, VN; Novak, A; Palmer, AJ; Raval, P, 2023) |
| "Tranexamic acid was given intravenously or topically during the perioperative period." | 3.01 | Interventions for reducing red blood cell transfusion in adults undergoing hip fracture surgery: an overview of systematic reviews. ( Estcourt, LJ; Griffin, XL; Lewis, SR; Pritchard, MW; Stanworth, SJ, 2023) |
| "Tranexamic acid is an antifibrinolytic agent and is already known for its role in the prevention and treatment of perioperative bleeding in the fields of orthopaedics, cardiovascular surgery and gynaecology." | 3.01 | ( Allert, S; Frey, E; Isaev, R; Motamedi, M, 2023) |
| "Tranexamic acid has been shown to reduce blood loss following transurethral resection of the prostate and open radical prostatectomy." | 3.01 | Effect of Perioperative Tranexamic Acid on Blood Loss following Open Simple Prostatectomy: A Prospective Review in Nigerian Men. ( Adeyemo, A; Badmus, TA; David, RA; Jeje, EA; Olasehinde, OO; Onyeze, CI; Owojuyigbe, AM; Salako, AA, 2023) |
| "Elderly patients with intertrochanteric fractures exhibit post-traumatic hidden blood loss (HBL)." | 3.01 | Early intravenous tranexamic acid intervention reduces post-traumatic hidden blood loss in elderly patients with intertrochanteric fracture: a randomized controlled trial. ( Chen, X; He, T; Li, M; Liu, L; Liu, X; Long, X; Ma, H; Wang, H; Wang, W; Xu, Z, 2021) |
| "Tranexamic acid (TXA) is a well-studied, widely used intravenous hemostatic; however, the potential benefit during resection of ACTH-secreting pituitary adenoma is unstudied." | 3.01 | Perioperative Tranexamic Acid for ACTH-Secreting Pituitary Adenomas: Implementation Protocol Results and Trial Prospectus. ( Carlstrom, LP; Choby, G; Cohen, SC; Graffeo, CS; Perry, A; Van Gompel, JJ, 2021) |
| "Hemorrhage is a leading cause of death after trauma and childbirth." | 2.94 | Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials. ( Bates, I; Bello, A; Chaudhri, R; Kolin, DA; Roberts, I; Shakur-Still, H, 2020) |
| "In trauma patients with severe injury, 4 g intravenous bolus dosing of TXA has minimal immunomodulatory effects with respect to leukocyte phenotypes and circulating cytokine levels." | 2.94 | The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial. ( Baty, J; Bochicchio, GV; Bochicchio, K; Cap, AP; Coleoglou Centeno, AA; Fuchs, A; Horn, CB; Levy, JH; Meledeo, MA; Pusateri, AE; Reese, S; Schuerer, D; Shea, SM; Spinella, PC; Thomas, KA; Turnbull, IR, 2020) |
| "Bleeding is an important cause of death in trauma victims." | 2.90 | Introduction of a standardised protocol, including systematic use of tranexamic acid, for management of severe adult trauma patients in a low-resource setting: the MSF experience from Port-au-Prince, Haiti. ( Benedetti, G; Edema, N; Jachetti, A; Massénat, RB; Trelles, M; Van Den Bergh, R; Woolley, SC, 2019) |
| "Future trauma trials that evaluate tranexamic acid use should also consider functional status as an important outcome." | 2.90 | The Effect of Tranexamic Acid on Functional Outcomes: An Exploratory Analysis of the CRASH-2 Randomized Controlled Trial. ( Kuppermann, N; Nishijima, DK; Roberts, I; Tancredi, DJ; VanBuren, JM, 2019) |
| "Menorrhagia is a regular menstrual cycle lasting more than seven days and/or blood loss over 80 mL per cycle." | 2.90 | "Evaluation of the effect of roasted lentil flour (lentil savigh) as a functional food in menstrual bleeding reduction". ( Amouzegar, H; Heidari, A; Khani, S; Nojavan, F; Shafiee, M, 2019) |
| "No episodes of transfusion, pulmonary embolism, or major bleeding occurred in either group." | 2.84 | Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study. ( Huang, Q; Ma, J; Pei, F; Xie, J; Yue, C, 2017) |
| "Bleeding is the leading cause of maternal mortality in the world." | 2.82 | Tranexamic acid for prevention of bleeding in cesarean delivery: An overview of systematic reviews. ( Boet, S; Burns, JK; Deng, MX; Edwards, W; Etherington, C; Hurskainen, T; Martin Calderon, L; Moher, D, 2022) |
| "Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma patients and cardiovascular, orthopedic, and gynecological surgical patients." | 2.82 | Tranexamic acid: Beyond antifibrinolysis. ( Carter, D; Falank, C; Kacer, D; Kramer, R; Palmeri, M; Prudovsky, I; Rappold, J; Zucco, VV, 2022) |
| "Tranexamic acid (TXA) is an antifibrinolytic drug that was shown to increase survival in trauma patients, but the mechanisms remain unclear." | 2.82 | Double-blinded, placebo-controlled study of early tranexamic acid treatment in swine uncontrolled hemorrhage model. ( Aden, JK; Cap, AP; de Guzman, R; Dubick, MA; Hanson, MA; Polykratis, IA; Prince, MD; Sondeen, JL, 2016) |
| "The evidence gap in mature civilian trauma systems is limiting the widespread use of TXA and its potential benefits on survival." | 2.80 | Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study. ( Brohi, K; Cole, E; Davenport, R; Willett, K, 2015) |
| "The trial included 20,127 trauma patients with significant bleeding from 274 hospitals in 40 countries." | 2.79 | Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study. ( Altman, DG; Clayton, T; Croft, P; Douglas, I; Hemingway, H; Hingorani, A; Morley, KI; Perel, P; Riley, R; Roberts, I; Timmis, A; Van der Windt, D, 2014) |
| "Tranexamic acid (TA) has been widely used in the treatment of these severe bleeds but with no properly designed trial." | 2.79 | Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. ( Boutitie, F; Capitaine, AL; Dupuis-Girod, S; Gaillard, S; Gueyffier, F; Hatron, PY; Kaminsky, P; Manfredi, G; Morinière, S; Plauchu, H; Rivière, S; Roy, P, 2014) |
| "The trial included 20,127 trauma patients with, or at risk of, significant bleeding, within 8 hours of injury." | 2.78 | Development and validation of a prognostic model to predict death in patients with traumatic bleeding, and evaluation of the effect of tranexamic acid on mortality according to baseline risk: a secondary analysis of a randomised controlled trial. ( Perel, P; Prieto-Merino, D; Roberts, I; Shakur, H, 2013) |
| "Tranexamic acid is an antifibrinolytic that is known to reduce operative bleeding." | 2.78 | Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial. ( Chiarella, A; Côté, DW; Dziegielewski, PT; Langille, MA; Mulholland, G; Sowerby, LJ; Wright, ED, 2013) |
| "A quality assurance review of eligible trauma patients across the province was performed using a convenience sample." | 2.72 | Assessing the clinical utilization of tranexamic acid by paramedics for patients with major trauma (ACUTE). ( Acker, J; Jenneson, S; Mabasa, VH; Su, G; Tallon, JM; Wan, W; Wong, D, 2021) |
| "Neonatal bleeding was described in 6 affected male neonates, mostly after instrumental delivery or emergency CS, but insufficient information was provided to reliably investigate neonatal outcome in relation to management." | 2.72 | Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. ( Bloemenkamp, KWM; Driessens, MHE; Duvekot, JJ; Eikenboom, J; Kruip, MJHA; Lely, AT; Makelburg, ABU; Mauser-Bunschoten, EP; Middeldorp, JM; Nieuwenhuizen, L; Peters, M; Punt, MC; Schutgens, REG; van Galen, KPM; Waning, ML, 2021) |
| "Case material included 25 patients with hemophilia (9 children and 16 adults) with high-responding inhibitors and 3 patients with acquired factor VIII inhibitors." | 2.70 | Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. ( Baudo, F; Gringeri, A; Morfini, M; Rocino, A; Santagostino, E; Scaraggi, FA, 2001) |
| "The bleeding was effectively controlled within 1 to 48 h in five of nine bleeding episodes." | 2.69 | Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. ( Angchaisuksiri, P; Chuansumrit, A; Hathirat, P; Isarangkura, P; Jorgensen, LN; Sriudomporn, N; Tanpowpong, K, 2000) |
| " (3) The appropriate, empirically established, dosage and administration patterns of TEA for CDH repair during ECMO seem to be one bolus of 4 mg/kg TEA intravenously 30 minutes before the anticipated CDH repair and a continuous infusion of 1 mg/kg/h TEA during the 24 hours after CDH repair." | 2.68 | Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid. ( de Haan, AF; Festen, C; Geven, WB; van der Staak, FH, 1997) |
| "Tranexamic acid was found as effective as aprotinin on platelets function." | 2.67 | [The use of antifibrinolytics in heart surgery. 3 prospective studies]. ( Benmosbah, L; Boughenou, F; Cousin, MT; Madi-Jebara, S; Massonnet-Vastel, S, 1993) |
| "Hemorrhage is the leading cause of preventable death in combat trauma and the secondary cause of death in civilian trauma." | 2.66 | Hemostatic agents for prehospital hemorrhage control: a narrative review. ( Peng, HT, 2020) |
| "Transfusion therapy in hemorrhaging trauma patients is associated with the development of thromboembolic events." | 2.66 | The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. ( Goslings, JC; Juffermans, NP; Schalkers, DV; Wirtz, MR, 2020) |
| "Acute blood loss in trauma requires quick identification and action to restore circulating volume and save the patient." | 2.66 | Massive transfusion protocol in adult trauma population. ( Boneva, D; Elkbuli, A; McKenney, M; Meneses, E, 2020) |
| "Tranexamic acid appears to be an effective and well-tolerated agent for reduction of blood loss caused by local hyperfibrinolysis." | 2.64 | [Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy]. ( Castelli, G; Vogt, E, 1977) |
| "Uncontrolled hemorrhage and subsequent trauma-induced coagulopathy (TIC) are still the principle causes for preventable death after trauma and early detection and aggressive management have been associated with reduced mortality." | 2.55 | Updated concepts on the pathophysiology and the clinical management of trauma hemorrhage and coagulopathy. ( Gu, ZT; Huang, QB; Maegele, M; Yang, H, 2017) |
| " Aprotinin is associated with a reduction in bleeding and transfusion requirements following major surgery, and has a dose-response profile, compared with no dose-response effect in the one study investigating tranexamic acid in cardiac surgical patients." | 2.52 | The current place of aprotinin in the management of bleeding. ( Royston, D, 2015) |
| "In most trauma centres, coagulation therapy is established with transfusion of high volumes of fresh frozen plasma." | 2.52 | Management of traumatic haemorrhage--the European perspective. ( Schlimp, CJ; Schöchl, H; Voelckel, W, 2015) |
| " In major cardiac surgery tranexamic acid has been used in a large number of controlled trials with various dosing schemes in which the highest dosages seem to be associated with neurotoxicity; therefore a maximum total dose of 100mg/kg especially in patients over 50years of age is recommended by ISMICS (International Society for Minimally Invasive Cardiothoracic Surgery)." | 2.52 | Tranexamic acid--an old drug still going strong and making a revival. ( Berntorp, E; Blombäck, M; Tengborn, L, 2015) |
| "Uncontrolled bleeding is an important cause of death in trauma victims." | 2.52 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, TJ; Ker, K; Roberts, I; Shakur, H, 2015) |
| "Herein, we explore the underpinnings of trauma associated coagulopathy, the basic science behind the role of fibrinogen in acute traumatic coagulopathy, and the rationale behind and the data derived from management of hypofibrinogenemia as well as hyperfibrinolysis." | 2.50 | Role of fibrinogen in massive injury. ( Kaplan, LJ; Maung, AA, 2014) |
| "The coagulopathy induced by trauma is independently associated with mortality, increased transfusion requirements, multiple organ dysfunction, infections, increased intensive care unit (ICU) length of stay, and costs." | 2.50 | A systematic review of antifibrinolytics and massive injury. ( Faraoni, D; Van Der Linden, P, 2014) |
| "Fibrinogen depletes early after severe trauma; therefore, it seems to be reasonable to maintain plasma fibrinogen as early as possible." | 2.50 | Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use? ( Maegele, M; Schlimp, CJ; Schöchl, H, 2014) |
| "Bleeding and coagulopathy after trauma increases mortality in both adults and children." | 2.50 | Tranexamic acid in pediatric trauma: why not? ( Ackery, AD; Beno, S; Callum, J; Rizoli, S, 2014) |
| " It reduces total blood loss and the need for blood transfusion, particularly in the using of high dosage of TXA (≥ 15 mg/kg), yet does not increase the risk of postoperative DVT." | 2.49 | Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials. ( Fu, X; Li, ZJ; Ma, XL; Xing, D; Zang, JC; Zhang, HF, 2013) |
| "Tranexamic acid was generally well tolerated." | 2.48 | Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. ( McCormack, PL, 2012) |
| "Future treatment of trauma-induced coagulopathy may be based on systemic antifibrinolytics, local haemostatics and individualized point-of-care-guided rational use of coagulation factor concentrates such as fibrinogen, prothrombin complex concentrate, recombinant factor VIIa and factor XIII." | 2.48 | Emerging treatment strategies for trauma-induced coagulopathy. ( Fries, D; Sorensen, B, 2012) |
| "Uncontrolled bleeding is an important cause of death in trauma victims." | 2.47 | Antifibrinolytic drugs for acute traumatic injury. ( Coats, T; Ker, K; Roberts, I; Shakur, H, 2011) |
| "Tranexamic acid (TXA) is an antifibrinolytic that inhibits both plasminogen activation and plasmin activity, thus preventing clot break-down rather than promoting new clot formation." | 2.47 | Tranexamic acid for trauma patients: a critical review of the literature. ( Aden, J; Baer, DG; Blackbourne, LH; Cap, AP; Orman, JA; Ryan, K, 2011) |
| "Perioperative prophylactic treatment for high-bleeding-risk surgery in patients with severe FXI deficiency is based on fresh frozen plasma (FFP) transfusions or FXI concentrate (where available)." | 1.91 | [PERIOPERATIVE MANAGEMENT OF AN ADOLESCENT GIRL WITH SEVERE FACTOR XI DEFICIENCY AND INHIBITORS]. ( Berger-Achituv, S; Keren-Politansky, A; Mandel-Shorer, N; Oren-Malek, L; Revel-Vilk, S, 2023) |
| "Hemorrhage is the leading cause of preventable death after injury." | 1.91 | Time to early resuscitative intervention association with mortality in trauma patients at risk for hemorrhage. ( Brown, JB; Claridge, JA; Daley, BJ; Deeb, AP; Eastridge, BJ; Guyette, FX; Harbrecht, BG; Joseph, B; Miller, RS; Nirula, R; Phelan, HA; Sperry, JL; Vercruysse, GA, 2023) |
| "Oral tranexamic acid was trialed with stabilization of the hemoglobin." | 1.91 | Life-Threatening Retroperitoneal Hemorrhage Following Cyst Rupture in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Case Report. ( Chebib, FT; Chedid, M; Duriseti, P; Hanna, C; Potrezke, TA; Radhakrishnan, Y, 2023) |
| "Peri-procedural management of von Willebrand disease (VWD) utilizes von Willebrand factor (VWF) concentrates or desmopressin (DDAVP) to increase VWF levels." | 1.91 | Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes. ( Chandrakumaran, P; Hews-Girard, J; Poon, MC, 2023) |
| "She was diagnosed with thrombasthenia and was being treated with oral tranexamic acid and carbazochrome." | 1.91 | A lethal case of massive hemorrhage after percutaneous liver biopsy in a patient with thrombasthenia. ( Aoki, Y; Fukuta, M; Kanno, S; Kato, H; Nakamura, Y; Ohtaki, J, 2023) |
| "Hemorrhage is responsible for 91% of preventable prehospital deaths in combat." | 1.91 | Ruggedized Self-Propelling Hemostatic Gauze Delivers Low Dose of Thrombin and Systemic Tranexamic Acid and Achieves High Survival in Swine With Junctional Hemorrhage. ( Ali-Mohamad, N; Baylis, JR; Beckett, A; Cau, MF; Kastrup, CJ; Khavari, A; Naveed, A; Peng, H; Peng, N; Ringgold, K; Semple, H; Sherwood, C; Tenn, C; Wang, X; White, NJ; Zhang Gao, H; Zhang, Y, 2023) |
| "Second, we examined data from the Trauma and Audit Research Network (TARN) to explore sex differences in the receipt of TXA." | 1.72 | Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data. ( Ageron, FX; Brenner, A; Nutbeam, T; Roberts, I; Shakur-Still, H; Weekes, L, 2022) |
| "The optimal treatment of aortic dissection-related DIC remains controversial." | 1.72 | Management of disseminated intravascular coagulation after thoracic endovascular aortic repair of type B aortic dissection: a case report. ( Lai, J; Liu, H; Liu, Y, 2022) |
| "Abnormal bleeding is sometimes observed in patients with immunoglobulin light chain (AL) amyloidosis." | 1.56 | Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid. ( Arahata, M; Asakura, H; Ichinose, A; Kadohira, Y; Morishita, E; Takamatsu, H; Yamada, S, 2020) |
| "Tranexamic acid (TXA) has been demonstrated to decrease mortality in adult trauma, particularly in those with massive transfusions needs sustained in combat injury." | 1.56 | Tranexamic acid in pediatric combat trauma requiring massive transfusions and mortality. ( Aden, JK; Borgman, MA; Hamele, M, 2020) |
| "Tranexamic acid has been proven to reduce all causes of mortality and mortality due to bleeding." | 1.51 | Administration of tranexamic acid for victims of severe trauma within pre-hospital care ambulance services (PHCAS) in Malaysia. ( Ahmad Ibrahim, KB; Ahmad Tajuddin, MN; Aik Howe, T; Anandakumar, K; Fatahul Laham, M; Fitzgerald, M; Kiat Kee, G; Mathew, J; Md Saed, M; Mohd Amin, M; Mohd Idzwan, Z; Mohd Khairizam, MY; Nurul Azlean, N; Ridzuan, MI; Sabariah Faizah, J; Shah Jahan, MY; Shamila, MA, 2019) |
| " A single very low dose of rFVIIa along with TXA is a simple and safe treatment to control hemostasis in severe FXI-deficient patients undergoing diverse type of surgical procedure at various sites." | 1.51 | Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. ( Avishai, E; Bashari, D; Budnik, I; Dardik, R; Livnat, T; Salomon, O; Tamarin, I, 2019) |
| "Hemorrhage is the leading cause of potentially survivable deaths in combat." | 1.51 | An Analysis of Adherence to Tactical Combat Casualty Care Guidelines for the Administration of Tranexamic Acid. ( April, MD; Carius, BM; Fisher, AD; Maddry, JK; Naylor, JF; Schauer, SG, 2019) |
| "Adult major trauma patients with, or at risk of, active bleeding who were managed according to the MTP during the years 2011-2012, or the ECS protocol during the years 2013-2014 and were considered at risk of multiple transfusions, were enrolled." | 1.51 | Early coagulation support protocol: A valid approach in real-life management of major trauma patients. Results from two Italian centres. ( Antonelli, M; Barelli, R; Bianchi, M; Bocci, MG; Caricato, A; Cingolani, E; Cutuli, SL; De Candia, E; De Pascale, G; Dell'Anna, AM; Fiore, V; Grieco, DL; Maresca, M; Mercurio, G; Nardi, G; Palma, A; Rondinelli, MB; Tersali, A; Veronesi, G, 2019) |
| "We prospectively recruited hemorrhaging trauma patients in six level-1 trauma centres in Europe." | 1.51 | Towards patient-specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry. ( Baksaas-Aasen, K; Balvers, K; Brohi, K; Gaarder, C; Goslings, JC; Johansson, PI; Juffermans, NP; Maegele, M; Naess, PA; Stanworth, S; Stensballe, J; van Dieren, S; Wirtz, MR, 2019) |
| "The TXA-loaded trauma-targeted nanovesicles (T-tNVs) were evaluated in vitro in rat blood, and then in vivo in a liver trauma model in rats." | 1.51 | Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model. ( Banerjee, A; Girish, A; Hickman, DA; Huang, S; Luc, N; Ma, Y; Miyazawa, K; Sekhon, UDS; Sen Gupta, A; Sun, M, 2019) |
| "During the period studied, 27 adult trauma patients who required activation of the MTP were identified." | 1.48 | Use of tranexamic acid in trauma patients requiring massive transfusion protocol activation: an audit in a major trauma centre in New Zealand. ( Chapman, N, 2018) |
| "The clinical significance of immune thrombocytopenia (ITP) is mainly reflected by bleeding and/or bleeding risks, which, in some cases, cannot be adequately controlled by standard therapy." | 1.46 | Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia. ( Mayer, B; Salama, A, 2017) |
| "Sprague-Dawley rats were subjected to polytrauma (laparotomy, and trauma to intestines, liver, right leg skeletal muscle, and right femur fracture), then bled 40% of their blood volume." | 1.46 | Tranexamic Acid Attenuates The Loss of Lung Barrier Function in a Rat Model of Polytrauma And Hemorrhage With Resuscitation. ( Cap, AP; Darlington, DN; Dubick, MA; Schwacha, MG; Wu, X, 2017) |
| "Fibrinogen level was normalized within two days (2." | 1.43 | Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report. ( Cvetković, Z; Kulić, A; Libek, V, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 1.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "Of a total of 259 patients with craniosynostosis, 187 had nonsyndromic single-suture involvement; 69 of these patients (36." | 1.43 | Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis. ( Diggs, B; Esmonde, N; Gries, H; Koh, J; Kuang, AA; Martin, DT; Schreiber, M; Selden, NR, 2016) |
| "All bleedings were spontaneous and involving the gastro-intestinal tract." | 1.42 | Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report. ( Cappelli, R; Landini, G; Lorenzini, G; Masotti, L; Panigada, G; Schulman, S; Seravalle, C, 2015) |
| "Excessive bleeding is a risk associated with cardiac surgery." | 1.42 | Protocol guided bleeding management improves cardiac surgery patient outcomes. ( Drake, L; Faulke, D; Fraser, JF; Fung, YL; Pearse, BL; Rapchuk, IL; Ryan, EG; Smith, I; Tesar, P; Wall, D; Ziegenfuss, M, 2015) |
| "Bleeding was successfully treated using the antifibrinolytic agent tranexamic acid." | 1.42 | Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta. ( Gembruch, U; Merz, WM; Pötzsch, B; Rühl, H; Schröder, L, 2015) |
| "Tranexamic acid was used in 61." | 1.40 | No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin. ( Mallett, SV; Schofield, N; Sugavanam, A; Thompson, K, 2014) |
| "Tranexamic acid (TEA) was injected through a 22-gauge Wang cytology needle into the lesion in nominal doses of 250-500 mg." | 1.40 | Bronchoscopic intratumoral injection of tranexamic acid to prevent excessive bleeding during multiple forceps biopsies of lesions with a high risk of bleeding: a prospective case series. ( Zamani, A, 2014) |
| "and U." | 1.39 | Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. ( Dubose, JJ; Jansen, JO; Midwinter, MJ; Morrison, JJ; Rasmussen, TE; Ross, JD, 2013) |
| "Tranexamic acid is an antifibrinolytic drug." | 1.39 | Tranexamic acid and thrombosis. ( , 2013) |
| "Massive hemorrhage is the leading cause of death in the first few hours following multiple trauma, therefore, early and aggressive treatment of clotting disorders and surgical intervention to stop the bleeding are of utmost importance." | 1.38 | [Coagulation management of trauma patients with unstabile circulation : establishment of a hemoglobin-oriented standard operating procedure]. ( Hilbert, P; Hofmann, GO; Jakubetz, J; Stuttmann, R; Teichmann, J; zur Nieden, K, 2012) |
| "It is present in 2-8% of trauma patients and associated with shock and increased mortality." | 1.37 | [Hyperfibrinolysis as the cause of haemorrhage and increased mortality in trauma patients]. ( Afshari, A; Johansson, PI; Stensballe, J; Wikkelsø, AJ, 2011) |
| "Cerebral ischemia was treated with vigorous plasma volume expansion under intermittent monitoring of pulmonary wedge pressure, cardiac output, and arterial blood pressure, aiming for a hematocrit of 0." | 1.30 | Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage. ( Avezaat, CJ; Bijvoet, HW; Hasan, D; Vermeij, FH, 1998) |
| "In hamsters with pulmonary embolism given 0." | 1.29 | Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis. ( Collen, D; Lijnen, HR; Stassen, JM, 1995) |
| " The protamine dose necessary to reverse heparin after extracorporeal circulation (ECC) was assessed in ten patients from individual heparin dose-response curves (HDR group)." | 1.27 | The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation. ( Hatteland, K; Ottesen, S; Stormorken, H, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 25 (5.32) | 18.7374 |
| 1990's | 20 (4.26) | 18.2507 |
| 2000's | 26 (5.53) | 29.6817 |
| 2010's | 249 (52.98) | 24.3611 |
| 2020's | 150 (31.91) | 2.80 |
| Authors | Studies |
|---|---|
| Orbe, J | 1 |
| Sánchez-Arias, JA | 1 |
| Rabal, O | 1 |
| Rodríguez, JA | 1 |
| Salicio, A | 1 |
| Ugarte, A | 1 |
| Belzunce, M | 1 |
| Xu, M | 1 |
| Wu, W | 1 |
| Tan, H | 1 |
| Ma, H | 2 |
| Páramo, JA | 2 |
| Oyarzabal, J | 1 |
| Steinmetzer, T | 1 |
| Pilgram, O | 1 |
| Wenzel, BM | 1 |
| Wiedemeyer, SJA | 1 |
| Hurskainen, T | 1 |
| Deng, MX | 1 |
| Etherington, C | 1 |
| Burns, JK | 1 |
| Martin Calderon, L | 1 |
| Moher, D | 1 |
| Edwards, W | 1 |
| Boet, S | 1 |
| Gauss, T | 1 |
| Moyer, JD | 1 |
| Bouzat, P | 1 |
| Spinella, PC | 5 |
| Leonard, JC | 2 |
| Gaines, BA | 1 |
| Luther, JF | 1 |
| Wisniewski, SR | 1 |
| Josephson, CD | 2 |
| Leeper, CM | 2 |
| Smith, CT | 1 |
| Arnolds, DE | 1 |
| Lim, G | 1 |
| Rossetto, A | 2 |
| Vulliamy, P | 2 |
| Lee, KM | 1 |
| Brohi, K | 6 |
| Davenport, R | 6 |
| Murao, S | 2 |
| Nakata, H | 2 |
| Roberts, I | 40 |
| Yamakawa, K | 2 |
| VanBuren, JM | 3 |
| Casper, TC | 2 |
| Nishijima, DK | 7 |
| Kuppermann, N | 5 |
| Lewis, RJ | 1 |
| Dean, JM | 1 |
| McGlothlin, A | 1 |
| Goodwin, L | 2 |
| Nicholson, H | 2 |
| Robinson, M | 3 |
| Bedson, A | 2 |
| Black, S | 2 |
| Kirby, K | 2 |
| Taylor, H | 2 |
| Voss, S | 2 |
| Benger, J | 1 |
| MacDonald, M | 1 |
| Ilie, G | 1 |
| Power, L | 1 |
| Whalen, S | 1 |
| Parker, R | 1 |
| Skinner, TA | 1 |
| Powers, AGL | 1 |
| Manoukian, MAC | 2 |
| Tancredi, DJ | 2 |
| Singh, A | 1 |
| Trivedi, R | 1 |
| Ahmed, N | 1 |
| Karl, V | 1 |
| Thorn, S | 1 |
| Mathes, T | 1 |
| Hess, S | 1 |
| Maegele, M | 9 |
| Devereaux, PJ | 1 |
| Marcucci, M | 1 |
| Painter, TW | 1 |
| Conen, D | 1 |
| Lomivorotov, V | 1 |
| Sessler, DI | 1 |
| Chan, MTV | 3 |
| Borges, FK | 1 |
| Martínez-Zapata, MJ | 1 |
| Wang, CY | 1 |
| Xavier, D | 1 |
| Ofori, SN | 1 |
| Wang, MK | 1 |
| Efremov, S | 1 |
| Landoni, G | 3 |
| Kleinlugtenbelt, YV | 1 |
| Szczeklik, W | 1 |
| Schmartz, D | 1 |
| Garg, AX | 1 |
| Short, TG | 1 |
| Wittmann, M | 1 |
| Meyhoff, CS | 1 |
| Amir, M | 1 |
| Torres, D | 1 |
| Patel, A | 1 |
| Duceppe, E | 1 |
| Ruetzler, K | 1 |
| Parlow, JL | 1 |
| Tandon, V | 1 |
| Fleischmann, E | 1 |
| Polanczyk, CA | 1 |
| Lamy, A | 1 |
| Astrakov, SV | 1 |
| Rao, M | 1 |
| Wu, WKK | 1 |
| Bhatt, K | 1 |
| de Nadal, M | 1 |
| Likhvantsev, VV | 1 |
| Paniagua, P | 1 |
| Aguado, HJ | 1 |
| Whitlock, RP | 1 |
| McGillion, MH | 1 |
| Prystajecky, M | 1 |
| Vincent, J | 1 |
| Eikelboom, J | 1 |
| Copland, I | 1 |
| Balasubramanian, K | 1 |
| Turan, A | 1 |
| Bangdiwala, SI | 1 |
| Stillo, D | 1 |
| Gross, PL | 1 |
| Cafaro, T | 1 |
| Alfonsi, P | 1 |
| Roshanov, PS | 1 |
| Belley-Côté, EP | 1 |
| Spence, J | 1 |
| Richards, T | 1 |
| VanHelder, T | 1 |
| McIntyre, W | 1 |
| Guyatt, G | 2 |
| Yusuf, S | 1 |
| Leslie, K | 1 |
| Deeb, AP | 2 |
| Hoteit, L | 1 |
| Li, S | 1 |
| Guyette, FX | 2 |
| Eastridge, BJ | 3 |
| Nirula, R | 3 |
| Vercruysse, GA | 3 |
| O'Keeffe, T | 2 |
| Joseph, B | 4 |
| Neal, MD | 4 |
| Sperry, JL | 4 |
| Brown, JB | 3 |
| Grainger, BT | 1 |
| Merriman, E | 1 |
| Royle, G | 1 |
| Eaddy, N | 1 |
| Ockelford, P | 1 |
| Young, L | 1 |
| Wang, X | 5 |
| Liang, F | 1 |
| Yu, Y | 1 |
| Han, R | 1 |
| Nutbeam, T | 1 |
| Weekes, L | 1 |
| Shakur-Still, H | 8 |
| Brenner, A | 2 |
| Ageron, FX | 6 |
| Negahi, A | 1 |
| Teimoury, T | 1 |
| Alimohamadi, Y | 1 |
| Vaziri, M | 1 |
| Khaleghian, M | 1 |
| Moore, EE | 5 |
| Moore, HB | 6 |
| Sauaia, A | 3 |
| Gernsheimer, TB | 2 |
| Brown, SP | 2 |
| Triulzi, DJ | 2 |
| Key, NS | 2 |
| El Kassar, N | 2 |
| Herren, H | 2 |
| Poston, JN | 1 |
| Boyiadzis, M | 1 |
| Reeves, BN | 1 |
| Selukar, S | 1 |
| Pagano, MB | 1 |
| Emerson, S | 1 |
| May, S | 2 |
| Lanthier, L | 1 |
| Plourde, MÉ | 1 |
| Cauchon, M | 1 |
| Champagne, PA | 1 |
| Bourassa, M | 1 |
| Desjardins, MP | 1 |
| Cloutier, S | 1 |
| Demers, C | 1 |
| Singbo, NU | 1 |
| Néron, H | 1 |
| Pelland-Marcotte, MC | 1 |
| Cole, E | 4 |
| Curry, N | 3 |
| Bochicchio, K | 2 |
| Thomas, KA | 2 |
| Staudt, A | 1 |
| Shea, SM | 2 |
| Pusateri, AE | 5 |
| Schuerer, D | 2 |
| Levy, JH | 6 |
| Cap, AP | 6 |
| Bochicchio, G | 1 |
| Hubble, MW | 1 |
| Renkiewicz, GK | 1 |
| Schiro, S | 1 |
| Van Vleet, L | 1 |
| Houston, S | 1 |
| Jafry, AH | 1 |
| Raza, SM | 1 |
| Bajwa, A | 1 |
| Hassan, A | 1 |
| Akhtar, KH | 1 |
| Salat, H | 1 |
| Abdo, T | 1 |
| Prudovsky, I | 3 |
| Kacer, D | 3 |
| Zucco, VV | 1 |
| Palmeri, M | 2 |
| Falank, C | 1 |
| Kramer, R | 2 |
| Carter, D | 3 |
| Rappold, J | 3 |
| Waberski, AT | 1 |
| Busack, C | 1 |
| d'Acoz, YD | 1 |
| Matisoff, AJ | 1 |
| Liu, H | 1 |
| Liu, Y | 2 |
| Lai, J | 1 |
| Shi, J | 1 |
| Zhou, C | 1 |
| Pan, W | 1 |
| Sun, H | 1 |
| Liu, S | 1 |
| Feng, W | 1 |
| Wang, W | 2 |
| Cheng, Z | 1 |
| Wang, Y | 1 |
| Zheng, Z | 1 |
| Schober, P | 1 |
| Loer, SA | 1 |
| Schwarte, LA | 1 |
| Lin, YT | 1 |
| Ho, MP | 1 |
| Patel, S | 2 |
| Angelidis, IK | 1 |
| Malsin, ES | 1 |
| Smith, S | 3 |
| Pawale, A | 1 |
| Budd, AN | 1 |
| Ilich, A | 1 |
| Holle, LA | 1 |
| Lucas, AT | 1 |
| de Laat, B | 1 |
| Wolberg, AS | 1 |
| Borgman, MA | 2 |
| Russo, RM | 1 |
| Lozano, R | 1 |
| Ruf, AC | 1 |
| Ho, JW | 1 |
| Strayve, D | 1 |
| Zakaluzny, SA | 1 |
| Keeney-Bonthrone, TP | 1 |
| Biffi, A | 2 |
| Porcu, G | 2 |
| Castellini, G | 2 |
| Napoletano, A | 2 |
| Coclite, D | 2 |
| D'Angelo, D | 2 |
| Fauci, AJ | 2 |
| Iacorossi, L | 2 |
| Latina, R | 2 |
| Salomone, K | 2 |
| Iannone, P | 2 |
| Gianola, S | 2 |
| Chiara, O | 2 |
| Ausen, K | 1 |
| Pleym, H | 1 |
| Spigset, O | 1 |
| Mandel-Shorer, N | 1 |
| Oren-Malek, L | 1 |
| Keren-Politansky, A | 1 |
| Berger-Achituv, S | 1 |
| Revel-Vilk, S | 1 |
| Daley, BJ | 1 |
| Miller, RS | 1 |
| Harbrecht, BG | 1 |
| Claridge, JA | 1 |
| Phelan, HA | 1 |
| Jan, KM | 1 |
| Mohapatra, S | 1 |
| Moon, TS | 1 |
| Hmidan Simsam, M | 1 |
| Delorme, L | 1 |
| Grimm, D | 1 |
| Priestap, F | 1 |
| Bohnert, S | 1 |
| Descoteaux, M | 1 |
| Hilsden, R | 1 |
| Laverty, C | 1 |
| Mickler, J | 1 |
| Parry, N | 1 |
| Rochwerg, B | 1 |
| Sherman, C | 1 |
| Toole, J | 1 |
| Vogt, K | 1 |
| Wilson, S | 1 |
| Ball, I | 1 |
| Beverly, A | 1 |
| Ong, G | 1 |
| Kimber, C | 1 |
| Sandercock, J | 1 |
| Dorée, C | 6 |
| Welton, NJ | 1 |
| Wicks, P | 1 |
| Estcourt, LJ | 7 |
| Lourijsen, E | 1 |
| Avdeeva, K | 1 |
| Gan, KL | 1 |
| Pundir, V | 1 |
| Fokkens, W | 1 |
| Duriseti, P | 1 |
| Radhakrishnan, Y | 1 |
| Chedid, M | 1 |
| Hanna, C | 1 |
| Potrezke, TA | 1 |
| Chebib, FT | 1 |
| White, K | 1 |
| Gagnon, Z | 1 |
| Cocchio, C | 1 |
| Grassin-Delyle, S | 2 |
| Chaudhri, R | 2 |
| Geer, A | 1 |
| Arribas, M | 1 |
| Lamy, E | 2 |
| Mansukhani, R | 1 |
| Lubeya, MK | 1 |
| Javaid, K | 1 |
| Kayani, A | 1 |
| Israr, N | 1 |
| Mazhar, SB | 1 |
| Urien, S | 2 |
| Bouazza, N | 1 |
| Foissac, F | 1 |
| Prowse, D | 2 |
| Carrington, L | 1 |
| Barrow, C | 1 |
| Onandia, JG | 1 |
| Balogun, E | 2 |
| Morkos, K | 1 |
| Maingard, J | 1 |
| Barras, C | 1 |
| Kok, HK | 1 |
| Hall, J | 1 |
| Russell, J | 1 |
| Thijs, V | 1 |
| Slater, LA | 1 |
| Chong, W | 1 |
| Chandra, R | 1 |
| Jhamb, A | 1 |
| Brooks, M | 1 |
| Asadi, H | 1 |
| Revelo, AE | 1 |
| Pastis, NJ | 1 |
| Machnitzky, E | 1 |
| Fung, A | 1 |
| Greene, A | 1 |
| Kolodziej, JH | 1 |
| Zenati, MS | 1 |
| Chandrakumaran, P | 1 |
| Hews-Girard, J | 1 |
| Poon, MC | 1 |
| Scotney, N | 1 |
| Briscoe, S | 1 |
| Thompson Coon, J | 1 |
| Benger, JR | 1 |
| Bailey, ZS | 1 |
| Yang, X | 1 |
| Cardiff, K | 1 |
| Wang, P | 1 |
| Houchins, M | 1 |
| Lu, XC | 1 |
| Cao, Y | 1 |
| Gilsdorf, J | 1 |
| Scultetus, A | 1 |
| Shear, D | 1 |
| Gibbs, VN | 1 |
| Geneen, LJ | 1 |
| Champaneria, R | 1 |
| Raval, P | 1 |
| Brunskill, SJ | 3 |
| Novak, A | 1 |
| Palmer, AJ | 1 |
| Lewis, SR | 1 |
| Pritchard, MW | 1 |
| Stanworth, SJ | 7 |
| Griffin, XL | 1 |
| Ragni, MV | 1 |
| Rothenberger, SD | 1 |
| Feldman, R | 1 |
| Nance, D | 1 |
| Leavitt, AD | 1 |
| Malec, L | 1 |
| Kulkarni, R | 1 |
| Sidonio, R | 1 |
| Kraut, E | 1 |
| Lasky, J | 1 |
| Pruthi, R | 1 |
| Angelini, D | 1 |
| Philipp, C | 1 |
| Hwang, N | 1 |
| Wheeler, AP | 1 |
| Seaman, C | 1 |
| Machin, N | 1 |
| Xavier, F | 1 |
| Meyer, M | 1 |
| Bellissimo, D | 1 |
| Humphreys, G | 1 |
| Smith, KJ | 1 |
| Merricks, EP | 1 |
| Nichols, TC | 1 |
| Ivanco, D | 1 |
| Vehec, D | 1 |
| Koerbel, G | 1 |
| Althouse, AD | 1 |
| Shin, TJ | 1 |
| Hasnain, F | 1 |
| Shay, EO | 1 |
| Ye, MJ | 1 |
| Matt, BH | 1 |
| Elghouche, AN | 1 |
| Lee, YS | 1 |
| Jenkins, AS | 1 |
| Gonzalez-Albo, G | 1 |
| Ball, CT | 1 |
| Porter, SB | 1 |
| Dora, CD | 1 |
| Isaev, R | 1 |
| Frey, E | 1 |
| Motamedi, M | 1 |
| Allert, S | 1 |
| Bell, KT | 1 |
| Salmon, CM | 1 |
| Purdy, BA | 1 |
| Canfield, SG | 1 |
| Bao, L | 1 |
| Zhang, Z | 1 |
| Li, X | 1 |
| Zhang, L | 1 |
| Tian, H | 1 |
| Zhao, M | 1 |
| Ye, T | 1 |
| Cui, W | 1 |
| Kato, H | 1 |
| Kanno, S | 1 |
| Ohtaki, J | 1 |
| Fukuta, M | 1 |
| Nakamura, Y | 1 |
| Aoki, Y | 1 |
| Zhao, S | 1 |
| Wang, J | 1 |
| Wen, C | 1 |
| Zhang, Y | 2 |
| Freeman, SC | 1 |
| Heath, MS | 1 |
| Neill, B | 1 |
| Morris, C | 1 |
| Lucero, OM | 1 |
| Yu, W | 1 |
| Bar, A | 1 |
| Leitenberger, JJ | 1 |
| Eising, HP | 1 |
| Punt, MC | 2 |
| Leemans, JC | 1 |
| Bongers, MY | 1 |
| Onyeze, CI | 1 |
| Badmus, TA | 1 |
| Salako, AA | 1 |
| Owojuyigbe, AM | 1 |
| Jeje, EA | 1 |
| Olasehinde, OO | 1 |
| Adeyemo, A | 1 |
| David, RA | 1 |
| Eisinger, EC | 1 |
| Forsythe, L | 1 |
| Joergensen, S | 1 |
| Murali, S | 1 |
| Cannon, JW | 2 |
| Reilly, PM | 1 |
| Kim, PK | 1 |
| Kaufman, EJ | 1 |
| Wilhelm, K | 1 |
| Toy, J | 2 |
| Jakowenko, ND | 1 |
| Seelhammer, TG | 1 |
| Nabzdyk, CGS | 1 |
| Macielak, RJ | 1 |
| Nei, SD | 1 |
| Kalvelage, EL | 1 |
| Wieruszewski, PM | 1 |
| Ali-Mohamad, N | 1 |
| Cau, MF | 1 |
| Khavari, A | 1 |
| Ringgold, K | 1 |
| Naveed, A | 1 |
| Sherwood, C | 1 |
| Peng, N | 1 |
| Zhang Gao, H | 1 |
| Semple, H | 1 |
| Peng, H | 1 |
| Tenn, C | 1 |
| Baylis, JR | 4 |
| Beckett, A | 1 |
| White, NJ | 3 |
| Kastrup, CJ | 4 |
| Singleton, L | 1 |
| Kennedy, C | 1 |
| Philip, B | 1 |
| Navaei, A | 1 |
| Bhar, S | 1 |
| Ankola, A | 1 |
| Ontaneda, A | 1 |
| Spruce, MW | 1 |
| Beyer, CA | 1 |
| Caples, CM | 1 |
| DeSoucy, ES | 1 |
| Kashtan, HW | 1 |
| Hoareau, GL | 1 |
| Grayson, JK | 1 |
| Johnson, MA | 1 |
| Choi, JY | 1 |
| Kim, JH | 1 |
| Han, HJ | 1 |
| Shah Jahan, MY | 1 |
| Shamila, MA | 1 |
| Nurul Azlean, N | 1 |
| Mohd Amin, M | 1 |
| Anandakumar, K | 1 |
| Ahmad Ibrahim, KB | 1 |
| Ahmad Tajuddin, MN | 1 |
| Aik Howe, T | 1 |
| Md Saed, M | 1 |
| Fatahul Laham, M | 1 |
| Ridzuan, MI | 1 |
| Mohd Idzwan, Z | 1 |
| Mohd Khairizam, MY | 1 |
| Mathew, J | 1 |
| Fitzgerald, M | 3 |
| Sabariah Faizah, J | 1 |
| Kiat Kee, G | 1 |
| Walsh, K | 2 |
| O'Keeffe, F | 1 |
| Mitra, B | 5 |
| Salomon, O | 1 |
| Budnik, I | 1 |
| Avishai, E | 1 |
| Tamarin, I | 1 |
| Bashari, D | 1 |
| Dardik, R | 1 |
| Livnat, T | 1 |
| Neeves, KB | 1 |
| Lallemand, MS | 1 |
| Martin, MJ | 2 |
| Wu, X | 2 |
| Benov, A | 2 |
| Darlington, DN | 2 |
| Keesee, JD | 1 |
| Liu, B | 1 |
| McQuilten, Z | 1 |
| Powter, G | 1 |
| Dyer, C | 1 |
| Curnow, E | 1 |
| Wood, EM | 2 |
| Jachetti, A | 1 |
| Massénat, RB | 1 |
| Edema, N | 1 |
| Woolley, SC | 1 |
| Benedetti, G | 1 |
| Van Den Bergh, R | 1 |
| Trelles, M | 1 |
| Dixon, A | 1 |
| Emigh, B | 1 |
| Spitz, K | 1 |
| Teixeira, P | 1 |
| Coopwood, B | 1 |
| Trust, M | 1 |
| Daley, M | 1 |
| Ali, S | 1 |
| Brown, C | 1 |
| Aydelotte, J | 1 |
| Fisher, AD | 1 |
| Carius, BM | 1 |
| April, MD | 2 |
| Naylor, JF | 1 |
| Maddry, JK | 1 |
| Schauer, SG | 1 |
| Forbat, E | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Eberle, ML | 1 |
| Schechter-Perkins, EM | 1 |
| Altawil, Z | 1 |
| Bocci, MG | 1 |
| Nardi, G | 2 |
| Veronesi, G | 1 |
| Rondinelli, MB | 1 |
| Palma, A | 1 |
| Fiore, V | 1 |
| De Candia, E | 1 |
| Bianchi, M | 1 |
| Maresca, M | 1 |
| Barelli, R | 1 |
| Tersali, A | 1 |
| Dell'Anna, AM | 1 |
| De Pascale, G | 1 |
| Cutuli, SL | 1 |
| Mercurio, G | 1 |
| Caricato, A | 1 |
| Grieco, DL | 1 |
| Antonelli, M | 1 |
| Cingolani, E | 1 |
| Faraoni, D | 2 |
| Lier, H | 2 |
| Shander, A | 2 |
| Simon, RP | 1 |
| Oromendia, C | 1 |
| Sanso, LM | 1 |
| Ramos, LG | 1 |
| Rajwani, K | 1 |
| Marlière, C | 1 |
| Maindiaux, L | 1 |
| Lambert, C | 1 |
| Hermans, C | 1 |
| Godier, A | 5 |
| Roquet, F | 1 |
| Hamada, SR | 1 |
| Arahata, M | 1 |
| Takamatsu, H | 1 |
| Morishita, E | 1 |
| Kadohira, Y | 1 |
| Yamada, S | 1 |
| Ichinose, A | 1 |
| Asakura, H | 1 |
| Viejo-Moreno, R | 1 |
| Puncel, CB | 1 |
| Carriedo Scher, C | 1 |
| Heidet, M | 1 |
| Fenger-Eriksen, C | 1 |
| Lindholm, AD | 1 |
| Krogh, L | 1 |
| Hell, T | 1 |
| Berger, M | 1 |
| Hermann, M | 1 |
| Fries, D | 4 |
| Juul, N | 1 |
| Rasmussen, M | 1 |
| Hvas, AM | 1 |
| Thomson, JM | 1 |
| Huynh, HH | 1 |
| Drone, HM | 1 |
| Jantzer, JL | 1 |
| Tsai, AK | 1 |
| Jancik, JT | 1 |
| Raitt, J | 1 |
| Lewis, P | 1 |
| Dearman, J | 1 |
| Poole, K | 1 |
| Surendra Kumar, D | 1 |
| Erramouspe, PJ | 1 |
| García-Pintos, MF | 1 |
| Benipal, S | 1 |
| Santamarina, JL | 1 |
| Shawagga, HG | 1 |
| Vo, LL | 1 |
| Galante, JM | 2 |
| Nishijima, D | 1 |
| Gayet-Ageron, A | 1 |
| Ker, K | 6 |
| Coats, TJ | 4 |
| Peng, HT | 1 |
| Gao, HL | 1 |
| Zhang, JC | 1 |
| He, Y | 1 |
| Zhai, WT | 1 |
| Xiao, LB | 1 |
| Shi, Q | 1 |
| July, J | 1 |
| Pranata, R | 1 |
| Hamele, M | 1 |
| Aden, JK | 2 |
| Fernau, J | 1 |
| Draxler, DF | 2 |
| Medcalf, RL | 3 |
| Barrett, CD | 3 |
| Yaffe, MB | 3 |
| Briggs, GD | 1 |
| Balogh, ZJ | 2 |
| King, KL | 1 |
| Merideth, MA | 1 |
| Introne, WJ | 1 |
| Wang, JA | 1 |
| O'Brien, KJ | 1 |
| Huizing, M | 1 |
| Gochuico, BR | 1 |
| Wu, TB | 1 |
| Orfeo, T | 1 |
| Sumislawski, JJ | 1 |
| Cohen, MJ | 4 |
| Petzold, LR | 1 |
| Mendieta-Eckert, M | 1 |
| Rodero Ortiz, R | 1 |
| Rincón Piñeiro, R | 1 |
| Landa Gundin, N | 1 |
| Lasry, A | 1 |
| Gil, Y | 1 |
| Balayla, J | 1 |
| Kolin, DA | 1 |
| Bello, A | 1 |
| Bates, I | 1 |
| de Faria, JL | 1 |
| da Silva Brito, J | 1 |
| Costa E Silva, LT | 1 |
| Kilesse, CTSM | 1 |
| de Souza, NB | 1 |
| Pereira, CU | 1 |
| Figueiredo, EG | 1 |
| Rabelo, NN | 1 |
| Wirtz, MR | 2 |
| Schalkers, DV | 1 |
| Goslings, JC | 3 |
| Juffermans, NP | 3 |
| Thies, KC | 1 |
| Truhlář, A | 1 |
| Keene, D | 1 |
| Hinkelbein, J | 1 |
| Rützler, K | 1 |
| Brazzi, L | 1 |
| Vivien, B | 2 |
| Choi-Toche, LD | 1 |
| Furyk, J | 1 |
| Banks, C | 1 |
| Picetti, R | 1 |
| Frimley, L | 1 |
| Jarman, H | 1 |
| McGuinness, W | 1 |
| Moss, P | 1 |
| Pott, J | 1 |
| Tai, N | 1 |
| Thayne, A | 1 |
| Gilliam, C | 1 |
| Pynn, H | 1 |
| Turnbull, IR | 1 |
| Fuchs, A | 1 |
| Reese, S | 1 |
| Coleoglou Centeno, AA | 1 |
| Horn, CB | 1 |
| Baty, J | 1 |
| Meledeo, MA | 1 |
| Bochicchio, GV | 2 |
| Schelde, AB | 1 |
| Petersen, J | 1 |
| Jensen, TB | 1 |
| Gromov, K | 1 |
| Overgaard, S | 1 |
| Olesen, JB | 1 |
| Jimenez-Solem, E | 1 |
| Hanley, C | 1 |
| Callum, J | 2 |
| Jerath, A | 2 |
| Meneses, E | 1 |
| Boneva, D | 1 |
| McKenney, M | 1 |
| Elkbuli, A | 1 |
| Hayward, CPM | 1 |
| Tasneem, S | 1 |
| Rivard, GE | 2 |
| Yocum, AD | 1 |
| Bacharach, D | 1 |
| Simon, EL | 1 |
| Cornelissen, LL | 1 |
| Caram-Deelder, C | 1 |
| Meier, RT | 1 |
| Zwaginga, JJ | 1 |
| Evers, D | 1 |
| Vigneshwar, N | 1 |
| Dhara, S | 1 |
| Chandler, J | 2 |
| Chapman, MP | 3 |
| Franz, ND | 1 |
| Machado-Aranda, D | 1 |
| Miller, JT | 1 |
| Farina, N | 1 |
| Černý, V | 1 |
| Agostini, V | 1 |
| Leal-Noval, SR | 2 |
| Nardai, G | 1 |
| Östlund, A | 1 |
| Schöchl, H | 4 |
| Darioli, V | 1 |
| Morales-Cané, I | 1 |
| Valverde-León, MDR | 1 |
| Rodríguez-Borrego, MA | 1 |
| López Soto, PJ | 1 |
| Wang, H | 1 |
| Long, X | 1 |
| Xu, Z | 1 |
| Chen, X | 1 |
| Li, M | 1 |
| He, T | 1 |
| Liu, L | 1 |
| Liu, X | 1 |
| Almuwallad, A | 1 |
| Ross, J | 3 |
| Perkins, Z | 1 |
| Pekrul, I | 1 |
| Schachtner, T | 1 |
| Zwißler, B | 1 |
| Möhnle, P | 1 |
| Burton, H | 1 |
| Mossadegh, S | 1 |
| McCarthy, R | 1 |
| Kozhimala, M | 1 |
| Asselin, N | 1 |
| Zonfrillo, MR | 1 |
| Wong, D | 2 |
| Su, G | 1 |
| Mabasa, VH | 1 |
| Tallon, JM | 2 |
| Acker, J | 1 |
| Wan, W | 1 |
| Jenneson, S | 1 |
| Wu, WC | 1 |
| Tarng, DC | 1 |
| Yang, CY | 1 |
| Waning, ML | 1 |
| Mauser-Bunschoten, EP | 1 |
| Kruip, MJHA | 1 |
| Eikenboom, J | 1 |
| Nieuwenhuizen, L | 1 |
| Makelburg, ABU | 1 |
| Driessens, MHE | 1 |
| Duvekot, JJ | 1 |
| Peters, M | 1 |
| Middeldorp, JM | 1 |
| Bloemenkamp, KWM | 1 |
| Schutgens, REG | 1 |
| Lely, AT | 1 |
| van Galen, KPM | 1 |
| Stein-Wit, MA | 1 |
| Meijer, K | 1 |
| Ockerman, A | 1 |
| Miclotte, I | 1 |
| Vanhaverbeke, M | 1 |
| Vanassche, T | 1 |
| Belmans, A | 1 |
| Vanhove, J | 1 |
| Meyns, J | 1 |
| Nadjmi, N | 1 |
| Van Hemelen, G | 1 |
| Winderickx, P | 1 |
| Jacobs, R | 1 |
| Politis, C | 1 |
| Verhamme, P | 1 |
| Desborough, MJR | 2 |
| Obaji, S | 1 |
| Lowe, GC | 1 |
| Thomas, W | 1 |
| Wong, J | 1 |
| George, RB | 1 |
| Hanley, CM | 1 |
| Saliba, C | 1 |
| Yee, DA | 1 |
| Moreno-Drada, JA | 1 |
| Abreu, LG | 1 |
| Lino, PA | 1 |
| Parreiras Martins, MA | 1 |
| Pordeus, IA | 1 |
| Nogueira Guimarães de Abreu, MH | 1 |
| Cabanilla, MG | 1 |
| Villalobos, NE | 1 |
| Ahmed, S | 1 |
| Li, SR | 1 |
| Guyette, F | 1 |
| Brown, J | 1 |
| Zenati, M | 1 |
| Reitz, KM | 1 |
| Eastridge, B | 1 |
| Zuckerbraun, BS | 1 |
| Duque, P | 1 |
| Gonzalez-Zarco, L | 1 |
| Martínez, R | 1 |
| Gago, S | 1 |
| Varela, JA | 1 |
| Erwin, DZ | 1 |
| Heichel, PD | 1 |
| Wright, LM | 1 |
| Goldstein, NA | 1 |
| McEvoy, TP | 1 |
| Earley, MA | 1 |
| Meyer, AD | 1 |
| Garcés Garcés, FJ | 1 |
| Corral Torres, E | 1 |
| Simoes da Silva Pereira, EJ | 1 |
| Hernández-Tejedor, A | 1 |
| Graffeo, CS | 1 |
| Carlstrom, LP | 1 |
| Cohen, SC | 1 |
| Perry, A | 1 |
| Choby, G | 1 |
| Van Gompel, JJ | 1 |
| Linakis, SW | 1 |
| Stanley, RM | 3 |
| Hewes, H | 1 |
| Myers, S | 1 |
| Bobinski, M | 2 |
| Ghetti, S | 2 |
| Schalick, WO | 2 |
| Rampotas, A | 1 |
| Watson, E | 1 |
| Burton, K | 1 |
| Hill, QA | 1 |
| Pavord, S | 1 |
| Madden, A | 1 |
| Hulme, P | 1 |
| Pabinger, I | 1 |
| Streif, W | 1 |
| Toller, W | 1 |
| La Rochelle, P | 1 |
| Gu, ZT | 1 |
| Huang, QB | 1 |
| Yang, H | 1 |
| Huebner, BR | 1 |
| Dorlac, WC | 2 |
| Cribari, C | 1 |
| Sharma, R | 1 |
| Letson, HL | 1 |
| Dobson, GP | 1 |
| Neeki, MM | 1 |
| Dong, F | 1 |
| Vaezazizi, R | 1 |
| Powell, J | 2 |
| Jabourian, N | 1 |
| Jabourian, A | 1 |
| Vara, R | 1 |
| Seiler, K | 1 |
| Pennington, TW | 1 |
| Yoshida-McMath, C | 1 |
| Kissel, S | 1 |
| Schulz-Costello, K | 1 |
| Mistry, J | 1 |
| Surrusco, MS | 1 |
| O'Bosky, KR | 1 |
| Van Stralen, D | 1 |
| Ludi, D | 1 |
| Sporer, K | 1 |
| Benson, P | 1 |
| Kwong, E | 1 |
| Pitts, R | 1 |
| Culhane, JT | 1 |
| Borger, R | 1 |
| Xi, C | 1 |
| Zhu, L | 1 |
| Zhuang, Y | 1 |
| Wang, S | 1 |
| Sun, G | 1 |
| Wang, D | 1 |
| Geist, MJP | 1 |
| Kessler, J | 1 |
| Frankenhauser, S | 1 |
| Bardenheuer, HJ | 1 |
| Mayer, B | 1 |
| Salama, A | 1 |
| Johnston, LR | 1 |
| Rodriguez, CJ | 2 |
| Elster, EA | 1 |
| Bradley, MJ | 1 |
| Moore, KT | 1 |
| Schneider, D | 1 |
| Marcsisin, VS | 1 |
| Ariyawansa, J | 1 |
| Weitz, JI | 1 |
| Dries, DJ | 1 |
| Kim, YH | 1 |
| Park, JW | 1 |
| Kim, JS | 1 |
| Seo, DH | 1 |
| Honda, Y | 1 |
| Furugohri, T | 1 |
| Morishima, Y | 1 |
| Butwick, AJ | 1 |
| Deneux-Tharaux, C | 1 |
| Sentilhes, L | 1 |
| Zhou, K | 1 |
| Shakya, H | 1 |
| Luo, Z | 1 |
| Zhou, Z | 1 |
| Pei, F | 2 |
| González-Castro, A | 1 |
| Rodriguez-Borregán, JC | 1 |
| Chicote, E | 1 |
| Escudero, P | 1 |
| Ferrer, D | 1 |
| Kulić, A | 1 |
| Cvetković, Z | 1 |
| Libek, V | 1 |
| Bonhomme, F | 1 |
| Lecompte, T | 1 |
| Samama, CM | 2 |
| Fontana, P | 1 |
| Carroll, ND | 1 |
| Restrepo, CS | 1 |
| Stasik, CN | 1 |
| Olaussen, A | 1 |
| Bade-Boon, J | 1 |
| Fitzgerald, MC | 1 |
| Gilley, M | 1 |
| Beno, S | 2 |
| El-Menyar, A | 1 |
| Sathian, B | 1 |
| Asim, M | 1 |
| Latifi, R | 1 |
| Al-Thani, H | 1 |
| Hildyard, CAT | 1 |
| Ng, M | 1 |
| Perrott, J | 1 |
| Burgess, S | 1 |
| Rostetter, C | 1 |
| Finkenstädt, T | 1 |
| Rücker, M | 1 |
| Lübbers, HT | 1 |
| Khan, M | 1 |
| Jehan, F | 1 |
| Bulger, EM | 1 |
| OʼKeeffe, T | 1 |
| Holcomb, JB | 3 |
| Wade, CE | 1 |
| Schreiber, MA | 2 |
| Lewandowski, B | 1 |
| Wojnar, J | 1 |
| Brodowski, R | 1 |
| Mucha, M | 1 |
| Czenczek-Lewandowska, E | 1 |
| Brzęcka, D | 1 |
| Myers, SP | 1 |
| Kutcher, ME | 1 |
| Rosengart, MR | 1 |
| Peitzman, AB | 1 |
| Chapman, N | 1 |
| VanBuren, J | 1 |
| Hewes, HA | 2 |
| Myers, SR | 1 |
| Adelson, PD | 1 |
| Barnhard, SE | 1 |
| Holmes, JF | 1 |
| Tran, NK | 1 |
| Tzimenatos, LS | 1 |
| Michael Dean, J | 1 |
| Liu, J | 2 |
| Chen, CW | 1 |
| Huang, D | 1 |
| Luo, D | 1 |
| Du, L | 1 |
| Myles, PS | 3 |
| Smith, JA | 3 |
| Kasza, J | 2 |
| Silbert, B | 3 |
| Jayarajah, M | 3 |
| Painter, T | 3 |
| Cooper, DJ | 3 |
| Marasco, S | 3 |
| McNeil, J | 3 |
| Bussières, JS | 3 |
| McGuinness, S | 3 |
| Wallace, S | 3 |
| Forbes, A | 3 |
| Hawkins, RB | 1 |
| Mehaffey, JH | 1 |
| Byrne, K | 2 |
| Fragoso-Iñiguez, M | 1 |
| Kong, YW | 1 |
| Sriram, G | 1 |
| Lim, D | 1 |
| Balvers, K | 2 |
| Baksaas-Aasen, K | 2 |
| van Dieren, S | 2 |
| Gaarder, C | 2 |
| Naess, PA | 1 |
| Stanworth, S | 3 |
| Johansson, PI | 4 |
| Stensballe, J | 4 |
| Labott, JR | 1 |
| Wyles, CC | 1 |
| Houdek, MT | 1 |
| Tollefson, MM | 1 |
| Driscoll, DJ | 1 |
| Shaughnessy, WJ | 1 |
| Sierra, RJ | 1 |
| Tomaszewski, M | 1 |
| Bienz, M | 1 |
| Kherad, O | 1 |
| Restellini, S | 1 |
| Laflèche, T | 1 |
| Barkun, A | 1 |
| Warner, M | 1 |
| Bessissow, T | 1 |
| Guth, C | 1 |
| Vassal, O | 1 |
| Friggeri, A | 1 |
| Wey, PF | 1 |
| Inaba, K | 2 |
| Decullier, E | 1 |
| David, JS | 2 |
| Maniar, RN | 1 |
| Pradhan, P | 1 |
| Bhatnagar, N | 1 |
| Maniar, A | 1 |
| Bidwai, R | 1 |
| Bindal, P | 1 |
| Hansen, KC | 1 |
| Pieracci, FM | 1 |
| Soul, T | 1 |
| Kumpel, C | 1 |
| Pyburn, K | 1 |
| Barrett, K | 1 |
| DeMambro, V | 1 |
| Alexandrov, I | 1 |
| Brandina, I | 1 |
| Harris, M | 1 |
| Thaventhiran, AJ | 1 |
| Davenport, RA | 1 |
| Bridwell, RE | 1 |
| Long, B | 1 |
| Shafiee, M | 1 |
| Heidari, A | 1 |
| Amouzegar, H | 1 |
| Khani, S | 1 |
| Nojavan, F | 1 |
| Lee, MM | 1 |
| St John, AE | 2 |
| Simonson, E | 2 |
| Cau, M | 1 |
| Kazerooni, A | 1 |
| Gusti, V | 1 |
| Statz, ML | 2 |
| Yoon, JSJ | 1 |
| Liggins, RT | 2 |
| Adams, TR | 1 |
| Reeder, JA | 1 |
| Alqassab, F | 1 |
| Gilbert, BW | 1 |
| Boutonnet, M | 1 |
| Osorio Cajes, G | 1 |
| Pasquier, P | 1 |
| Ausset, S | 1 |
| Marsden, MER | 1 |
| Duffield, CAB | 1 |
| Woolley, TGD | 1 |
| Buxton, WP | 1 |
| Steynberg, S | 1 |
| Bagga, R | 1 |
| Tai, NRM | 1 |
| Girish, A | 1 |
| Hickman, DA | 1 |
| Banerjee, A | 1 |
| Luc, N | 1 |
| Ma, Y | 1 |
| Miyazawa, K | 1 |
| Sekhon, UDS | 1 |
| Sun, M | 1 |
| Huang, S | 1 |
| Sen Gupta, A | 1 |
| Trappey, AF | 1 |
| Thompson, KM | 1 |
| Stephenson, JT | 1 |
| Nuno, MA | 1 |
| Meyers, SR | 1 |
| Shakur, H | 13 |
| Coats, T | 7 |
| Hunt, B | 3 |
| Barnetson, L | 1 |
| Cook, L | 1 |
| Kawahara, T | 1 |
| Perel, P | 8 |
| Prieto-Merino, D | 6 |
| Ramos, M | 1 |
| Cairns, J | 2 |
| Guerriero, C | 2 |
| Low, TH | 1 |
| Huang, J | 1 |
| Reid, C | 1 |
| Elliott, M | 1 |
| Clark, JR | 1 |
| Davis, A | 1 |
| Walsh, M | 2 |
| McCarthy, P | 2 |
| Brown, G | 1 |
| Roberts, S | 1 |
| Tran, H | 1 |
| Street, A | 2 |
| Fong, CY | 1 |
| Kemp, W | 1 |
| Susen, S | 1 |
| Li, ZJ | 1 |
| Fu, X | 1 |
| Xing, D | 1 |
| Zhang, HF | 1 |
| Zang, JC | 1 |
| Ma, XL | 1 |
| Ortmann, E | 1 |
| Besser, MW | 1 |
| Klein, AA | 2 |
| Morrison, JJ | 1 |
| Ross, JD | 1 |
| Dubose, JJ | 2 |
| Jansen, JO | 1 |
| Midwinter, MJ | 1 |
| Rasmussen, TE | 1 |
| Wells, JC | 1 |
| Stevermer, JJ | 1 |
| Napolitano, LM | 1 |
| Cotton, BA | 3 |
| Maung, AA | 1 |
| Kaplan, LJ | 1 |
| Reade, MC | 4 |
| Pitt, V | 1 |
| Gruen, RL | 7 |
| Bozzette, A | 1 |
| Aeron-Thomas, A | 1 |
| Karaman, R | 1 |
| Ghareeb, H | 1 |
| Dajani, KK | 1 |
| Scrano, L | 1 |
| Hallak, H | 1 |
| Abu-Lafi, S | 1 |
| Mecca, G | 1 |
| Bufo, SA | 1 |
| Beecher, D | 1 |
| Alvarado, JC | 1 |
| Dewan, Y | 3 |
| Elsayed, HF | 1 |
| Gogichaishvili, T | 2 |
| Gupta, S | 2 |
| Hunt, BJ | 8 |
| Iribhogbe, P | 2 |
| Izurieta, M | 2 |
| Khamis, H | 2 |
| Komolafe, EO | 1 |
| Mantilla, JH | 1 |
| Miranda, J | 2 |
| Uribe, CH | 1 |
| Olaomi, O | 2 |
| Olldashi, F | 2 |
| Ramana, PV | 2 |
| Ravi, RR | 2 |
| Wardrop, D | 1 |
| Trivella, M | 2 |
| Murphy, MF | 2 |
| Goodloe, JM | 2 |
| Howerton, DS | 1 |
| McAnallen, D | 1 |
| Reed, H | 1 |
| Jacobs, IG | 2 |
| Engelbrecht, S | 1 |
| Cole-Sinclair, MF | 1 |
| Meurer, WJ | 1 |
| Lipsky, AM | 1 |
| Abramovich, A | 2 |
| Nadler, R | 2 |
| Feinstein, U | 1 |
| Shaked, G | 1 |
| Kreiss, Y | 1 |
| Glassberg, E | 2 |
| Harvey, V | 1 |
| Perrone, J | 1 |
| Kim, P | 1 |
| Wright, C | 1 |
| He, S | 2 |
| Johnsson, H | 2 |
| Zabczyk, M | 2 |
| Hultenby, K | 2 |
| Wallén, H | 1 |
| Blombäck, M | 3 |
| Porta, CR | 1 |
| Nelson, D | 1 |
| McVay, D | 1 |
| Salgar, S | 1 |
| Eckert, M | 1 |
| Izenberg, S | 1 |
| Van Der Linden, P | 1 |
| Schlimp, CJ | 2 |
| Livingstone, C | 1 |
| Aoki, M | 1 |
| Goto, Y | 1 |
| Ogawa, S | 1 |
| Baba, H | 1 |
| Okawa, Y | 1 |
| Pham, HP | 1 |
| Shaz, BH | 1 |
| Schofield, N | 1 |
| Sugavanam, A | 1 |
| Thompson, K | 1 |
| Mallett, SV | 1 |
| Zamani, A | 2 |
| Jarman, J | 1 |
| Brier, A | 1 |
| Mazur, S | 1 |
| Cameron, PA | 2 |
| Bernard, S | 1 |
| Burns, B | 1 |
| Smith, A | 1 |
| Rashford, S | 1 |
| Smith, K | 1 |
| Schlitter, MC | 1 |
| Rühl, H | 2 |
| Thiesler, T | 1 |
| Penner, AH | 1 |
| Berens, C | 1 |
| Wolf, D | 1 |
| Mayer, K | 1 |
| Nikkhah, D | 1 |
| Dheansa, B | 1 |
| Clayton, T | 1 |
| Altman, DG | 1 |
| Croft, P | 1 |
| Douglas, I | 1 |
| Hemingway, H | 1 |
| Hingorani, A | 1 |
| Morley, KI | 1 |
| Riley, R | 1 |
| Timmis, A | 1 |
| Van der Windt, D | 1 |
| Breau, RH | 1 |
| Kokolo, MB | 1 |
| Punjani, N | 1 |
| Cagiannos, I | 1 |
| Beck, A | 1 |
| Niznick, N | 1 |
| Buenaventura, C | 1 |
| Cowan, J | 1 |
| Knoll, G | 1 |
| Momoli, F | 1 |
| Morash, C | 1 |
| Ruzicka, M | 1 |
| Schachkina, S | 1 |
| Tinmouth, A | 2 |
| Xie, HY | 1 |
| Fergusson, DA | 1 |
| Gaillard, S | 1 |
| Dupuis-Girod, S | 1 |
| Boutitie, F | 1 |
| Rivière, S | 1 |
| Morinière, S | 1 |
| Hatron, PY | 1 |
| Manfredi, G | 1 |
| Kaminsky, P | 1 |
| Capitaine, AL | 1 |
| Roy, P | 1 |
| Gueyffier, F | 1 |
| Plauchu, H | 1 |
| Ackery, AD | 1 |
| Rizoli, S | 3 |
| Ackery, A | 2 |
| Masotti, L | 1 |
| Lorenzini, G | 1 |
| Seravalle, C | 1 |
| Panigada, G | 1 |
| Landini, G | 1 |
| Cappelli, R | 1 |
| Schulman, S | 2 |
| Gendler, S | 1 |
| Strugo, R | 1 |
| Franchini, M | 1 |
| Mannucci, PM | 4 |
| Schwameis, M | 1 |
| Thaler, J | 1 |
| Schober, A | 1 |
| Schörgenhofer, C | 1 |
| Kulinna-Cosentini, C | 1 |
| Laggner, A | 1 |
| Röggla, M | 1 |
| Jilma, B | 1 |
| Bogert, JN | 1 |
| Harvin, JA | 1 |
| Willett, K | 2 |
| Bailey, CR | 1 |
| Royston, D | 1 |
| Voelckel, W | 1 |
| Manno, D | 1 |
| Tengborn, L | 1 |
| Berntorp, E | 1 |
| Sculco, PK | 1 |
| Pagnano, MW | 1 |
| Friesecke, S | 1 |
| Stecher, SS | 1 |
| Greinacher, A | 1 |
| Madershahian, N | 1 |
| Scherner, M | 1 |
| Pfister, R | 1 |
| Rudolph, T | 1 |
| Deppe, AC | 1 |
| Slottosch, I | 1 |
| Kuhn, E | 1 |
| Choi, YH | 1 |
| Wahlers, T | 1 |
| Pearse, BL | 1 |
| Smith, I | 1 |
| Faulke, D | 1 |
| Wall, D | 1 |
| Fraser, JF | 1 |
| Ryan, EG | 1 |
| Drake, L | 1 |
| Rapchuk, IL | 1 |
| Tesar, P | 1 |
| Ziegenfuss, M | 1 |
| Fung, YL | 1 |
| Schröder, L | 1 |
| Pötzsch, B | 1 |
| Gembruch, U | 1 |
| Merz, WM | 1 |
| Allard, S | 1 |
| Keeling, D | 1 |
| Norfolk, D | 1 |
| Pendry, K | 1 |
| Etxaniz, A | 1 |
| Pita, E | 1 |
| Oh, S | 1 |
| Peters, JI | 1 |
| Folch, E | 1 |
| Muñoz Gómez, M | 1 |
| Bisbe Vives, E | 1 |
| Basora Macaya, M | 1 |
| García Erce, JA | 1 |
| Gómez Luque, A | 1 |
| Colomina, MJ | 1 |
| Comin Colet, J | 1 |
| Contreras Barbeta, E | 1 |
| Cuenca Espiérrez, J | 1 |
| Garcia de Lorenzo Y Mateos, A | 1 |
| Gomollón García, F | 1 |
| Izuel Ramí, M | 1 |
| Moral García, MV | 1 |
| Montoro Ronsano, JB | 1 |
| Páramo Fernández, JA | 1 |
| Pereira Saavedra, A | 1 |
| Quintana Diaz, M | 1 |
| Remacha Sevilla, Á | 1 |
| Salinas Argente, R | 1 |
| Sánchez Pérez, C | 1 |
| Tirado Anglés, G | 1 |
| Torrabadella de Reinoso, P | 1 |
| Gerecht, R | 1 |
| Heier, HE | 1 |
| Badloe, J | 1 |
| Bohonek, M | 1 |
| Cap, A | 1 |
| Doughty, H | 1 |
| Korsak, J | 1 |
| Medby, C | 1 |
| Pfaff, RM | 1 |
| Rentas, FJ | 1 |
| Sailliol, A | 1 |
| Schilha, M | 1 |
| Söderström, T | 1 |
| Paudyal, P | 1 |
| Smith, J | 1 |
| South, A | 1 |
| Higginson, I | 1 |
| Reuben, A | 1 |
| Shaffee, J | 1 |
| Logan, S | 1 |
| Kluj, P | 1 |
| Aleksandrowicz, D | 1 |
| Machała, W | 1 |
| Gaszyński, T | 1 |
| Thurston, B | 1 |
| Chowdhury, S | 1 |
| Edu, S | 1 |
| Nicol, AJ | 1 |
| Navsaria, PH | 1 |
| Wood, B | 1 |
| Sholzberg, M | 1 |
| Butler, FK | 1 |
| Blackbourne, LH | 2 |
| Gross, K | 1 |
| Panteli, M | 1 |
| Pountos, I | 1 |
| Giannoudis, PV | 1 |
| Sondeen, JL | 1 |
| Hanson, MA | 1 |
| Prince, MD | 1 |
| de Guzman, R | 1 |
| Polykratis, IA | 1 |
| Dubick, MA | 2 |
| Gaines-Dillard, N | 1 |
| Bartley, MK | 1 |
| Rosini, JM | 1 |
| Sharfman, ZT | 2 |
| Campbell, JC | 2 |
| Mirocha, JM | 1 |
| Spitzer, AI | 2 |
| Appelmann, I | 1 |
| Kreher, S | 1 |
| Parmentier, S | 1 |
| Wolf, HH | 1 |
| Bisping, G | 1 |
| Kirschner, M | 1 |
| Bergmann, F | 1 |
| Schilling, K | 1 |
| Brümmendorf, TH | 1 |
| Petrides, PE | 1 |
| Tiede, A | 1 |
| Matzdorff, A | 1 |
| Griesshammer, M | 1 |
| Riess, H | 1 |
| Koschmieder, S | 1 |
| Desborough, M | 2 |
| Hopewell, S | 2 |
| Stevens, LM | 1 |
| Noiseux, N | 1 |
| Prieto, I | 1 |
| Hardy, JF | 1 |
| Lim, EB | 1 |
| Chien, D | 1 |
| Stern, SA | 1 |
| Chan, KY | 1 |
| Jawa, RS | 1 |
| Singer, A | 1 |
| Mccormack, JE | 1 |
| Huang, EC | 1 |
| Rutigliano, DN | 1 |
| Vosswinkel, JA | 1 |
| Sagheer, S | 1 |
| Atkins, A | 1 |
| McRae, S | 1 |
| Fox, A | 1 |
| Windyga, J | 1 |
| Stefanska-Windyga, E | 1 |
| Odnoczko, E | 1 |
| Baran, B | 1 |
| Czubak, G | 1 |
| Eghbali, A | 1 |
| Melikof, L | 1 |
| Taherahmadi, H | 1 |
| Bagheri, B | 1 |
| Bonilla, GA | 1 |
| Gutierrez, C | 1 |
| Bautista, MP | 1 |
| Llinas, AM | 1 |
| Monsalvo, DJ | 1 |
| Daniel, Y | 1 |
| Habas, S | 1 |
| Malan, L | 1 |
| Escarment, J | 1 |
| Peyrefitte, S | 1 |
| Martin, DT | 1 |
| Gries, H | 1 |
| Esmonde, N | 1 |
| Diggs, B | 1 |
| Koh, J | 1 |
| Selden, NR | 1 |
| Schreiber, M | 1 |
| Kuang, AA | 1 |
| Schwacha, MG | 1 |
| Evaniew, N | 1 |
| Bhandari, M | 1 |
| Kunze-Szikszay, N | 1 |
| Krack, LA | 1 |
| Wildenauer, P | 1 |
| Wand, S | 1 |
| Heyne, T | 1 |
| Walliser, K | 1 |
| Spering, C | 1 |
| Bauer, M | 1 |
| Quintel, M | 1 |
| Roessler, M | 1 |
| Studer, NM | 1 |
| Yassin, AH | 1 |
| Keen, DE | 1 |
| Wong, H | 1 |
| Chan, MT | 1 |
| Hadjinicolaou, AV | 1 |
| Chaimani, A | 1 |
| Vyas, P | 1 |
| Tay, J | 1 |
| Allan, D | 1 |
| Beattie, S | 1 |
| Bredeson, C | 1 |
| Fergusson, D | 1 |
| Maze, D | 1 |
| Sabloff, M | 1 |
| Thavorn, K | 1 |
| Sánchez-Luceros, A | 1 |
| Woods, AI | 1 |
| Bermejo, E | 1 |
| Shukla, S | 1 |
| Acharya, S | 1 |
| Lavin, M | 2 |
| Rydz, N | 1 |
| Othman, M | 1 |
| Ramirez, RJ | 1 |
| O'Donnell, JS | 1 |
| Steinmetz, J | 1 |
| Eaglestone, S | 1 |
| Ostrowski, SR | 1 |
| Edwards, P | 1 |
| Prieto, D | 1 |
| Joshi, M | 1 |
| Mahmood, A | 1 |
| Calmette, L | 1 |
| Martin, AC | 1 |
| Le Bonniec, B | 1 |
| Zlotnik, D | 1 |
| Gouin-Thibault, I | 1 |
| Bachelot-Loza, C | 1 |
| Gaussem, P | 1 |
| Xie, J | 1 |
| Ma, J | 1 |
| Huang, Q | 1 |
| Yue, C | 1 |
| Zickenrott, V | 1 |
| Greb, I | 1 |
| Henkelmann, A | 1 |
| Balzer, F | 1 |
| Casu, S | 1 |
| Kaufner, L | 1 |
| von Heymann, C | 1 |
| Zacharowski, K | 1 |
| Weber, CF | 1 |
| Khan, MA | 1 |
| Raja, AS | 1 |
| Como, JJ | 1 |
| Fox, EE | 1 |
| Duchesne, JC | 1 |
| Shiraishi, A | 1 |
| Kushimoto, S | 1 |
| Otomo, Y | 1 |
| Matsui, H | 1 |
| Hagiwara, A | 1 |
| Murata, K | 1 |
| Bodrozic, JN | 1 |
| Miljic, PS | 1 |
| Lekovic, DR | 1 |
| Petronijevic, MA | 1 |
| Antic, DA | 1 |
| Mitrovic, MM | 1 |
| Petronijevic-Vrzic, SM | 1 |
| Djunic, IS | 1 |
| Ghosh, K | 2 |
| Wiseman, DM | 1 |
| Meidler, R | 1 |
| Lyahovetsky, Y | 1 |
| Kurman, E | 1 |
| Horn, S | 1 |
| Nur, I | 1 |
| De Bourg, L | 1 |
| Redfern, S | 1 |
| Gupte, G | 1 |
| Brenni, M | 1 |
| Worn, M | 1 |
| Brüesch, M | 1 |
| Spahn, DR | 1 |
| Ganter, MT | 1 |
| Yilmaz, D | 1 |
| Akin, M | 1 |
| Ay, Y | 1 |
| Balkan, C | 1 |
| Celik, A | 1 |
| Ergün, O | 1 |
| Kavakli, K | 1 |
| Troccola, A | 1 |
| Maruccia, M | 1 |
| Zampieri, AE | 1 |
| Dessy, LA | 1 |
| Bautista, R | 1 |
| Caballero, J | 1 |
| El-Sayed, H | 1 |
| Herrera, J | 1 |
| Komolafe, E | 1 |
| Marrero, MA | 1 |
| Mejía-Mantilla, J | 1 |
| Morales, C | 2 |
| Peto, R | 1 |
| Yutthakasemsunt, S | 1 |
| Hewson, I | 1 |
| Makhmalbaf, P | 1 |
| Casati, V | 1 |
| Romano, A | 1 |
| Novelli, E | 1 |
| D'Angelo, A | 1 |
| Yeguiayan, JM | 2 |
| Rosencher, N | 2 |
| Freysz, M | 1 |
| Bajaj, MS | 1 |
| Ogueli, GI | 1 |
| Kumar, Y | 1 |
| Vadivel, K | 1 |
| Lawson, G | 1 |
| Shanker, S | 1 |
| Schmidt, AE | 1 |
| Bajaj, SP | 1 |
| Peitsidis, P | 1 |
| Kadir, RA | 1 |
| Chalmers, I | 1 |
| Nicholl, J | 1 |
| Afolabi, A | 1 |
| Gando, S | 1 |
| Woolley, T | 1 |
| Redman, T | 1 |
| Schiessling, S | 1 |
| Diener, MK | 1 |
| Post, S | 1 |
| Büchler, MW | 1 |
| Seiler, CM | 1 |
| Wikkelsø, AJ | 1 |
| Afshari, A | 1 |
| Sydenham, E | 1 |
| Williams-Johnson, JA | 1 |
| McDonald, AH | 1 |
| Strachan, GG | 1 |
| Williams, EW | 1 |
| Nelson, R | 1 |
| Ting, JY | 1 |
| Baer, DG | 1 |
| Orman, JA | 1 |
| Aden, J | 1 |
| Ryan, K | 1 |
| Midura-Nowaczek, K | 1 |
| Kaczyńska, J | 1 |
| Bruzgo, I | 1 |
| Markowska, A | 1 |
| Drozdowska, D | 1 |
| Zhang, H | 1 |
| Chen, J | 1 |
| Chen, F | 1 |
| Que, W | 1 |
| Culligan, WB | 1 |
| Tien, HC | 1 |
| Kmietowicz, Z | 1 |
| Blavignac, J | 1 |
| Bunimov, N | 1 |
| Hayward, CP | 1 |
| Weightman, WM | 1 |
| Gibbs, NM | 1 |
| Lei, J | 1 |
| Gao, GY | 1 |
| Jiang, JY | 1 |
| McCormack, PL | 1 |
| Sorensen, B | 1 |
| Levi, M | 1 |
| Luz, Ld | 1 |
| Sankarankutty, A | 1 |
| Passos, E | 1 |
| Fraga, GP | 1 |
| Nascimento, B | 1 |
| Al-Shahi Salman, R | 1 |
| Brum, MR | 1 |
| Miura, MS | 1 |
| Castro, SF | 1 |
| Machado, GM | 1 |
| Lima, LH | 1 |
| Lubianca Neto, JF | 1 |
| Noble, S | 1 |
| Chitnis, J | 1 |
| Hilbert, P | 1 |
| Hofmann, GO | 1 |
| zur Nieden, K | 1 |
| Teichmann, J | 1 |
| Jakubetz, J | 1 |
| Stuttmann, R | 1 |
| Lecky, F | 1 |
| Borhany, M | 1 |
| Fatima, H | 1 |
| Naz, A | 1 |
| Patel, H | 1 |
| Shamsi, T | 1 |
| Langille, MA | 1 |
| Chiarella, A | 1 |
| Côté, DW | 1 |
| Mulholland, G | 1 |
| Sowerby, LJ | 1 |
| Dziegielewski, PT | 1 |
| Wright, ED | 1 |
| Li, D | 1 |
| Li, P | 1 |
| Zang, J | 1 |
| Weiskopf, RB | 1 |
| Bebarta, V | 1 |
| Butler, F | 1 |
| Cestero, RF | 1 |
| Chaudry, IH | 1 |
| Deal, V | 1 |
| Gerhardt, RT | 1 |
| Given, MB | 1 |
| Hansen, DR | 1 |
| Hoots, WK | 1 |
| Klein, HG | 1 |
| Macdonald, VW | 1 |
| Mattox, KL | 1 |
| Michael, RA | 1 |
| Mogford, J | 1 |
| Montcalm-Smith, EA | 1 |
| Niemeyer, DM | 1 |
| Prusaczyk, WK | 1 |
| Rappold, JF | 2 |
| Rassmussen, T | 1 |
| Rentas, F | 1 |
| Thompson, C | 1 |
| Tucker, LD | 1 |
| Georgiou, C | 1 |
| Neofytou, K | 1 |
| Demetriades, D | 1 |
| Cao, H | 1 |
| Gumbert, S | 1 |
| Taparia, M | 1 |
| Cordingley, FT | 1 |
| Leahy, MF | 1 |
| Hanss, MM | 1 |
| Farcis, M | 1 |
| Ffrench, PO | 1 |
| de Mazancourt, P | 1 |
| Dechavanne, M | 1 |
| Hui, AC | 1 |
| Wong, TY | 1 |
| Chow, KM | 1 |
| Szeto, CC | 1 |
| Garneti, N | 1 |
| Field, J | 1 |
| González González, G | 1 |
| Rodríguez Agea, E | 1 |
| Ruiz Zafra, V | 1 |
| Drobin, D | 1 |
| Sjostrand, F | 1 |
| Piros, D | 1 |
| Hedin, A | 1 |
| Heinius, G | 1 |
| Hahn, RG | 1 |
| Arango, M | 1 |
| Martínez Rodríguez, E | 1 |
| Mato, M | 1 |
| Otero, J | 1 |
| Ferri, JR | 1 |
| Gonzálvez, A | 1 |
| Torres, LM | 1 |
| Dyer, O | 1 |
| Ryan, KL | 1 |
| Cortez, DS | 1 |
| Dick, EJ | 1 |
| Castaman, G | 1 |
| Rodeghiero, F | 1 |
| Tosetto, A | 1 |
| Cappelletti, A | 1 |
| Baudo, F | 2 |
| Eikenboom, JC | 1 |
| Federici, AB | 2 |
| Lethagen, S | 1 |
| Linari, S | 1 |
| Lusher, J | 1 |
| Nishino, M | 1 |
| Petrini, P | 1 |
| Srivastava, A | 1 |
| Ungerstedt, JS | 1 |
| Alberca, I | 1 |
| Asuero, MS | 1 |
| Bóveda, JL | 1 |
| Carpio, N | 1 |
| Contreras, E | 1 |
| Fernández-Mondéjar, E | 1 |
| Forteza, A | 1 |
| García-Erce, JA | 1 |
| García de Lorenzo, A | 1 |
| Gomar, C | 1 |
| Gómez, A | 1 |
| Llau, JV | 1 |
| López-Fernández, MF | 1 |
| Moral, V | 1 |
| Muñoz, M | 1 |
| Torrabadella, P | 1 |
| Quintana, M | 1 |
| Sánchez, C | 1 |
| Downey, P | 1 |
| Tagle, R | 1 |
| Pereira, J | 1 |
| Mezzano, D | 1 |
| Coetzee, MJ | 1 |
| Hodson, A | 1 |
| Niego, B | 1 |
| Horvath, A | 1 |
| Coughlin, PB | 1 |
| Pugsley, MK | 1 |
| Sabato, AF | 1 |
| Foti, A | 1 |
| De Cosmo, G | 1 |
| Bondoli, A | 1 |
| Prentice, CR | 3 |
| Grundsell, H | 1 |
| Larsson, G | 1 |
| Bekassy, Z | 1 |
| Ottesen, S | 1 |
| Stormorken, H | 1 |
| Hatteland, K | 1 |
| Miller, RA | 1 |
| May, MW | 1 |
| Hendry, WF | 1 |
| Whitfield, HN | 1 |
| Wickham, JE | 1 |
| Yoshioka, A | 1 |
| Kamitsuji, H | 1 |
| Takase, T | 1 |
| Iida, Y | 1 |
| Tsukada, S | 1 |
| Mikami, S | 1 |
| Fukui, H | 1 |
| Smart, CJ | 1 |
| Valsecchi, A | 1 |
| Lijnen, HR | 1 |
| Stassen, JM | 1 |
| Collen, D | 2 |
| Cousin, MT | 1 |
| Boughenou, F | 1 |
| Madi-Jebara, S | 1 |
| Massonnet-Vastel, S | 1 |
| Benmosbah, L | 1 |
| de Bono, DP | 1 |
| More, RS | 1 |
| Coffey, A | 1 |
| Pittmam, J | 1 |
| Halbrook, H | 1 |
| Fehrenbacher, J | 1 |
| Beckman, D | 1 |
| Hormuth, D | 1 |
| Ali, IM | 1 |
| Landymore, RW | 1 |
| Horrow, J | 1 |
| Strong, MD | 2 |
| Van Riper, DF | 1 |
| Lindoff, C | 1 |
| Rybo, G | 1 |
| Astedt, B | 1 |
| Ovrum, E | 1 |
| Am Holen, E | 1 |
| Abdelnoor, M | 1 |
| Oystese, R | 1 |
| Ringdal, ML | 1 |
| Shpilberg, O | 1 |
| Blumenthal, R | 1 |
| Sofer, O | 1 |
| Katz, Y | 1 |
| Chetrit, A | 1 |
| Ramot, B | 1 |
| Eldor, A | 1 |
| Ben-Bassat, I | 1 |
| Katsaros, D | 1 |
| Petricevic, M | 1 |
| Snow, NJ | 1 |
| Woodhall, DD | 1 |
| Van Bergen, R | 1 |
| van der Staak, FH | 1 |
| de Haan, AF | 1 |
| Geven, WB | 1 |
| Festen, C | 1 |
| Vermeij, FH | 1 |
| Hasan, D | 1 |
| Bijvoet, HW | 1 |
| Avezaat, CJ | 1 |
| Sacco, R | 1 |
| Stabile, F | 1 |
| Carpenedo, M | 1 |
| Zingaro, E | 1 |
| Chuansumrit, A | 1 |
| Isarangkura, P | 1 |
| Angchaisuksiri, P | 1 |
| Sriudomporn, N | 1 |
| Tanpowpong, K | 1 |
| Hathirat, P | 1 |
| Jorgensen, LN | 1 |
| Webster, K | 1 |
| Wilde, J | 1 |
| Cattaneo, M | 1 |
| Santagostino, E | 1 |
| Morfini, M | 1 |
| Rocino, A | 1 |
| Scaraggi, FA | 1 |
| Gringeri, A | 1 |
| Mekontso-Dessap, A | 1 |
| Collet, JP | 1 |
| Lebrun-Vignes, B | 1 |
| Soubrié, C | 1 |
| Thomas, D | 1 |
| Montalescot, G | 1 |
| Verstraete, M | 2 |
| Tyberghein, J | 1 |
| De Greef, Y | 1 |
| Daems, L | 1 |
| Van Hoof, A | 1 |
| Bramsen, T | 2 |
| Forrester, JV | 1 |
| Edgar, W | 1 |
| Forbes, CD | 1 |
| Williamson, J | 1 |
| Missotten, L | 1 |
| De Clippeleir, L | 1 |
| Van Tornout, I | 1 |
| Beenders, P | 1 |
| Castelli, G | 1 |
| Vogt, E | 1 |
| Hefnawi, F | 1 |
| Yacout, MM | 1 |
| Hosni, M | 1 |
| El-Sheika, Z | 1 |
| Hassanein, M | 1 |
| Ali, G | 1 |
| Ascanelli, L | 1 |
| Pagliuso, G | 1 |
| Nilsson, IM | 1 |
| Sugawara, T | 1 |
| Okuda, M | 1 |
| Yamaguchi, Y | 1 |
| Endo, K | 1 |
| Yoshinaga, K | 1 |
| McElligott, E | 1 |
| Quigley, C | 1 |
| Hanks, GW | 1 |
| Takada, A | 1 |
| Takada, Y | 1 |
| Mori, T | 1 |
| Sakaguchi, S | 1 |
| Carthew, P | 1 |
| Dorman, BM | 1 |
| Edwards, RE | 1 |
| Fricke, W | 1 |
| Alling, D | 1 |
| Kimball, J | 1 |
| Griffith, P | 1 |
| Klein, H | 1 |
| Horrow, JC | 1 |
| Hlavacek, J | 1 |
| Collier, W | 1 |
| Brodsky, I | 1 |
| Goldman, SM | 1 |
| Goel, IP | 1 |
| Vaughan, DE | 1 |
| Declerck, PJ | 1 |
| De Mol, M | 1 |
| Avvisati, G | 1 |
| ten Cate, JW | 1 |
| Büller, HR | 1 |
| Mandelli, F | 1 |
| Parsons, MR | 1 |
| Merritt, DR | 1 |
| Ramsay, RC | 1 |
| Auvinen, O | 1 |
| Baer, GA | 1 |
| Nordback, I | 1 |
| Saaristo, J | 1 |
| Laatikainen, L | 1 |
| Summanen, P | 1 |
| Immonen, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PeriOperative ISchemic Evaluation-3 Trial[NCT03505723] | Phase 3 | 9,535 participants (Actual) | Interventional | 2018-06-27 | Completed | ||
| Outcome Impact of Different Tranexamic Acid Regimen in Cardiac Surgery With Cardiopulmonary Bypass (the OPTIMAL Study)[NCT03782350] | Phase 4 | 3,079 participants (Actual) | Interventional | 2018-12-26 | Completed | ||
| A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia[NCT03136445] | Phase 3 | 616 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Effects of the Application of a New Pharmacological Protocol for Shoulder Arthroscopy in Beach Chair Position[NCT05397652] | Phase 4 | 104 participants (Actual) | Interventional | 2021-05-24 | Completed | ||
| TRACE STUDY: A Randomized Controlled Trial Using Tranexamic Acid in the Treatment of Subdural Hematoma[NCT05713630] | Phase 3 | 130 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial[NCT00872469] | Phase 3 | 20,060 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Large Randomised Placebo Controlled Trial Among Trauma Patients With, or at Risk of, Significant Haemorrhage, of the Effects of Antifibrinolytic Treatment on Death and Transfusion Requirement[NCT00375258] | Phase 3 | 20,211 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Pharmacokinetics of Intramuscular Tranexamic Acid in Trauma Patients: a Clinical Trial[NCT03875937] | Phase 1/Phase 2 | 31 participants (Actual) | Interventional | 2019-09-17 | Completed | ||
| Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury (TAMPITI TRIAL)[NCT02535949] | Phase 2 | 150 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| "External Validation of the Clinical Pre-hospital Red- Flag Alert for Activation of Intra-hospital Hemorrhage Control Response in Blunt Trauma. A Prospective Multicentric Study"[NCT05820217] | 630 participants (Anticipated) | Observational | 2023-05-10 | Not yet recruiting | |||
| Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction[NCT03413891] | Phase 4 | 222 participants (Actual) | Interventional | 2018-02-07 | Terminated (stopped due to Advice from DSMB) | ||
| The Efficacy and Safety of Intrauterine Misoprostol Versus Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Delivery in Patients With Placenta Previa: A Randomized Controlled Trial[NCT05340205] | Phase 4 | 81 participants (Actual) | Interventional | 2022-05-04 | Completed | ||
| Evaluation of the Safety and Efficacy of the Second Dose of Tranexamic Acid Administration of Trauma Patients: A Randomized, Double-blind Controlled Clinical Trial[NCT03846973] | Phase 3 | 220 participants (Actual) | Interventional | 2018-12-02 | Completed | ||
| Tranexamic Acid in Prehospital and In Hospital Civilian Trauma Care in Antifibrinolytic Therapy Study[NCT03469947] | Phase 3 | 200 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study[NCT02840097] | Phase 2 | 31 participants (Actual) | Interventional | 2019-03-04 | Completed | ||
| Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study[NCT04387305] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 2024-10-01 | Not yet recruiting | ||
| Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery: A Double-Blind Randomized Controlled Trial[NCT04863339] | Phase 2 | 0 participants (Actual) | Interventional | 2022-03-31 | Withdrawn (stopped due to Challenges in recruitment) | ||
| Randomized Study on the Topical Application of Tranexamic Acid to Wound Bed for Hemostasis in the Setting Granulating Wounds Following Mohs Micrographic Surgery[NCT04541303] | Early Phase 1 | 62 participants (Anticipated) | Interventional | 2020-10-08 | Recruiting | ||
| The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty[NCT03795649] | 80 participants (Anticipated) | Interventional | 2018-12-18 | Recruiting | |||
| Tranexamic Acid to Prevent Bleeding After Endoscopic Resection of Large Colorectal Polyps: A Pilot Project[NCT04559880] | Phase 4 | 25 participants (Actual) | Interventional | 2020-09-10 | Active, not recruiting | ||
| Evaluation of a Transfusion Therapy Using Whole Blood Versus Fractionated Blood Products in the Management of Coagulopathy in Patients Admitted to Hospital for Acute Traumatic Hemorrhage[NCT04431999] | Phase 3 | 200 participants (Anticipated) | Interventional | 2021-12-04 | Recruiting | ||
| Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.[NCT02579941] | 40 participants (Actual) | Interventional | 2015-11-30 | Completed | |||
| Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding[NCT02492087] | Phase 3 | 84 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Tranexamic Acid's Effects in Patients Undergoing Laparoscopic Radical Prostatectomy: a Randomized, Double-blind, Placebo-controlled Trial[NCT05816668] | Phase 3 | 122 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| A Multi-centre Randomised, Double-blinded, Placebo-controlled Trial of Pre-hospital Treatment With Tranexamic Acid for Severely Injured Patients at Risk of Acute Traumatic Coagulopathy.[NCT02187120] | Phase 3 | 1,310 participants (Actual) | Interventional | 2014-07-28 | Completed | ||
| The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial[NCT03074994] | Phase 2 | 108 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| Precise Application of Topical Tranexamic Acid to Enhance Endoscopic Hemostasis for Peptic Ulcer Bleeding: A Randomized Controlled Study[NCT05248321] | 60 participants (Actual) | Interventional | 2022-03-24 | Completed | |||
| Efficacy of Local Hemostatic Management in Implant Surgery in Anticoagulated Patients on Warfarin: a Randomized Clinical Study[NCT04846114] | 71 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty[NCT02569658] | 110 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Role of Tranexamic Acid (TXA) in the Reduction of Post-operative Hematoma and Seroma in Patients Undergoing Panniculectomy or Abdominoplasty, a Pilot Study.[NCT04902950] | Phase 4 | 9 participants (Actual) | Interventional | 2020-08-17 | Terminated (stopped due to Logistics) | ||
| Pilot RCT: Use of Tranexamic Acid (TXA) in Post Mastectomy Patients for Seroma and Hematoma Prevention[NCT03738527] | Phase 4 | 100 participants (Anticipated) | Interventional | 2019-10-07 | Recruiting | ||
| Topical Application Effect of Tranexamic Acid in Postoperative Bleeding and Blood Products Transfusion After Cardiac Surgery[NCT05708690] | Phase 4 | 132 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia[NCT03251547] | 76 participants (Actual) | Observational | 2017-08-21 | Completed | |||
| Prophylactic Topical Epinephrine to Reduce Transbronchial Lung Biopsy-related Hemorrhage in Lung Transplant Recipients: a Prospective Double-blind Placebo-controlled Trial (PROPHylactic Epinephrine in Transbronchial Biopsy [PROPHET] Trial)[NCT03126968] | Phase 2/Phase 3 | 100 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Single Centre Randomised Controlled Trial to Assess the Effect of the Addition of Twenty-four Hours of Oral Tranexamic Acid Post-operatively to a Single Intra-operative Intravenous Dose of Tranexamic Acid on Calculated Blood Loss Following Primary Hip and[NCT03690037] | Phase 4 | 1,089 participants (Actual) | Interventional | 2016-07-07 | Completed | ||
| The Relationship Between the Use of a Continuous a Zero-heat Flux Temperature Monitor on Initial Discharge Hypothermia Rate Among Severely Injured Trauma Patients: a Randomized Controlled Trial. (RUZIT Trial)[NCT03313258] | 0 participants (Actual) | Interventional | 2018-07-01 | Withdrawn (stopped due to PI left institution) | |||
| The Effect of Red Blood Cells Transfusion in Trauma Patients: A Risk Stratified Analysis[NCT01746953] | 20,211 participants (Actual) | Observational | 2005-05-31 | Completed | |||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome. Beneficial or Iatrogenic Effects.[NCT00355108] | Phase 3 | 170 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Evaluation of the Use of Tranexamic Acid in Tibial Osteotomies: a Randomised Controlled Clinical Trial.[NCT04785651] | 84 participants (Anticipated) | Interventional | 2021-02-22 | Recruiting | |||
| Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage[NCT05554211] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-07-12 | Recruiting | ||
| Do Peri-operative High Doses of Intravenous Glucocorticoids Improve Short-term Functional Outcome After Direct Anterior Total Hip Arthroplasty? A Randomized, Single Surgeon, Placebo Controlled, Double Blind Study[NCT04317872] | 70 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | |||
| Point-of-care (POC) Approach to Management of Coagulopathy in Lung Transplantation Versus Standard Approach and Their Effect on Primary Graft Dysfunction (PGD), Randomized Controlled Study[NCT03598907] | 67 participants (Actual) | Observational | 2018-01-01 | Terminated (stopped due to After interim statistical analysis, a statistician reccommended to stop study, because results are significant and in favour of POC approach.) | |||
| Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial[NCT02739815] | Phase 4 | 200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section[NCT02780245] | Phase 4 | 100 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| [NCT01938768] | 110 participants (Actual) | Observational | 2013-11-30 | Completed | |||
| The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery[NCT04951128] | Phase 4 | 50 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491] | Phase 3 | 11,000 participants (Actual) | Interventional | 2018-03-15 | Completed | ||
| DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery[NCT03376061] | Phase 4 | 97 participants (Actual) | Interventional | 2017-12-21 | Completed | ||
| Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery (DEPOSITION) Study[NCT03954314] | Phase 3 | 3,242 participants (Actual) | Interventional | 2019-09-17 | Terminated (stopped due to Upon the Data Safety Monitoring Board review of the interim analysis (75% of participants have finished their follow-up) on November 17, 2023, they made a recommendation to stop recruitment into the trial.) | ||
| Platelet Transfusion Requirements in Hematopoietic Transplantation(PATH Pilot)[NCT02650791] | Phase 3 | 100 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial[NCT03069859] | Phase 2 | 31 participants (Actual) | Interventional | 2018-03-06 | Active, not recruiting | ||
| Peroperative Tranexamic Acid as Prophylaxis of Haemorrhage in Benign Hysterectomy - a Randomized, Placebo-controlled Trial[NCT01940419] | Phase 4 | 332 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Range of Motion and Function Following Primary Repair of Traumatic Zone 1 or Zone 2 Digit Flexor Tendon Injuries - Impact of Tranexamic Acid Use - A Prospective Study[NCT04178655] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2019-11-30 | Not yet recruiting | ||
| The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery[NCT01980355] | 76 participants (Actual) | Interventional | 2012-06-12 | Completed | |||
| Pre-hospital Administration of Tranexamic Acid for Adults With Moderate and Severe Traumatic Brain Injury: a Randomized, Double-blinded, Placebo-controlled Trial[NCT02645552] | Phase 3 | 400 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial[NCT02650856] | Phase 3 | 40 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Novel Technique Of Uterine Cooling During Repeated Cesarean Section For Reducing Blood Loss[NCT03793153] | 99 participants (Actual) | Interventional | 2018-12-19 | Completed | |||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| The Impact of Topical Tranexamic Acid on Pre- and Post-operative Hemoglobin / Hematocrit in Isolated Operative Posterior Wall Acetabular Fractures: a Prospective, Randomized, Double-blinded, Multicenter Study[NCT05357079] | Early Phase 1 | 98 participants (Anticipated) | Interventional | 2017-08-25 | Recruiting | ||
| Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)[NCT03326596] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2018-04-20 | Recruiting | ||
| The Effects of the Timing of Tranexamic Acid Administration on Blood Loss in Hip Fractures.[NCT04488367] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2020-07-06 | Recruiting | ||
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT03113253] | Phase 4 | 121 participants (Actual) | Interventional | 2016-09-22 | Active, not recruiting | ||
| Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery[NCT01655641] | Phase 2/Phase 3 | 118 participants (Anticipated) | Interventional | 2012-07-31 | Active, not recruiting | ||
| Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial[NCT02302456] | Phase 3 | 4,079 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial[NCT02278263] | Phase 4 | 150 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| Use of TRanEXamic Acid in Reduction Mammoplasty (TREX-ARM): a Double-blinded Randomized Controlled Trial[NCT04947514] | Phase 4 | 98 participants (Actual) | Interventional | 2021-10-29 | Completed | ||
| The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial[NCT02753816] | 25 participants (Actual) | Interventional | 2016-04-30 | Terminated (stopped due to Study enrollment and goals unable to be reached.) | |||
| [NCT02644473] | Phase 4 | 0 participants (Actual) | Interventional | 2016-02-29 | Withdrawn (stopped due to Study did not receive IRB approval, so did not start) | ||
| The Use of Tranexamic Acid in Irrigation Fluid to Improve Arthroscopic Visualization in Shoulder Surgery: A Randomized Controlled Trial[NCT04594408] | Phase 4 | 128 participants (Actual) | Interventional | 2020-09-01 | Active, not recruiting | ||
| Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery[NCT03856164] | Phase 2/Phase 3 | 110 participants (Actual) | Interventional | 2019-06-17 | Completed | ||
| The Effect of Using Tranexamic Acid Soaked Absorbable Gelatin Sponge in Reducing Rectus Sheath Hematoma Formation After Cesarean Section in Patients Using Warfarin Compounds[NCT05439694] | Phase 4 | 63 participants (Actual) | Interventional | 2022-07-03 | Completed | ||
| Estimation of Coagulation Factor XIII Activity Based on the Initial Plasma Fibrinogen Level in Trauma[NCT03634215] | 357 participants (Actual) | Observational | 2018-09-01 | Completed | |||
| Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children[NCT01228136] | Phase 4 | 95 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty[NCT00375440] | 0 participants (Actual) | Interventional | 2005-02-28 | Withdrawn (stopped due to Study halted prematurely as investigator left the institution.) | |||
| Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty[NCT02043132] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Cardiac Surgery : In Vivo Titration of Protamine[NCT00684450] | 138 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study[NCT00740116] | Phase 4 | 100 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial[NCT02829346] | Phase 2 | 60 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Blood was drawn from patients at baseline (0 h, just before placebo or drug administration) and at 72 hours post placebo or drug administration. Leukocytes in these blood samples were stained with fluroescent antibodies specific for CD45, CD14, and HLA-DR, analyzed by flow cytometry, and the median fluorescen intensity (MFI) of HLA-DR signal was recorded for monocytes (CD45+CD14+). The fold change in HLA-DR expression from prior to placebo/drug administration to 72 h after placebo/drug administration (0 h : 72 h) was calculated as HLA-DR MFI72hours ÷ HLA-DR CD14 MFI0hours. Non-paramteric one-way ANOVA (Kruskal-Wallis test) was performed between each treatment group at the given time pont, and the p-value reported." (NCT02535949)
Timeframe: Samples Drawn through 72 hours after study initiation
| Intervention | fold change (Median) |
|---|---|
| Tranexamic Acid 2 Gram | 0.503 |
| Tranexamic Acid 4 Gram | 0.509 |
| Placebo | 0.532 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~CL equals clearance of TXA in mL/(min*70kg)." (NCT02535949)
Timeframe: 24 hours
| Intervention | mL/(min*70kg) (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | 109 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~Creatinine Count CL equals clearance (CL) affected by the covariate of Creatinine levels (SCRint). This value is unitless per NONMEM reporting." (NCT02535949)
Timeframe: 24 hours
| Intervention | unitless (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | -0.084 |
All adverse events were totaled for each of the three study groups based on the number of incidents. (NCT02535949)
Timeframe: Hospital Discharge (average 10 days)
| Intervention | events (Number) |
|---|---|
| Tranexamic Acid 2 Gram | 168 |
| Tranexamic Acid 4 Gram | 264 |
| Placebo | 138 |
The incidence of seizures at 24 hours in all three study groups. Number of participants with seizures are reported (NCT02535949)
Timeframe: 24 hours following TXA
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid 2 Gram | 0 |
| Tranexamic Acid 4 Gram | 1 |
| Placebo | 0 |
The number of events per group for the incidence of thromboembolic events (DVT, MI, PE, Stroke) in all three study groups. (NCT02535949)
Timeframe: Hospital Discharge (average 10 days)
| Intervention | events (Number) |
|---|---|
| Tranexamic Acid 2 Gram | 13 |
| Tranexamic Acid 4 Gram | 16 |
| Placebo | 6 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~Near Infrared Spectroscopy CL equals clearance (CL) affected by the covariate of Near Infrared Spectroscopy (NIRSint). This value is unitless per NONMEM reporting." (NCT02535949)
Timeframe: 24 hours
| Intervention | unitless (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | -0.27 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~Platelet Count CL equals clearance (CL) affected by the covariate of Platelet Count (PLTint). This value is unitless per NONMEM reporting." (NCT02535949)
Timeframe: 24 hours
| Intervention | unitless (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | 0.45 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~Q equals intercompartmental clearance in L/70kg." (NCT02535949)
Timeframe: 24 hours
| Intervention | L/70kg (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | 174 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~Total Transfusion Volume CL equals clearance (CL) affected by the covariate of Total Transfusion Volume (TxTot). This value is unitless per NONMEM reporting." (NCT02535949)
Timeframe: 24 hours
| Intervention | unitless (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | 0.03 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~V1 equals central volume in L/70kg." (NCT02535949)
Timeframe: 24 hours
| Intervention | L/70kg (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | 1160 |
"Pharmacokinetic data was analyzed with NONMEM, using both the first-order and conditional non-Laplacian (with centering) estimation techniques. We considered two- and three-compartment models, parameterized in terms of both compartment volumes and clearances (distribution and elimination). We compared a basic model (in which pharmacokinetic parameters were independent of weight) to a model in which the pharmacokinetic parameters were assumed to be proportional to weight. The optimal model was selected on the basis of the objective function logarithm of the likelihood of the results) using standard criteria (NONMEM guide).~Equations from optimal model:~CL=109*((WT/70)**0.75) * (SCRint^-0.084) * ((NIRSInt)/96)^ -0.27 ) * ((PLTint)/130)^0.45) V1=1,160*(WT/70) * (TxTot)^0.03) Q=174*((WT/70)**0.75) V2=1080 *(WT/70)~V2 equals Peripheral Volume in L/70kg." (NCT02535949)
Timeframe: 24 hours
| Intervention | L/70kg (Mean) |
|---|---|
| Tranexamic Acid 2 Gram and 4 Gram | 1080 |
"To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:~a. Cytokines measured from time 0 to 72 hours." (NCT02535949)
Timeframe: Samples Drawn through 72 hours after study initiation
| Intervention | pg/mL (Median) | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ITAC hour 0 | ITAC hour 72 | GM-CSF hour 0 | GM-CSF hour 72 | Factalkine hour 0 | Factalkine hour 72 | IFNgamma hour 0 | IFNgamma hour 72 | IL-10 hour 0 | IL-10 hour 72 | MIP-3a hour 0 | MIP-3a hour 72 | IL-12p70 hour 0 | IL-12p70 hour 72 | IL-13 hour 0 | IL-13 hour 72 | IL -17A hour 0 | IL-17A hour 72 | IL-1beta hour 0 | IL-1beta hour 72 | IL-2 hour 0 | IL-2 hour 72 | IL-21 hour 0 | IL-21 hour 72 | IL-4 hour 0 | IL-4 hour 72 | IL-23 hour 0 | IL-23 hour 72 | IL-5 hour 0 | IL-5 hour 72 | IL-6 hour 0 | IL-6 hour 72 | IL-7 hour 0 | IL-7 hour 72 | IL-8 hour 0 | IL-8 hour 72 | MIP-1alpha hour 0 | MIP-1alpha hour 72 | MIP-beta hour 0 | MIP-beta hour 72 | TNFa hour 0 | TNFa hour 72 | |
| Placebo | 29.34 | 21.58 | 64.69 | 61.41 | 141.8 | 100.51 | 17.47 | 12.98 | 105.07 | 32.38 | 22.95 | 31.54 | 8.78 | 7.58 | 9.08 | 10.28 | 18.73 | 14 | 3.9 | 3.11 | 4.01 | 4.12 | 7.02 | 5.51 | 58.16 | 35.53 | 406.46 | 399.74 | 9.06 | 8.32 | 63.56 | 41.9 | 16.52 | 16.8 | 13.78 | 17.64 | 27.85 | 25.47 | 35.44 | 28.15 | 16.4 | 16.16 |
| Tranexamic Acid 2 Gram | 34.24 | 25.67 | 67.79 | 69.22 | 223.61 | 174.91 | 23.46 | 17.89 | 115.98 | 31.76 | 22.95 | 38.49 | 9.5 | 9.67 | 11.8 | 11.11 | 21.51 | 20.06 | 4.17 | 4.15 | 4.17 | 4.26 | 6.28 | 6.44 | 69.45 | 49.99 | 724.45 | 589.73 | 9.3 | 8.68 | 54.48 | 73.97 | 18.53 | 18.47 | 15.25 | 26.9 | 32.57 | 28.57 | 44.91 | 36.78 | 19.16 | 19.38 |
| Tranexamic Acid 4 Gram | 32.75 | 21.69 | 67.58 | 52.88 | 146.23 | 124.23 | 17.59 | 14.79 | 84.39 | 42.39 | 21.94 | 27.61 | 8.64 | 9.45 | 11.11 | 10.27 | 15.05 | 16.67 | 3.75 | 3.44 | 4.29 | 3.49 | 6.13 | 6.95 | 58.24 | 40.5 | 428.26 | 351.47 | 9.48 | 8.05 | 39.7 | 67.95 | 15.33 | 16.24 | 13.59 | 23.05 | 30.98 | 27.24 | 37.66 | 29.02 | 16.4 | 20.09 |
"To evaluate the effects of TXA on immune function parameters we will, in a RCT, analyze samples from 150 patients (50 in each study group), at multiple time points. Parameters are:~a. Flow cytometric analyses on leukocytes measured from time 0 to 72 hours." (NCT02535949)
Timeframe: Samples Drawn through 72 hours after study initiation
| Intervention | Fold Change (Median) | |
|---|---|---|
| CD 11b+ | CD 16+ | |
| Placebo | 0.844 | 0.817 |
| Tranexamic Acid 2 Gram | 0.875 | 0.917 |
| Tranexamic Acid 4 Gram | 0.967 | 0.870 |
Total volume of packed red blood cells, platelets, fresh frozen plasma, and cryoprecipitate (NCT02840097)
Timeframe: First 48 hours after randomization
| Intervention | ml (Mean) |
|---|---|
| Tranexamic Acid Dose A | 367.4 |
| Tranexamic Acid Dose B | 150.4 |
| Placebo | 303.6 |
Intracranial hemorrhage progression on cranial computed tomography (CT) imaging; hemorrhage will be measured using the ABC/2 volume estimation and relative to the total brain volume (calculated by the XYZ/2 volume estimation); more intracranial hemorrhage progression represents a worse outcome. Change is calculated as the difference between the baseline and repeat cranial CT imaging. The repeat CT is conducted 24 hours (±6 hours) after the baseline CT. (NCT02840097)
Timeframe: 24 hours (±6 hours)
| Intervention | Proportional change (Mean) |
|---|---|
| Tranexamic Acid Dose A | 0.003 |
| Tranexamic Acid Dose B | 0.001 |
| Placebo | 0.003 |
Any non-cerebral venous or arterial thrombosis on standard diagnostic imaging post-randomization (NCT02840097)
Timeframe: Day 7 of hospitalization or hospital discharge (whichever comes first)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Dose A | 0 |
| Tranexamic Acid Dose B | 0 |
| Placebo | 0 |
Clinical or electroencephalogram-documented (NCT02840097)
Timeframe: 24 hours after receiving drug
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Dose A | 0 |
| Tranexamic Acid Dose B | 0 |
| Placebo | 1 |
Neurocognitive functioning and quality-of-life measures; range from 0 to 100 quality of life units with higher scores representing better outcomes. Measurements occur at 1 week, 1 month, 3 months, and 6 months to generate an area under the curve of quality of life units. (NCT02840097)
Timeframe: 6 months
| Intervention | Quality of life units * months (Mean) |
|---|---|
| Tranexamic Acid Dose A | 64.9 |
| Tranexamic Acid Dose B | 60.2 |
| Placebo | 67.2 |
Test of working memory; higher scores represent a better outcome, range from 0 to infinity (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | score on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total forward digit span, 1 week | Total backward digit span, 1 week | Total forward digit span, 1 month | Total backward digit span, 1 month | Total forward digit span, 3 months | Total backward digit span, 3 months | Total forward digit span, 6 months | Total backward digit span, 6 months | |
| Placebo | 8.8 | 7.3 | 7.5 | 5.3 | 8.6 | 6.5 | 8.4 | 5.8 |
| Tranexamic Acid Dose A | 8.4 | 6.0 | 7.2 | 6.2 | 9.1 | 8.7 | 11.7 | 10.4 |
| Tranexamic Acid Dose B | 8.4 | 6.0 | 7.9 | 6.2 | 10.4 | 7.8 | 10.0 | 6.0 |
Global functioning; range is 1 to 8 with higher scores representing better outcomes; 1=death, 2=vegetative state, 3=lower severe disability, 4=upper severe disability, 5=lower moderate disability, 6=upper moderate disability, 7=lower good recovery, 8=upper good recovery (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| 1 week | 1 month | 3 months | 6 months | |
| Placebo | 5.3 | 4.5 | 4.2 | 4.3 |
| Tranexamic Acid Dose A | 4.6 | 4.9 | 3.8 | 3.7 |
| Tranexamic Acid Dose B | 5.2 | 5.1 | 4.6 | 2.9 |
Neurocognitive functioning and quality-of-life measures; range from 0 to 100 with higher scores representing better outcomes (NCT02840097)
Timeframe: 1 week, 1 month, 3 months, and 6 months
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| 1 week | 1 month | 3 months | 6 months | |
| Placebo | 57.9 | 60.5 | 68.9 | 68.9 |
| Tranexamic Acid Dose A | 43.7 | 57.0 | 77.3 | 81.6 |
| Tranexamic Acid Dose B | 52.4 | 61.5 | 77.5 | 84.3 |
Must be diagnosed via ultrasound duplex (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 1 |
Must be diagnosed via CT chest or V/Q lung scan (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Must be diagnosed via CT scan or MRI (NCT02569658)
Timeframe: 30 days post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Patients who received a post-op transfusion of pack red blood cells (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Units of pack red blood cells that the patients recieved (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | Units of PRBCs (Number) |
|---|---|
| Tranexamic Acid Group | 0 |
| Placebo Group | 0 |
Equated based on the patient's predicted blood volume and change in hemoglobin from the pre-operative level to the lowest post-operative level. (NCT02569658)
Timeframe: Average of 3 days post-operatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid Group | 152.2 |
| Placebo Group | 178.0 |
The number of days that the post surgical drains remain in place after the surgery. When less than 30 cc per drain in a 24-hour period, the participants are to call and schedule drain removal. (NCT04902950)
Timeframe: Up to 56 days post operatively.
| Intervention | Days (Mean) |
|---|---|
| Group 1 | 16 |
| Group 2 | 22 |
Return to the operating room for evacuation post surgical operative hematoma or seroma assessed by clinical evaluation to include palpation for ballotable fluid collection and assessment of skin for a shiny/tight appearance suggestive of an underlying fluid collection. (NCT04902950)
Timeframe: Up to 8 weeks postoperatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 | 0 |
| Group 2 | 0 |
Patients will be monitored clinically at each post-operative visit for signs of post-operative hematoma or seroma. Each patient will be evaluated one week, three weeks, and eight weeks following their procedure to assess overall wound healing. (NCT04902950)
Timeframe: Up to 8 weeks postoperatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Group 1 | 0 |
| Group 2 | 1 |
[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum
| Intervention | grams per deciliter (Mean) |
|---|---|
| Tranexamic Acid | -1.8 |
| Placebo | -1.9 |
Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days
| Intervention | days (Median) |
|---|---|
| Tranexamic Acid | 3 |
| Placebo | 3 |
(NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 35 |
| Placebo | 32 |
This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 108 |
| Placebo | 109 |
This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 233 |
| Placebo | 231 |
[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 892 |
| Placebo | 986 |
Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 20 |
| Placebo | 19 |
This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 29 |
| Placebo | 31 |
This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 649 |
| Placebo | 732 |
[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 12 |
| Placebo | 13 |
[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 339 |
| Placebo | 368 |
Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 201 |
| Placebo | 233 |
[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 162 |
| Placebo | 125 |
This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 0 |
Plasma TxA concentrations measured from blood samples taken upon arrival in the ICU (NCT03376061)
Timeframe: on arrival in ICU within 3 hours
| Intervention | microgram per milliliter per kilogram (Mean) |
|---|---|
| Topical TxA (Intervention) | 0.58 |
| Intravenous TxA (Control) | 1.10 |
Number of hours participants spent in the intensive care unit (ICU) (NCT03376061)
Timeframe: Number of hours spent in ICU from arrival to exit (collected at the Post-Operative Visit).
| Intervention | hours (Median) |
|---|---|
| Topical TxA (Intervention) | 23 |
| Intravenous TxA (Control) | 26 |
Cumulative volume (mL) of fluid collected from mediastinal drainage tubes 24 hours after the surgical procedure (NCT03376061)
Timeframe: Fluid collected in the first 24 hours after the surgical procedure
| Intervention | mL (Median) |
|---|---|
| Topical TxA (Intervention) | 500 |
| Intravenous TxA (Control) | 540 |
The occurrence of death due to any cause (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 1 |
| Intravenous TxA (Control) | 1 |
Patients requiring a red blood cell transfusion (NCT03376061)
Timeframe: Intra-operative and post-operative RBC transfusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 19 |
| Intravenous TxA (Control) | 23 |
Occurrence of re-operation for the purpose of bleeding or cardiac tamponade (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Patients experiencing a post-operative seizure (NCT03376061)
Timeframe: Patients will be followed post-operatively until hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Topical TxA (Intervention) | 0 |
| Intravenous TxA (Control) | 1 |
Surgical blood loss estimation (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 450 |
| Placebo | 365 |
To determine the impact of perioperative administration of tranexamic acid on blood loss and transfusion rates in major oncologic surgery (NCT01980355)
Timeframe: From time of surgery to 90 days post hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 8 |
| Placebo | 5 |
The blood quantification will be taken at 6am every day. (NCT02650856)
Timeframe: up to 2nd day post operative (24 and 48 hrs)
| Intervention | mL (Mean) | |
|---|---|---|
| 24 hours | 48 hours | |
| Group 1 Tranexamic Acid | 246.4 | 120.8 |
| Group 2 Platelet Rich Plasma | 263.2 | 140.2 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | percentage of Hematocrite (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 41.7 | 31.6 | 29.1 | 28.6 |
| Group 2 Platelet Rich Plasma | 41.5 | 29.8 | 27.7 | 27.3 |
The blood test will be taken at 6am every day. Using the same laboratory parameters. (NCT02650856)
Timeframe: up to 3rd day post operative (Baseline, 24, 48 and 72hrs)
| Intervention | g/dL (Mean) | |||
|---|---|---|---|---|
| Baseline | 24 hours | 48 hours | 72 hours | |
| Group 1 Tranexamic Acid | 13.6 | 10.3 | 9.5 | 9.3 |
| Group 2 Platelet Rich Plasma | 13.6 | 9.9 | 9.2 | 9.1 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
"The loss of haemoglobin (Hb) was then estimated according to the formula:~Hb(loss) = Blood volume (BV) x (Hbi-Hbe) x 0.001+Hbt~where Hb (loss) (g) is the amount of Hb lost, Hbi (g/L) the Hb concentration before surgery, Hbe (g/L) is the Hbe concentration on the third day after surgery, and Hbt (g) is the total amount of allogeneic Hb transfused. A unit of banked blood is considered to contain a minimum of 40g Hb (Blood component data sheet, New Zealand Blood Services [NZBS]). All units of blood are processed and stored in a nationally standardised manner. The blood loss (ml) was related to the patient's preoperative Hb value (g/L):~Blood loss =1000 x Hb(loss) /Hbi" (NCT02278263)
Timeframe: Post operative day 3
| Intervention | mls (Mean) |
|---|---|
| Control | 1090 |
| Intraarticular | 716 |
| Systemic | 746 |
Day of surgery is counted as Day 0. (NCT02278263)
Timeframe: Average length of stay is expected to be 3 to 5 days
| Intervention | days (Median) |
|---|---|
| Control | 4 |
| Topical | 4 |
| Systemic | 4 |
"Those patients receiving blood products. Standardised protocol is as follows:~The criterion for transfusion of blood products will be a haemoglobin < 80g/L or a haemoglobin <100g/L in a patient with ischaemic heart disease or with significant symptomatology" (NCT02278263)
Timeframe: Participants will be followed for the duration of their hospital stay expected to be an average of 3-5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Topical | 1 |
| Systemic | 0 |
Intravenous fluid (excluding blood transfusion) given during and first 24 hours after surgery (NCT02278263)
Timeframe: Day 1
| Intervention | mls (Mean) |
|---|---|
| Control | 1765 |
| Topical | 1613 |
| Systemic | 1807 |
Rates of deep vein thrombosis (DVT) and pulmonary embolus (PE) in each group recorded as a percentage (NCT02278263)
Timeframe: Postoperatively within 30 days after surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| DVT | PE | |
| Control | 0 | 0 |
| Systemic | 0 | 1 |
| Topical | 0 | 2 |
Range of motion measured in degrees on postoperative days 1-3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 57 | 71 | 75 |
| Systemic | 58 | 72 | 78 |
| Topical | 65 | 75 | 82 |
Range of motion measured in degrees for postoperative days 1 to 3 (NCT02278263)
Timeframe: Days 1-3
| Intervention | degrees (Mean) | ||
|---|---|---|---|
| Day 1 | Day 2 | Day 3 | |
| Control | 65 | 76 | 82 |
| Systemic | 68 | 80 | 87 |
| Topical | 74 | 81 | 87 |
The number of breasts with clinically significant hematoma (collection of blood under the skin) requiring either conservative management or operative washout was determined. (NCT04947514)
Timeframe: Up to 30 days
| Intervention | breasts (Number) |
|---|---|
| Treatment Side (Right or Left) | 2 |
| Placebo Side (Right or Left) | 1 |
The number of participants requiring blood transfusion was based on the postoperative decline in hematocrit level (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
Incidence of clinically significant deep vein thrombosis or pulmonary embolism detected on imaging (ultrasound or CT scan) (NCT04947514)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Side (Right or Left) | 0 |
| Placebo Side (Right or Left) | 0 |
To determine the impact of perioperative administration of Tranexamic Acid on transfusion rates in major burn surgeries. (NCT02753816)
Timeframe: First burn surgery to hospital discharge
| Intervention | Patients with 1 or more transfusions (Number) |
|---|---|
| Tranexamic Acid | 2 |
| Placebo | 3 |
To determine the impact of Tranexamic Acid on total hospital length of stay by comparing the hospital admission date and the hospital discharge date. This determination will take into account current burn size and location, procedures performed and their effect on wound healing and skin graft survival. (NCT02753816)
Timeframe: Hospital admission to hospital discharge
| Intervention | Days (Median) |
|---|---|
| Tranexamic Acid | 23 |
| Placebo | 9 |
To determine the impact of perioperative administration of Tranexamic Acid on blood loss in major burn surgeries. (NCT02753816)
Timeframe: Intraoperative, average 122 minutes
| Intervention | mL (Median) |
|---|---|
| Tranexamic Acid | 100 |
| Placebo | 325 |
Total blood volume loss will be calculated in milliliters. (NCT03856164)
Timeframe: 24 hours postpartum.
| Intervention | milliliters (Mean) |
|---|---|
| Tranexamic Acid | 2274 |
| Placebo | 2407 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | µg/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 4.0 | 3.8 | 4.3 |
| Tranexamic Acid | 2.9 | 2.4 | 2.1 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 550.7 | 484.9 | 525.4 |
| Tranexamic Acid | 563.5 | 499.6 | 527.4 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | IU/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 61.7 | 63.3 | 22.1 |
| Tranexamic Acid | 81.8 | 67.0 | 20.7 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Before Surgery INTEM Clotting Time | After Delivery INTEM Clotting Time | P.O.D. 1 INTEM Clotting Time | Before Surgery EXTEM Clotting Time | After Delivery EXTEM Clotting Time | P.O.D. 1 EXTEM Clotting Time | |
| Placebo | 150.5 | 140.7 | 141.2 | 56.1 | 56.3 | 50.2 |
| Tranexamic Acid | 149.7 | 137.4 | 145.1 | 54.0 | 54.9 | 49.3 |
Rotational thromboelastometry is a whole blood viscoelastic test that analyzes deficits in clotting factors, clot strength, and clot breakdown. EXTEM, INTEM, and FIBTEM tests measure the extrinsic pathway, intrinsic pathway, and fibrinogen levels, respectively. Compared to non-pregnant patients, FIBTEM/EXTEM/INTEM amplitudes and the FIBTEM maximum clot firmness are higher in pregnant women. The EXTEM and INTEM clotting time are shorter, indicating the relative hypercoagulability of pregnancy. Reference ranges for INTEM Clotting Time (100-240 seconds), INTEM Maximum Clot Firmness (50-72 millimeter), EXTEM Clotting Time (38-79 seconds), EXTEM Maximum Clot Firmness (50-72 millimeter), FIBTEM Maximum Clot Firmness (9-25 millimeter). (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | millimeter (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Before Surgery INTEM Maximum Clot Firmness | After Delivery INTEM Maximum Clot Firmness | P.O.D. 1 INTEM Maximum Clot Firmness | Before Surgery EXTEM Maximum Clot Firmness | After Delivery EXTEM Maximum Clot Firmness | P.O.D. 1 EXTEM Maximum Clot Firmness | Before Surgery FIBTEM Maximum Clot Firmness | After Delivery FIBTEM Maximum Clot Firmness | P.O.D. 1 FIBTEM Maximum Clot Firmness | |
| Placebo | 69.4 | 68.4 | 68.8 | 71.2 | 69.6 | 70.4 | 23.9 | 22.0 | 25.0 |
| Tranexamic Acid | 69.3 | 68.9 | 68.8 | 70.8 | 69.8 | 70.5 | 24.2 | 22.5 | 25.8 |
Measured from blood sample collection. (NCT03856164)
Timeframe: Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Before Surgery | After Delivery | P.O.D. 1 | |
| Placebo | 8.2 | 9.6 | 7.4 |
| Tranexamic Acid | 8.1 | 9.0 | 7.5 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Deep venous thrombosis" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Hematoma" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Infection" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Myocardial infarction" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 1 |
"The occurrence of the following systemic and surgical site complications within 6 weeks of surgery will be recorded. Data will be obtained from EMR and from patient at standard of care 2 week and 6 week follow-up appointment.~Pulmonary Embolism" (NCT02043132)
Timeframe: up to 6-weeks post-operatively
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 0 |
| Normal Saline | 0 |
Total Blood Loss as calculated according to method as described by Good et al. Total Blood Loss (mL) = 1000 X Hb(loss)/Hb(initial) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | Total Blood Loss (mL) (Mean) |
|---|---|
| Tranexamic Acid | 1122.4 |
| Normal Saline | 1472 |
Total Drain Output as measured postoperatively 0-48 hours (NCT02043132)
Timeframe: 0-48 hours postoperatively
| Intervention | mL (Mean) |
|---|---|
| Tranexamic Acid | 221 |
| Normal Saline | 372 |
Total hemoglobin loss estimated using the formula for total blood volume described by Nadler et al Hb(loss) = blood volume (L) x [Hb(initial)(g/L) - Hb(final)(g/L)] + Hb(transfused) (NCT02043132)
Timeframe: Preoperative through Postoperative Days 1 and 2
| Intervention | g (Mean) |
|---|---|
| Tranexamic Acid | 154.6 |
| Normal Saline | 200.1 |
Median number of red blood cells transfused among those who received RBC transfusions (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Median) |
|---|---|
| The Placebo Group | 2 |
| The Tranexamic Acid Group | 2 |
Total number of RBC-transfused women in each group (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | participants (Number) |
|---|---|
| Tranexamic Group | 15 |
| Placebo Group | 22 |
Thromboembolic events including arterial thrombosis, muscle vein thrombosis, superficial and deep venous thrombosis. (NCT00740116)
Timeframe: From time of operation to 5 weeks postoperatively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Group | 2 |
| Placebo Group | 5 |
Total number of red blood cells (RBC) transfused across all participants (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | units (Number) |
|---|---|
| Tranexamic Group | 38 |
| Placebo Group | 53 |
Estimation of total blood loss was based on the estimation of the Hb balance method (Brecher, et al.1997) with the assumption that the body blood volume was normalised on the fifth postoperative day. The haemoglobin level was assessed preoperatively and on the fifth postoperative day. The predicted blood volume (PBV, l) was calculated according to the method described by Nadler et al. (1962), using body weight and height. The extravasation of haemoglobin was calculated taking into account allogenic transfused haemoglobin. Total blood loss perioperatively was related to the patient's preoperative haemoglobin value. Blood loss due to haematomas or a reoperation within the first five days after surgery was also considered. (NCT00740116)
Timeframe: From start of operation to discharge from hospital, up to 5 weeks
| Intervention | milliliter (Median) |
|---|---|
| Tranexamic Group | 520 |
| Placebo Group | 730 |
112 reviews available for tranexamic acid and Hemorrhage
| Article | Year |
|---|---|
Tranexamic acid for prevention of bleeding in cesarean delivery: An overview of systematic reviews.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Pregnancy; Systematic Review | 2022 |
Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Antifibrinolytic Agents; Hemorrhage; Humans; Risk Assessment; Seizures; Str | 2021 |
Effect of Tranexamic Acid on Bleeding Outcomes After Percutaneous Nephrolithotomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Nephrolithotomy, Percutaneous; Ra | 2022 |
Therapeutic Strategies in Traumatic Intracranial Hemorrhage and Outcomes.
Topics: Hemorrhage; Humans; Intracranial Hemorrhage, Traumatic; Risk Factors; Tranexamic Acid | 2023 |
Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury: A Systematic Review and Meta-analysis.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Thromboembolism; Tranexamic | 2022 |
Effects of tranexamic acid treatment in severely and non-severely injured trauma patients.
Topics: Antifibrinolytic Agents; Glasgow Coma Scale; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injurie | 2022 |
Pulmonary hemorrhage after cardiac resynchronization therapy device implantation - A systematic review.
Topics: Cardiac Resynchronization Therapy Devices; Defibrillators, Implantable; Hemorrhage; Humans; Pacemake | 2022 |
Tranexamic acid: Beyond antifibrinolysis.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans | 2022 |
Antifibrinolytics in the treatment of traumatic brain injury.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Tranexamic Acid | 2022 |
A Systematic Review of Tranexamic Acid-Associated Venous Thromboembolic Events in Combat Casualties and Considerations for Prolonged Field Care.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Venous Thromboembolism; Venous Thrombo | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: a systematic review.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Hemostatics; Humans; Quality of Life | 2023 |
Alternative blood products in trauma.
Topics: Blood Coagulation Disorders; Fibrinogen; Hemorrhage; Hemostatics; Humans; Thrombelastography; Tranex | 2023 |
Efficacy of high dose tranexamic acid (TXA) for hemorrhage: A systematic review and meta-analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemorrhage; Humans; Randomi | 2023 |
Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta-analysis.
Topics: Adult; Aprotinin; Blood Transfusion; Deamino Arginine Vasopressin; Fibrin Tissue Adhesive; Hemorrhag | 2023 |
Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery.
Topics: Administration, Intranasal; Adrenal Cortex Hormones; Adult; Child; Hemorrhage; Humans; Nasal Polyps; | 2023 |
Tranexamic acid-associated intrathecal toxicity during spinal anaesthesia: A narrative review of 22 recent reports.
Topics: Anesthesia, Spinal; Anesthetics, Local; Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hemor | 2023 |
Factors that influence the administration of tranexamic acid (TXA) to trauma patients in prehospital settings: a systematic review.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Tranexamic Acid | 2023 |
Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures.
Topics: Arthroplasty, Replacement; Fibrinogen; Fractures, Bone; Hemorrhage; Hemostatics; Humans; Myocardial | 2023 |
Interventions for reducing red blood cell transfusion in adults undergoing hip fracture surgery: an overview of systematic reviews.
Topics: Aged; Anemia; Emergence Delirium; Erythrocyte Transfusion; Hemorrhage; Hip Fractures; Humans; Iron; | 2023 |
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Prospective Studies; Retrospective Studies; Surgery, Pl | 2023 |
EVALUATION OF TRANEXAMIC ACID AND CALCIUM CHLORIDE IN MAJOR TRAUMAS IN A PREHOSPITAL SETTING: A NARRATIVE REVIEW.
Topics: Antifibrinolytic Agents; Calcium Chloride; Emergency Medical Services; Hemorrhage; Humans; Tranexami | 2023 |
Prophylactic and therapeutic strategies for intraoperative bleeding in women with von Willebrand disease and heavy menstrual bleeding: A systematic review.
Topics: Female; Hemorrhage; Humans; Menorrhagia; Prospective Studies; Tranexamic Acid; von Willebrand Diseas | 2023 |
Effect of Perioperative Tranexamic Acid on Blood Loss following Open Simple Prostatectomy: A Prospective Review in Nigerian Men.
Topics: Aged; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Prostatectomy; Randomized Controll | 2023 |
Geographical Variance in the Use of Tranexamic Acid for Major Trauma Patients.
Topics: Antifibrinolytic Agents; Drug Utilization; Emergency Medical Services; Global Health; Hemorrhage; Hu | 2019 |
The emerging importance of tranexamic acid in dermatology.
Topics: Angioedema; Antifibrinolytic Agents; Dermatology; Hemorrhage; Humans; Melanosis; Pigmentation Disord | 2020 |
Tranexamic Acid for Acute Hemorrhage: A Narrative Review of Landmark Studies and a Critical Reappraisal of Its Use Over the Last Decade.
Topics: Acute Disease; Antifibrinolytic Agents; Fibrinolysis; Hemorrhage; Humans; Randomized Controlled Tria | 2019 |
Effect of tranexamic acid by baseline risk of death in acute bleeding patients: a meta-analysis of individual patient-level data from 28 333 patients.
Topics: Acute Disease; Adult; Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Randomized Controll | 2020 |
Hemostatic agents for prehospital hemorrhage control: a narrative review.
Topics: Blood Coagulation Factors; Blood Platelets; Emergency Medical Services; Hemorrhage; Hemostasis; Hemo | 2020 |
Tranexamic acid is associated with reduced mortality, hemorrhagic expansion, and vascular occlusive events in traumatic brain injury - meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Brain Injuries, Traumatic; Hemorrhage; Humans; Randomized Controlled Trials | 2020 |
Tranexamic acid in Neurosurgery: a controversy indication-review.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Brain Injuries, Traumatic; | 2021 |
The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Blood Component Transfusion; Factor VIIa; Fibrin | 2020 |
Massive transfusion protocol in adult trauma population.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Compon | 2020 |
Variations and obstacles in the use of coagulation factor concentrates for major trauma bleeding across Europe: outcomes from a European expert meeting.
Topics: Blood Coagulation Disorders; Blood Coagulation Factors; Fibrinogen; Hemorrhage; Hemostatics; Humans; | 2022 |
The impact of prehospital TXA on mortality among bleeding trauma patients: A systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Randomized Controlled Trial | 2021 |
[Tranexamic acid for bleeding prophylaxis in orthopedic surgery and trauma-standard or customized therapy?]
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Loss, Surgical; Hemorrhage; Humans; Orth | 2021 |
Assessing the clinical utilization of tranexamic acid by paramedics for patients with major trauma (ACUTE).
Topics: Allied Health Personnel; Antifibrinolytic Agents; British Columbia; Hemorrhage; Humans; Infant, Newb | 2021 |
Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review.
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Delivery, Obstetric; Female; Hemophilia A; Hemor | 2021 |
Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Deamino Arginine Vasopressin; Disease Manageme | 2021 |
Tranexamic acid: current use in obstetrics, major orthopedic, and trauma surgery.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Hemorrhage; Humans; Obstetrics; Tr | 2021 |
Effectiveness of local hemostatic to prevent bleeding in dental patients on anticoagulation: A systematic review and network meta-analysis.
Topics: Anticoagulants; Hemorrhage; Hemostatics; Humans; Network Meta-Analysis; Tranexamic Acid | 2021 |
Tranexamic acid for treatment and prophylaxis of bleeding and hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Dose-Response Relationship, | 2017 |
Updated concepts on the pathophysiology and the clinical management of trauma hemorrhage and coagulopathy.
Topics: Blood Coagulation Disorders; Blood Transfusion; Hemorrhage; Humans; Practice Guidelines as Topic; Re | 2017 |
Tranexamic Acid Use in Prehospital Uncontrolled Hemorrhage.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2017 |
Damage control resuscitation in pediatric trauma.
Topics: Adolescent; Antifibrinolytic Agents; Blood Transfusion; Child; Child, Preschool; Female; Fluid Thera | 2018 |
Efficacy of prehospital administration of tranexamic acid in trauma patients: A meta-analysis of the randomized controlled trials.
Topics: Antifibrinolytic Agents; Dose-Response Relationship, Drug; Emergency Medical Services; Hemorrhage; H | 2018 |
Therapeutic options to manage bleeding in a dentist’s office
Topics: Dentists; Hemorrhage; Humans; Tooth Extraction; Tranexamic Acid | 2018 |
What's new for trauma haemorrhage management?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Hemorrhage; Hemostatic Tech | 2019 |
Does Oral or Topical Tranexamic Acid Control Bleeding From Epistaxis?
Topics: Administration, Oral; Administration, Topical; Antifibrinolytic Agents; Epistaxis; Hemorrhage; Human | 2019 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2012 |
Treatment of bleeding upper aerodigestive tract tumor-a novel approach with antifibrinolytic agent: case series and literature review.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antifibrinolytic Agents; Carcinoma, Squamous Cell; Ep | 2013 |
Is tranexamic acid effective and safe in spinal surgery? A meta-analysis of randomized controlled trials.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Randomized Controlled Trials as T | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Antifibrinolytic agents in current anaesthetic practice.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced | 2013 |
Tranexamic acid in trauma: how should we use it?
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Thrombelastography; Tranexamic Acid; Treatment Outcome; | 2013 |
Role of fibrinogen in massive injury.
Topics: Afibrinogenemia; Animals; Antifibrinolytic Agents; Blood Component Transfusion; Fibrin; Fibrinogen; | 2014 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Topical application of tranexamic acid for the reduction of bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; Epistaxis; Hemorrhage; Human | 2013 |
Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2013 |
Trauma and severe bleeding. Tranexamic acid within one hour to reduce mortality.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Severity of Illness Index; Thrombosis; Time Factors; Tr | 2013 |
TXA: a difference-maker for trauma patients.
Topics: Antifibrinolytic Agents; Decision Making; Emergency Treatment; Hemorrhage; Humans; Tranexamic Acid; | 2013 |
Does the use of tranexamic acid improve trauma mortality?
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injuries | 2014 |
A systematic review of antifibrinolytics and massive injury.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemorrhage; Humans; Tranexamic Acid; Wounds an | 2014 |
Tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate: data to support prehospital use?
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Factors; Blood Transfusion; Brain Inju | 2014 |
Tranexamic acid in patients with major injuries and blood loss.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Multiple Trauma; Time Factors; Tranexamic Acid; United | 2013 |
Update on massive transfusion.
Topics: Blood Coagulation Disorders; Blood Coagulation Factors; Blood Transfusion; Hemorrhage; Humans; Throm | 2013 |
The effects of lysine analogs during pelvic surgery: a systematic review and meta-analysis.
Topics: Aminocaproic Acid; Blood Loss, Surgical; Blood Transfusion; Gynecologic Surgical Procedures; Hemorrh | 2014 |
Tranexamic acid in pediatric trauma: why not?
Topics: Adult; Antifibrinolytic Agents; Child; Hemorrhage; Hospital Mortality; Humans; Multicenter Studies a | 2014 |
Tranexamic acid for trauma-related hemorrhage.
Topics: Antifibrinolytic Agents; Canada; Hemorrhage; Humans; Time Factors; Tranexamic Acid; Wounds and Injur | 2014 |
Adjunct agents for bleeding.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Clinical Trials as Topic; Hemorrhage; Humans; | 2014 |
Damage Control Resuscitation.
Topics: Antifibrinolytic Agents; Blood Transfusion; Clinical Protocols; Crystalloid Solutions; Factor VIIa; | 2016 |
The current place of aprotinin in the management of bleeding.
Topics: Animals; Aprotinin; Hemorrhage; Hemostatics; Humans; Tranexamic Acid | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
The current place of tranexamic acid in the management of bleeding.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Postpartum Hemorrhage; Thrombosis | 2015 |
Management of traumatic haemorrhage--the European perspective.
Topics: Blood Coagulation Disorders; Europe; Hemorrhage; Humans; Platelet Transfusion; Thrombin; Tranexamic | 2015 |
Tranexamic acid--an old drug still going strong and making a revival.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Tranexamic Acid | 2015 |
The fibrinolytic system-more than fibrinolysis?
Topics: Animals; Central Nervous System; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans; Inflammation Mediat | 2015 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemo | 2015 |
Tranexamic acid in trauma: how should we use it?
Topics: Animals; Antifibrinolytic Agents; Fibrinolysis; Hemorrhage; Humans; Patient Selection; Risk Assessme | 2015 |
[Management of bleeding and coagulopathy following major trauma].
Topics: Blood Coagulation Disorders; Hemorrhage; Humans; Multiple Trauma; Tranexamic Acid; Transfusion React | 2016 |
[Advanced methods of prehospital bleeding management based on the experience and standards of tactical medicine].
Topics: Abdominal Injuries; Amputation, Traumatic; Antifibrinolytic Agents; Emergency Medical Services; Hemo | 2015 |
Pharmacological adjuncts to stop bleeding: options and effectiveness.
Topics: Acidosis; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Tests; Blood Trans | 2016 |
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis
Topics: Anticoagulants; Antineoplastic Agents; Blood Coagulation Factors; Blood Loss, Surgical; Blood Transf | 2016 |
Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Erythrocyte Transfusion; Hematologic Diseases; Hemorrhag | 2016 |
Halting hemorrhage with self-propelling particles and local drug delivery.
Topics: Animals; Blood Coagulation; Coagulants; Drug Carriers; Drug Delivery Systems; Hemorrhage; Humans; Na | 2016 |
Tactical damage control resuscitation in austere military environments.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; Blood Component Tra | 2016 |
Blood products and procoagulants in traumatic bleeding: use and evidence.
Topics: Blood Coagulation Disorders; Hemorrhage; Hemostasis; Humans; Plasma; Randomized Controlled Trials as | 2016 |
Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
Topics: Benzoates; Bone Marrow Diseases; Chronic Disease; Deamino Arginine Vasopressin; Hemorrhage; Hemostat | 2016 |
Tranexamic Acid Update in Trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injuries | 2017 |
New treatment approaches to von Willebrand disease.
Topics: Deamino Arginine Vasopressin; Hemorrhage; Humans; Tranexamic Acid; von Willebrand Diseases; von Will | 2016 |
[Haemostatic resuscitation in bleeding trauma patients].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Critical Illness; Fluid The | 2016 |
Antifibrinolytic drugs for acute traumatic injury.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Transfusion; Hemorrhage; Humans; Ran | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum.
Topics: Animals; Antifibrinolytic Agents; Blood Loss, Surgical; Clinical Trials as Topic; Female; Hemorrhage | 2011 |
Tranexamic acid for trauma patients: a critical review of the literature.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Hemorrhage; Humans; Injury Severity Score; Tranex | 2011 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
The effect of tranexamic acid on blood loss and use of blood products in total knee arthroplasty: a meta-analysis.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; H | 2012 |
Tranexamic acid autoinjector for prehospital care of noncompressible hemorrhage.
Topics: Antifibrinolytic Agents; Automation; Emergency Medical Services; Equipment Design; Hemorrhage; Hemos | 2011 |
Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment.
Topics: Antifibrinolytic Agents; Factor V Deficiency; Gene Duplication; Genetic Predisposition to Disease; H | 2011 |
Management of coagulation: an Australian perspective.
Topics: Australia; Blood Coagulation Disorders; Factor VIIa; Hemorrhage; Humans; Perioperative Care; Platele | 2012 |
Is management of acute traumatic brain injury effective? A literature review of published Cochrane Systematic Reviews.
Topics: Brain Injuries; Hemorrhage; Humans; Systematic Reviews as Topic; Tranexamic Acid | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.
Topics: Antifibrinolytic Agents; Cost-Benefit Analysis; Fibrinolysis; Hemorrhage; Humans; Randomized Control | 2012 |
Emerging treatment strategies for trauma-induced coagulopathy.
Topics: Acidosis; Anemia; Antifibrinolytic Agents; Bandages; Blood Coagulation Disorders; Blood Coagulation | 2012 |
Should antifibrinolytics be given in all patients with trauma?
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Emergency Medical Services; Hemorrhage; Humans; T | 2012 |
The frequency of thrombotic events among adults given antifibrinolytic drugs for spontaneous bleeding: systematic review and meta-analysis of observational studies and randomized trials.
Topics: Adult; Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Hemorrhage; Humans; Middle Aged; | 2012 |
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Postoperative Complications; Randomized Controlled Tria | 2013 |
Pharmacologic tools to reduce bleeding in surgery.
Topics: Administration, Oral; Antifibrinolytic Agents; Deamino Arginine Vasopressin; Factor Xa Inhibitors; F | 2012 |
Tranexamic acid in remote damage control resuscitation.
Topics: Antifibrinolytic Agents; Blood Component Transfusion; Hemorrhage; Humans; Resuscitation; Tranexamic | 2013 |
Local and systemic hemostatics as an adjunct to control bleeding in trauma.
Topics: Administration, Topical; Cellulose, Oxidized; Chitosan; Combined Modality Therapy; Factor VIIa; Fibr | 2013 |
Potential value of protocols in substantially bleeding trauma patients.
Topics: Blood Coagulation Disorders; Blood Coagulation Tests; Clinical Protocols; Hemorrhage; Humans; Thromb | 2013 |
Pharmacologic methods to reduce perioperative bleeding.
Topics: Aminocaproic Acid; Aprotinin; Deamino Arginine Vasopressin; Hemorrhage; Hemostatics; Humans; Meta-An | 2008 |
Basis of antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Caseins; Fibrin; Fibrinolysin; Fibrinolysis; | 1980 |
Basis of antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Caseins; Fibrin; Fibrinolysin; Fibrinolysis; | 1980 |
Basis of antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Caseins; Fibrin; Fibrinolysin; Fibrinolysis; | 1980 |
Basis of antifibrinolytic therapy.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Caseins; Fibrin; Fibrinolysin; Fibrinolysis; | 1980 |
Prevention and management of bleeding complications after thrombolysis.
Topics: Aprotinin; Clinical Trials as Topic; Coronary Angiography; Coronary Disease; Drug Interactions; Fibr | 1993 |
Hemostatic drugs.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surgica | 1998 |
Current status of non-transfusional haemostatic agents.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Blood Loss, Surg | 1999 |
Local fibrinolysis as a mechanism for haemorrhage.
Topics: Aminocaproates; Endometrium; Epistaxis; Female; Fibrinolysis; Gastric Juice; Gastrointestinal Hemorr | 1975 |
Indications for antifibrinolytic therapy.
Topics: Aminocaproates; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Disorders; Disseminated Intrav | 1975 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
70 trials available for tranexamic acid and Hemorrhage
| Article | Year |
|---|---|
Temporal Transitions in Fibrinolysis after Trauma: Adverse Outcome Is Principally Related to Late Hypofibrinolysis.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Tests; Cohort Studies; Female; Fibrinolysis; Hemor | 2022 |
The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children.
Topics: Antifibrinolytic Agents; Bayes Theorem; Child; Double-Blind Method; Hemorrhage; Humans; Tranexamic A | 2021 |
Effect of age on the efficacy of tranexamic acid: An analysis of heterogeneity of treatment effect within the CRASH-2 dataset.
Topics: Adult; Aged; Antifibrinolytic Agents; Bayes Theorem; Hemorrhage; Humans; Odds Ratio; Tranexamic Acid | 2022 |
Tranexamic Acid in Patients Undergoing Noncardiac Surgery.
Topics: Antifibrinolytic Agents; Canada; Hemorrhage; Humans; Surgical Procedures, Operative; Thrombosis; Tra | 2022 |
Prehospital synergy: Tranexamic acid and blood transfusion in patients at risk for hemorrhage.
Topics: Antifibrinolytic Agents; Blood Transfusion; Emergency Medical Services; Hemorrhage; Humans; Tranexam | 2022 |
The effect of early tranexamic acid on bleeding, blood product consumption, mortality and length of hospital stay in trauma cases with hemorrhagic shock: a randomized clinical trial.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Length of Stay; Shock, Hemorrhagic; Tranexamic Acid | 2021 |
Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
Topics: Adult; Antifibrinolytic Agents; Double-Blind Method; Female; Hematologic Neoplasms; Hemorrhage; Huma | 2022 |
The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial
Topics: Antifibrinolytic Agents; Double-Blind Method; Hemorrhage; Humans; Thromboembolism; Tranexamic Acid | 2022 |
Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Dose-Response R | 2022 |
Tranexamic acid in pediatric hemorrhagic trauma.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemorrhage; Humans; Prospective Studies; Retro | 2023 |
Alternative routes for tranexamic acid treatment in obstetric bleeding (WOMAN-PharmacoTXA trial): a randomised trial and pharmacological study in caesarean section births.
Topics: Administration, Intravenous; Antifibrinolytic Agents; Cesarean Section; Female; Hemorrhage; Humans; | 2023 |
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a phase 3, open-label, randomised, crossover trial.
Topics: Adolescent; Adult; Cross-Over Studies; Female; Hemorrhage; Humans; Menorrhagia; Middle Aged; Tranexa | 2023 |
The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled tri
Topics: Administration, Intravenous; Administration, Oral; Antifibrinolytic Agents; Australia; Double-Blind | 2019 |
Introduction of a standardised protocol, including systematic use of tranexamic acid, for management of severe adult trauma patients in a low-resource setting: the MSF experience from Port-au-Prince, Haiti.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Clinical Protocols; Developing Countries; Female; | 2019 |
Effect of Tranexamic Acid on Coagulation and Fibrin Clot Properties in Children Undergoing Craniofacial Surgery.
Topics: Blood Coagulation; Child; Child, Preschool; Craniosynostoses; Factor XIII; Female; Fibrin Clot Lysis | 2020 |
[Clinical study on the control of intra-articular hemorrhage by tranexamic acid after shoulder arthroscopy].
Topics: Arthroscopy; Child, Preschool; Female; Hemorrhage; Humans; Infant; Male; Range of Motion, Articular; | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cohort Studies; Double-Blind Method; Female; Hemo | 2020 |
The Immunologic Effect of Early Intravenous Two and Four Gram Bolus Dosing of Tranexamic Acid Compared to Placebo in Patients With Severe Traumatic Bleeding (TAMPITI): A Randomized, Double-Blind, Placebo-Controlled, Single-Center Trial.
Topics: Administration, Intravenous; Double-Blind Method; Female; Hemorrhage; Humans; Interleukin-6; L-Selec | 2020 |
Early intravenous tranexamic acid intervention reduces post-traumatic hidden blood loss in elderly patients with intertrochanteric fracture: a randomized controlled trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage | 2021 |
Tranexamic acid and bleeding in patients treated with non-vitamin K oral anticoagulants undergoing dental extraction: The EXTRACT-NOAC randomized clinical trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Belgium; Dou | 2021 |
Early Prehospital Tranexamic Acid Following Injury Is Associated With a 30-day Survival Benefit: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Double-Blind Method; Emergency Medical Services; | 2021 |
Perioperative Tranexamic Acid for ACTH-Secreting Pituitary Adenomas: Implementation Protocol Results and Trial Prospectus.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Antifibrinolytic Agents; Hemorrhage; Humans; Intraoperati | 2021 |
Enrollment with and without exception from informed consent in a pilot trial of tranexamic acid in children with hemorrhagic injuries.
Topics: Child; Hemorrhage; Humans; Informed Consent; Pilot Projects; Tranexamic Acid | 2021 |
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Topics: Adolescent; Adult; Antidotes; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Factors; | 2018 |
Traumatic injury clinical trial evaluating tranexamic acid in children (TIC-TOC): study protocol for a pilot randomized controlled trial.
Topics: Adolescent; Antifibrinolytic Agents; Brain Injuries, Traumatic; Child; Child, Preschool; Clinical Tr | 2018 |
Aspirin in coronary artery surgery: 1-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery trial.
Topics: Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Th | 2019 |
Tranexamic acid in coronary artery surgery: One-year results of the Aspirin and Tranexamic Acid for Coronary Artery Surgery (ATACAS) trial.
Topics: Activities of Daily Living; Aged; Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass; Coronary | 2019 |
The Effect of Tranexamic Acid on Functional Outcomes: An Exploratory Analysis of the CRASH-2 Randomized Controlled Trial.
Topics: Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Female; Hemorrhage; Humans; Male; Middle Aged | 2019 |
Role of Suction Drain after Knee Arthroplasty in the Tranexamic Acid Era: A Randomized Controlled Study.
Topics: Aged; Analgesics, Opioid; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Edema; Female; H | 2019 |
"Evaluation of the effect of roasted lentil flour (lentil savigh) as a functional food in menstrual bleeding reduction".
Topics: Adult; Female; Flour; Functional Food; Hemorrhage; Humans; Iran; Lens Plant; Menorrhagia; Menstruati | 2019 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Confidence Intervals; Craniocerebral Trauma; Fema | 2013 |
Tranexamic acid without prophylactic factor replacement for prevention of bleeding in hereditary bleeding disorder patients undergoing endoscopy: a pilot study.
Topics: Adult; Aged; Biopsy; Blood Coagulation Factors; Blood Loss, Surgical; Demography; Endoscopy; Female; | 2013 |
Development and validation of a prognostic model to predict death in patients with traumatic bleeding, and evaluation of the effect of tranexamic acid on mortality according to baseline risk: a secondary analysis of a randomised controlled trial.
Topics: Adult; Aged; Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Middle Aged; Models, Theoret | 2013 |
Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.
Topics: Adult; Cause of Death; Erythrocyte Transfusion; Hemorrhage; Humans; Odds Ratio; Risk; Risk Assessmen | 2014 |
Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.
Topics: Adult; Cause of Death; Erythrocyte Transfusion; Hemorrhage; Humans; Odds Ratio; Risk; Risk Assessmen | 2014 |
Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.
Topics: Adult; Cause of Death; Erythrocyte Transfusion; Hemorrhage; Humans; Odds Ratio; Risk; Risk Assessmen | 2014 |
Red blood cell transfusion and mortality in trauma patients: risk-stratified analysis of an observational study.
Topics: Adult; Cause of Death; Erythrocyte Transfusion; Hemorrhage; Humans; Odds Ratio; Risk; Risk Assessmen | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease.
Topics: Adult; Aged; Antifibrinolytic Agents; Cross-Over Studies; Double-Blind Method; Epistaxis; Europe; Fe | 2014 |
Tranexamic acid use in severely injured civilian patients and the effects on outcomes: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Drug Administration Schedule; F | 2015 |
Mechanism of action of tranexamic acid in bleeding trauma patients: an exploratory analysis of data from the CRASH-2 trial.
Topics: Antifibrinolytic Agents; Cause of Death; Exsanguination; Female; Hemorrhage; Humans; Male; Mortality | 2014 |
Double-blinded, placebo-controlled study of early tranexamic acid treatment in swine uncontrolled hemorrhage model.
Topics: Animals; Double-Blind Method; Female; Hemorrhage; Hydroxyethyl Starch Derivatives; Placebos; Plasma; | 2016 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Aspirin; Blood Transfusion; Coronary Artery Bypass | 2017 |
Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Blood Platelets; Female; Hematopoietic Stem Cell Transpl | 2016 |
Tranexamic acid in bleeding trauma patients: an exploration of benefits and harms.
Topics: Age Factors; Antifibrinolytic Agents; Blood Pressure; Chi-Square Distribution; Fibrinolysis; Glasgow | 2017 |
Comparison of Enoxaparin and Rivaroxaban in Balance of Anti-Fibrinolysis and Anticoagulation Following Primary Total Knee Replacement: A Pilot Study.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Drug Interactions; Enoxapa | 2017 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tra | 2010 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
Topics: Adult; Antifibrinolytic Agents; Hemorrhage; Humans; Logistic Models; Time Factors; Tranexamic Acid; | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Global Health; Hemorrhage; Hospit | 2011 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) A randomised, placebo-controlled trial.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Cause of Death; Chi-Square Distribution; Female; | 2010 |
Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial.
Topics: Adenoidectomy; Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Double-Blind | 2012 |
Effect of tranexamic acid on mortality in patients with traumatic bleeding: prespecified analysis of data from randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Drug Administration Schedule; Female; Hemor | 2012 |
Intravenous tranexamic acid and intraoperative visualization during functional endoscopic sinus surgery: a double-blind randomized controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Chemotherapy, | 2013 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
Bone bleeding during total hip arthroplasty after administration of tranexamic acid.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusi | 2004 |
The CRASH-2 trial of an antifibrinolytic agent in traumatic haemorrhage: an international collaboration.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; International Cooperation; Tranexamic Acid; World Healt | 2007 |
Use of an antifibrinolytic agent (tranexamic acid) and lateral sutures with laser conization of the cervix.
Topics: Carcinoma in Situ; Cervix Uteri; Clinical Trials as Topic; Curettage; Cyclohexanecarboxylic Acids; F | 1984 |
The prevention of secondary haemorrhage after prostatectomy: the value of antifibrinolytic therapy.
Topics: Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Hemorrhage; Humans; Male; Postoperative Compl | 1980 |
[The use of antifibrinolytics in heart surgery. 3 prospective studies].
Topics: Antifibrinolytic Agents; Aprotinin; Blood Platelets; Cardiac Surgical Procedures; Creatinine; Double | 1993 |
The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial.
Topics: Blood Transfusion; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Doub | 1995 |
Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations.
Topics: Adult; Aged; Blood Transfusion, Autologous; Body Surface Area; Coronary Artery Bypass; Early Ambulat | 1993 |
A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antifibrinolytic Agents; Double-Blind Method; Female; Hemorr | 1995 |
Tranexamic acid reduces postbypass blood use: a double-blinded, prospective, randomized study of 210 patients.
Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Cardiopulmonary Bypass; Double-Blind Method; Femal | 1996 |
Surgical repair of congenital diaphragmatic hernia during extracorporeal membrane oxygenation: hemorrhagic complications and the effect of tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Extracorporeal Membrane Oxygenatio | 1997 |
Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Deamino Arginine Vasopressin; D | 2000 |
Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Child, Preschool; Disease Management; Fact | 2000 |
Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Topics: Adult; Antigens; Blood Loss, Surgical; Child; Child, Preschool; Drug Administration Schedule; Electi | 2001 |
Double-blind trials with ethamsylate, batroxobin or tranexamic acid on blood loss after adenotonsillectomy.
Topics: Adenoidectomy; Batroxobin; Benzenesulfonates; Child; Clinical Trials as Topic; Cyclohexanecarboxylic | 1977 |
The effect of urokinase on central corneal thickness and vitreous haemorrhage.
Topics: Aged; Antifibrinolytic Agents; Clinical Trials as Topic; Cornea; Drug Evaluation; Endopeptidases; Ey | 1978 |
[Result of an antifibrinolytic treatment using tranexamic acid for the reduction of blood-loss during and after tonsillectomy].
Topics: Adolescent; Adult; Cyclohexanecarboxylic Acids; Drug Evaluation; Female; Hemorrhage; Humans; Male; M | 1977 |
Lack of efficacy of tranexamic acid in thrombocytopenic bleeding.
Topics: Anemia, Aplastic; Blood Transfusion; Hemorrhage; Humans; Myelodysplastic Syndromes; Platelet Transfu | 1991 |
Prophylactic tranexamic acid decreases bleeding after cardiac operations.
Topics: Adult; Aged; Blood Coagulation Factors; Blood Coagulation Tests; Coronary Artery Bypass; Cyclohexane | 1990 |
Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia.
Topics: Adolescent; Adult; Blood Transfusion; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Double- | 1989 |
Antifibrinolytic therapy for prevention of hemorrhage during surgery of the thyroid gland.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Cyclohexanecarboxylic Acids; Double-Blind Method; Fibrinoly | 1987 |
Effect of tranexamic acid on postvitrectomy haemorrhage in diabetic patients.
Topics: Adolescent; Adult; Aged; Cyclohexanecarboxylic Acids; Diabetes Complications; Diabetic Retinopathy; | 1987 |
288 other studies available for tranexamic acid and Hemorrhage
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of novel matrix metalloproteinase inhibitors as potent antihemorrhagic agents: from hit identification to an optimized lead.
Topics: Animals; Benzamides; Cell Membrane Permeability; Drug Design; Hemorrhage; Humans; Hydroxamic Acids; | 2015 |
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
Topics: Animals; Antifibrinolytic Agents; Catalytic Domain; Crystallography, X-Ray; Fibrinolysin; Fibrinolys | 2020 |
Massive transfusion in trauma: an evolving paradigm.
Topics: Blood Coagulation Disorders; Blood Transfusion; Hemorrhage; Humans; Tranexamic Acid; Wounds and Inju | 2022 |
Use of Antifibrinolytics in Pediatric Life-Threatening Hemorrhage: A Prospective Observational Multicenter Study.
Topics: Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Child; Child, Preschool; Female; Hemorrhage; | 2022 |
Tranexamic acid for obstetric hemorrhage: Prophylaxis, treatment, both, neither?
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Postpartum Hemorrhage; Pregnancy; Tranexamic Ac | 2021 |
Barriers and facilitators to the administration of prehospital tranexamic acid: a paramedic interview study using the theoretical domains framework.
Topics: Allied Health Personnel; Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Qu | 2022 |
Real-world decision-making in the management of patients presenting with major bleeding on rivaroxaban: the Auckland regional experience.
Topics: Anticoagulants; Hemorrhage; Humans; Retrospective Studies; Rivaroxaban; Tranexamic Acid | 2023 |
Safety and efficacy of intravenous or topical tranexamic acid administration in surgery: a protocol for a systematic review and network meta-analysis.
Topics: Administration, Intravenous; Administration, Topical; Antifibrinolytic Agents; Blood Loss, Surgical; | 2022 |
Use of tranexamic acid in major trauma: a sex-disaggregated analysis of the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2 and CRASH-3) trials and UK trauma registry (Trauma and Audit Research Network) data.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Registries; Tranexamic Acid; United Kingd | 2022 |
The role of tranexamic acid in trauma - a life-saving drug with proven benefit.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2022 |
Reply to 'The role of tranexamic acid in trauma - a life-saving drug with proven benefit'.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2022 |
Decolonising knowledge production: our experience researching tranexamic acid for trauma victims.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Knowledge; Tranexamic Acid | 2022 |
[In high-risk patients undergoing noncardiac surgery, does tranexamic acid result in a lower incidence of bleeding while being safe from a cardiovascular point of view compared to placebo?]
Topics: Antifibrinolytic Agents; Cardiovascular System; Hemorrhage; Humans; Incidence; Tranexamic Acid | 2022 |
Post-procedural bleeding rate and haemostatic treatment use for dental procedures before and after the implementation of a standardized protocol for people with inherited bleeding disorders.
Topics: Adult; Dentistry; Female; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Retrospective Studies | 2022 |
Sex discrimination after injury: is inequity in tranexamic acid administration just the tip of the iceberg?
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Randomized Controlled Trials as Topic; Se | 2022 |
Estimated Cost-Effectiveness of Implementing a Statewide Tranexamic Acid Protocol for the Management of Suspected Hemorrhage in the Prehospital Setting.
Topics: Adolescent; Antifibrinolytic Agents; Cost-Benefit Analysis; Emergency Medical Services; Hemorrhage; | 2023 |
Massive Clot Formation Following FEIBA and Tranexamic Acid Administration in Postcardiopulmonary Bypass Hemorrhage.
Topics: Blood Coagulation Factors; Factor VIII; Hemophilia A; Hemorrhage; Humans; Tranexamic Acid | 2022 |
Management of disseminated intravascular coagulation after thoracic endovascular aortic repair of type B aortic dissection: a case report.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aortic Dissection; Blood Vessel Prosthesis Implanta | 2022 |
Tranexamic acid for treatment of tenecteplase related hemorrhagic conversion.
Topics: Antifibrinolytic Agents; Fibrinolytic Agents; Hemorrhage; Humans; Tenecteplase; Tissue Plasminogen A | 2022 |
Inhaled Tranexamic Acid for the Management of Hemoptysis in a Patient With Right and Left Ventricular Assist Devices: A Case Report.
Topics: Anticoagulants; Heart-Assist Devices; Hemoptysis; Hemorrhage; Humans; Shock, Cardiogenic; Tranexamic | 2022 |
Absence of hyperfibrinolysis may explain lack of efficacy of tranexamic acid in hypoproliferative thrombocytopenia.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans | 2023 |
Topical tranexamic acid for prophylaxis of bleeding.
Topics: Administration, Topical; Hemorrhage; Humans; Tranexamic Acid | 2023 |
[PERIOPERATIVE MANAGEMENT OF AN ADOLESCENT GIRL WITH SEVERE FACTOR XI DEFICIENCY AND INHIBITORS].
Topics: Adolescent; Factor XI Deficiency; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He | 2023 |
Time to early resuscitative intervention association with mortality in trauma patients at risk for hemorrhage.
Topics: Blood Transfusion; Emergency Medical Services; Hemorrhage; Humans; Resuscitation; Shock, Hemorrhagic | 2023 |
Life-Threatening Retroperitoneal Hemorrhage Following Cyst Rupture in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Case Report.
Topics: Cysts; Hemorrhage; Humans; Kidney; Male; Middle Aged; Polycystic Kidney, Autosomal Dominant; Rupture | 2023 |
Rapid administration of Kcentra® during cardiopulmonary arrest.
Topics: Aged, 80 and over; Anticoagulants; Blood Coagulation Factors; Female; Heart Arrest; Hemorrhage; Huma | 2023 |
Tranexamic acid as a novel adjunct in the management of vessel perforation complicating Endovascular Clot Retrieval.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Case-Control Studies; Hemorrhage; Humans; Retrospecti | 2023 |
Where Does Tranexamic Acid Fit in the Armamentarium for Bronchoscopic Bleeding?
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2023 |
Anti-fibrinolytic agent tranexamic acid suppresses the endotoxin-induced expression of Tnfα and Il1α genes in a plasmin-independent manner.
Topics: Animals; Antifibrinolytic Agents; Endotoxins; Fibrinolysin; Fibrinolytic Agents; Hemorrhage; Lipopol | 2023 |
Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children.
Topics: Acute Kidney Injury; Adolescent; Aminocaproic Acid; Antifibrinolytic Agents; Blood Loss, Surgical; C | 2023 |
Desmopressin (DDAVP) use in patients with von Willebrand disease: A single-centre retrospective review of test response and clinical outcomes.
Topics: Adolescent; Adult; Deamino Arginine Vasopressin; Factor VIII; Hemorrhage; Humans; Retrospective Stud | 2023 |
EFFECTS OF TRANEXAMIC ACID ON NEUROPATHOLOGY, ELECTROENCEPHALOGRAPHY, AND CEREBRAL FIBRIN DEPOSITION IN A RAT MODEL OF POLYTRAUMA WITH CONCOMITANT PENETRATING TRAUMATIC BRAIN INJURY.
Topics: Animals; Antifibrinolytic Agents; Brain Injuries; Brain Injuries, Traumatic; Electroencephalography; | 2023 |
Treatment of post-tonsillectomy hemorrhage with nebulized tranexamic acid: A retrospective study.
Topics: Adult; Antifibrinolytic Agents; Child; Hemorrhage; Humans; Postoperative Hemorrhage; Retrospective S | 2023 |
Tranexamic Acid Was Not Associated With a Reduction in Bleeding Complications Related to Holmium Laser Enucleation of the Prostate.
Topics: Hemorrhage; Holmium; Humans; Laser Therapy; Lasers, Solid-State; Male; Prostate; Prostatic Hyperplas | 2023 |
Bacteriosynthetic Degradable Tranexamic Acid-Functionalized Short Fibers for Inhibiting Invisible Hemorrhage.
Topics: Animals; Blood Coagulation; Hemoglobins; Hemorrhage; Hemostatics; Liver Diseases; Rats; Tranexamic A | 2023 |
A lethal case of massive hemorrhage after percutaneous liver biopsy in a patient with thrombasthenia.
Topics: Biopsy; Female; Hemorrhage; Humans; Liver; Middle Aged; Thrombasthenia; Tranexamic Acid | 2023 |
Letter to Editor regarding article, "Medullary cavity application of tranexamic acid to reduce blood loss in tibial intramedullary nailing procedures-a randomized controlled trial".
Topics: Fracture Fixation, Intramedullary; Hemorrhage; Humans; Tibia; Tibial Fractures; Tranexamic Acid | 2023 |
Tranexamic Acid Prevention of Hemorrhagic Complications Following Interpolated Flap Repair: A Single-Center, Retrospective, Cohort Study.
Topics: Antifibrinolytic Agents; Cohort Studies; Hemorrhage; Humans; Retrospective Studies; Tranexamic Acid | 2023 |
Thromboembolic Complications Following Perioperative Tranexamic Acid Administration.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Retrospective Studies; Tranexamic | 2024 |
PATCHing Traumatic Hemorrhage With Out-of-Hospital Tranexamic Acid Administration.
Topics: Antifibrinolytic Agents; Hemorrhage; Hospitals; Humans; Tranexamic Acid | 2023 |
Tranexamic Acid for Bleeding Management in Adult Patients on Extracorporeal Membrane Oxygenation.
Topics: Adolescent; Adult; Extracorporeal Membrane Oxygenation; Hemorrhage; Hemostatics; Humans; Retrospecti | 2023 |
Ruggedized Self-Propelling Hemostatic Gauze Delivers Low Dose of Thrombin and Systemic Tranexamic Acid and Achieves High Survival in Swine With Junctional Hemorrhage.
Topics: Animals; Bandages; Blindness; Disease Models, Animal; Hemorrhage; Hemostatic Techniques; Hemostatics | 2023 |
Inhaled tranexamic acid use for pulmonary hemorrhage in children on ECMO.
Topics: Antifibrinolytic Agents; Child; Extracorporeal Membrane Oxygenation; Female; Hemorrhage; Humans; Lun | 2023 |
Pharmacokinetics of Tranexamic Acid Given as an Intramuscular Injection Compared to Intravenous Infusion in a Swine Model of Ongoing Hemorrhage.
Topics: Animals; Antifibrinolytic Agents; Disease Models, Animal; Female; Hemorrhage; Infusions, Intravenous | 2020 |
Suspected anaphylactic shock associated with administration of tranexamic acid in a dog.
Topics: Anaphylaxis; Animals; Cystitis; Cystotomy; Dog Diseases; Dogs; Hematuria; Hemorrhage; Male; Tranexam | 2019 |
Administration of tranexamic acid for victims of severe trauma within pre-hospital care ambulance services (PHCAS) in Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulances; Antifibrinolytic Agents; Child; Drug Adminis | 2019 |
Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Loss, Surgical; Drug Administration Schedule; Factor VII | 2019 |
Tranexamic acid for trauma: Repackaged and redelivered.
Topics: Antifibrinolytic Agents; Fibrin Clot Lysis Time; Fibrinolysis; Hemorrhage; Humans; Tranexamic Acid | 2019 |
Reply to Letter: No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model.
Topics: Administration, Intravenous; Animals; Hemorrhage; Infusions, Intraosseous; Swine; Tranexamic Acid | 2019 |
Effect of tranexamic acid administration on acute traumatic coagulopathy in rats with polytrauma and hemorrhage.
Topics: Animals; Antifibrinolytic Agents; Biomarkers; Blood Coagulation; Blood Coagulation Disorders; Diseas | 2019 |
Does tranexamic acid really work in an urban US level I trauma center? A single level 1 trauma center's experience.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Hospitals, Urban; Humans; Mal | 2019 |
An Analysis of Adherence to Tactical Combat Casualty Care Guidelines for the Administration of Tranexamic Acid.
Topics: Adolescent; Adult; Afghan Campaign 2001-; Antifibrinolytic Agents; Female; Guideline Adherence; Hemo | 2019 |
Topical tranexamic acid (TXA) for the management of a bleeding arteriovenous fistula.
Topics: Administration, Topical; Aged, 80 and over; Antifibrinolytic Agents; Arteriovenous Fistula; Emergenc | 2020 |
Early coagulation support protocol: A valid approach in real-life management of major trauma patients. Results from two Italian centres.
Topics: Adult; Aged; Blood Coagulation; Blood Coagulation Disorders; Blood Transfusion; Clinical Protocols; | 2019 |
Tranexamic Acid for Acute Hemorrhage: When Is Enough Evidence Enough?
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2019 |
Bronchoscopic delivery of aminocaproic acid as a treatment for pulmonary bleeding: A case series.
Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Bronchoscopy; Female; Hemoptysis; Hemorrhage; Huma | 2020 |
EHL-FIX in haemophilia B carriers with FIX deficiency.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Child; Factor IX; Female; Half-Life; Hemophilia A; Hemop | 2020 |
Tranexamic acid: One more step towards its widespread use.
Topics: Antifibrinolytic Agents; Brain Hemorrhage, Traumatic; Clinical Trials as Topic; Drug Utilization; He | 2020 |
Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
Topics: Adult; Aged; Aged, 80 and over; Blood Coagulation; Female; Fibrinolysis; Hemorrhage; Humans; Immunog | 2020 |
On the role of tranexamic acid in emergency department patients with trauma.
Topics: Emergency Service, Hospital; Hemorrhage; Humans; Tranexamic Acid | 2020 |
Tranexamic acid for acute traumatic hemorrhage in emergency medicine: why not, but….
Topics: Antifibrinolytic Agents; Emergency Medicine; Hemorrhage; Humans; Tranexamic Acid | 2020 |
Experience in an Urban Level 1 Trauma Center With Tranexamic Acid in Pediatric Trauma: A Retrospective Chart Review.
Topics: Antifibrinolytic Agents; Child; Hemorrhage; Humans; Retrospective Studies; Tranexamic Acid; Trauma C | 2021 |
Developing clinical performance indicators for pre-hospital blood transfusion: The Thames Valley Air Ambulance approach.
Topics: Air Ambulances; Blood Transfusion; Emergency Medical Services; Hemorrhage; Humans; Tranexamic Acid; | 2020 |
Mortality and Complication Rates in Adult Trauma Patients Receiving Tranexamic Acid: A Single-center Experience in the Post-CRASH-2 Era.
Topics: Adult; Aged; Antifibrinolytic Agents; Female; Hemorrhage; Humans; Injury Severity Score; Male; Middl | 2020 |
Tranexamic acid: the king is dead, long live the king!
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2020 |
Tranexamic acid in pediatric combat trauma requiring massive transfusions and mortality.
Topics: Adolescent; Afghanistan; Antifibrinolytic Agents; Blood Transfusion; Child; Child, Preschool; Combin | 2020 |
Commentary on: Local Infiltration of Tranexamic Acid With Local Anesthetic Reduces Intraoperative Facelift Bleeding: A Preliminary Report.
Topics: Anesthesia, Local; Anesthetics, Local; Hemorrhage; Humans; Rhytidoplasty; Tranexamic Acid | 2020 |
Fibrinolysis and tranexamic acid: mechanistic principles.
Topics: Antifibrinolytic Agents; Blood Coagulation; Fibrin; Fibrinolysin; Fibrinolysis; Hemorrhage; Humans; | 2020 |
Influence of tranexamic acid on the complement system in trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injuries | 2020 |
Tranexamic acid and inflammation in trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Inflammation; Tranexamic Acid; Wounds and Injuries | 2020 |
Perspectives on tranexamic acid in surgery.
Topics: Antifibrinolytic Agents; Blood Coagulation; Blood Loss, Surgical; Hemorrhage; Humans; Publications; | 2020 |
Genetic variants associated with Hermansky-Pudlak syndrome.
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Blood Platelets; Carrier Proteins; Contusions; Deamino A | 2020 |
Computational model of tranexamic acid on urokinase mediated fibrinolysis.
Topics: alpha 1-Antitrypsin; Antifibrinolytic Agents; Blood Coagulation; Blood Coagulation Disorders; Comput | 2020 |
Tranexamic Acid for Bleeding Control During a Hair Transplant Procedure.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2020 |
Use of Tranexamic Acid for the Treatment of Mittelschmerz in a Patient with Type 1 von Willebrand Disease and Recurrent Hemorrhagic Cysts.
Topics: Adult; Cysts; Female; Hemorrhage; Humans; Ovulation; Pain; Pelvic Pain; Tranexamic Acid; Treatment O | 2020 |
Safety of tranexamic acid in thrombotic adverse events and seizure in patients with haemorrhage: a protocol for a systematic review and meta-analysis.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Meta-Analysis as Topic; Patient Safety; Systematic Revi | 2020 |
Pre-hospital blood transfusion - an ESA survey of European practice.
Topics: Antifibrinolytic Agents; Blood Transfusion; Emergency Medical Services; Europe; Hemorrhage; Humans; | 2020 |
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Intestines; Tranexamic Acid; Treatment Failure | 2020 |
Tranexamic acid not a cure for all bleeding.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2020 |
Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Injections, Intramuscular; Male; Middle Aged; P | 2021 |
Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers.
Topics: Aged; Anti-Bacterial Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female | 2021 |
Tranexamic acid and trauma coagulopathy: where are we now?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Hemorrhage; Humans; Tranexamic Acid; Wounds an | 2021 |
Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Platelets; Factor V Deficiency; Fibrinol | 2020 |
An unusual presentation and treatment of a hemorrhaging plexiform neurofibroma.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Combined Modality Therapy; Embolization, Therapeu | 2021 |
Platelet transfusion and tranexamic acid to prevent bleeding in outpatients with a hematological disease: A Dutch nationwide survey.
Topics: Clinical Decision-Making; Disease Management; Disease Susceptibility; Health Care Surveys; Hematolog | 2021 |
Plasmin thrombelastography rapidly identifies trauma patients at risk for massive transfusion, mortality, and hyperfibrinolysis: A diagnostic tool to resolve an international debate on tranexamic acid?
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Blood Transfusion; Female; | 2020 |
Impact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Obesity; Retrospective Stu | 2021 |
Validation of the BATT score for prehospital risk stratification of traumatic haemorrhagic death: usefulness for tranexamic acid treatment criteria.
Topics: Adolescent; Adult; Aged; Antifibrinolytic Agents; Emergency Medical Services; Female; Hemorrhage; Hu | 2021 |
Tranexamic acid for head injuries: on the CRASH-3 trial.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Craniocerebral Trauma; Hemorrhage; Humans; Tranex | 2021 |
Hockey: a pain in the butt! Isolated superior gluteal artery rupture following blunt pelvic trauma - an unusual case.
Topics: Aneurysm, False; Antifibrinolytic Agents; Buttocks; Computed Tomography Angiography; Embolization, T | 2021 |
A Cross-sectional Survey on the Use of Tranexamic Acid in the Pre-hospital Setting.
Topics: Antifibrinolytic Agents; Cross-Sectional Studies; Hemorrhage; Hospitals; Humans; Tranexamic Acid; Wo | 2021 |
Tranexamic acid retention for gallbladder bleeding.
Topics: Aged, 80 and over; Antifibrinolytic Agents; Female; Gallbladder; Hemorrhage; Humans; Tranexamic Acid | 2021 |
[Tranexamic acid: widely applicable, few risks].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Female; Hemorrhage; Hemostatic Techniques; Hum | 2021 |
Tranexamic Acid Treatment for Trauma Victims.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Pharmaceutical Preparations; Risk Factors; Tranexamic A | 2021 |
A role for nebulized tranexamic acid in veno-venous ECMO patients.
Topics: Administration, Inhalation; Adult; Aged; Antifibrinolytic Agents; Extracorporeal Membrane Oxygenatio | 2022 |
Tranexamic acid use in severely injured patients, is it always appropriate?
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Fibrinolysis; Hemorrhage; Humans; Tranexamic A | 2021 |
Post-tonsillectomy hemorrhage control with nebulized tranexamic acid: A retrospective cohort study.
Topics: Antifibrinolytic Agents; Child; Hemorrhage; Humans; Postoperative Hemorrhage; Retrospective Studies; | 2021 |
Early prehospital administration of tranexamic acid in hemorrhagic trauma is associated with increased survival as an independent variable.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Tranexamic Acid; Wounds and | 2021 |
A real-world study of immune thrombocytopenia management during the COVID-19 pandemic in the UK.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Autoimmune Diseases; Combined M | 2022 |
BET 2: Topical tranexamic acid in postcircumcision bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Child, Preschool; Circumcision, Male; Hemorrhage; | 2021 |
Prehospital transfer strategies and tranexamic acid during major trauma.
Topics: Antifibrinolytic Agents; Blood Transfusion; Emergency Medical Services; Hemorrhage; Humans; Tranexam | 2017 |
Tranexamic acid leads to paradoxical coagulation changes during cardiac surgery: a pilot rotational thromboelastometry study.
Topics: Aged; Antifibrinolytic Agents; Blood Coagulation; Cardiac Surgical Procedures; Hemorrhage; Humans; M | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Efficacy and Safety of Tranexamic Acid in Prehospital Traumatic Hemorrhagic Shock: Outcomes of the Cal-PAT Study.
Topics: Adult; Antifibrinolytic Agents; California; Emergency Medical Services; Feasibility Studies; Female; | 2017 |
Experimental Evaluation of Tranexamic Acid-Loaded Porous Starch as a Hemostatic Powder.
Topics: Animals; Hemorrhage; Hemostasis; Hemostatics; Humans; Powders; Rats; Starch; Time Factors; Tranexami | 2018 |
Bleeding Control in Palliative Care Patients With the Help of Tranexamic Acid.
Topics: Aged, 80 and over; Antifibrinolytic Agents; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; | 2017 |
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia.
Topics: Adult; Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Middle Aged; Purpura, Thrombocytop | 2017 |
Evaluation of Military Use of Tranexamic Acid and Associated Thromboembolic Events.
Topics: Abdominal Injuries; Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Guideline Adherence; | 2018 |
Tranexamic acid: is it about time?
Topics: Antifibrinolytic Agents; Hemorrhage; Tranexamic Acid | 2018 |
Does tranexamic acid increase the risk of thromboembolism after bilateral simultaneous total knee arthroplasties in Asian Population?
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Asian Peop | 2018 |
Tranexamic Acid Failed to Reverse the Anticoagulant Effect and Bleeding by an Oral Direct Factor Xa Inhibitor Edoxaban.
Topics: Animals; Antifibrinolytic Agents; Factor Xa Inhibitors; Hemorrhage; Male; Pyridines; Rats, Sprague-D | 2018 |
Tranexamic Acid for the Management of Obstetric Hemorrhage.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Pregnancy; Tranexamic Acid | 2017 |
Letter to the Editor concerning ''Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis.'' by Yuan, QM. et al. (Eur Spine J; 2017. doi:10.1007/s00586-016-4899-0).
Topics: Hemorrhage; Humans; Scoliosis; Tranexamic Acid | 2018 |
Nebulized tranexamic acid as a therapeutic alternative in pulmonary hemorrhage.
Topics: Administration, Inhalation; Adolescent; Antifibrinolytic Agents; Hemorrhage; Humans; Lung Diseases; | 2018 |
Primary hyperfibrinolysis as the presenting sign of prostate cancer: A case report.
Topics: Adenocarcinoma; Antifibrinolytic Agents; Biomarkers; Blood Coagulation Disorders; Blood Coagulation | 2016 |
Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: A randomised, placebo-controlled study in a rabbit model.
Topics: Administration, Intravenous; Animals; Antifibrinolytic Agents; Deamino Arginine Vasopressin; Drug Ev | 2018 |
Left atrial thrombi following tranexamic acid in a bleeding trauma patient-A word of caution.
Topics: Adult; Anticoagulants; Antifibrinolytic Agents; Female; Heart Atria; Heart Diseases; Hemorrhage; Hep | 2018 |
Management of injured patients who were Jehovah's Witnesses, where blood transfusion may not be an option: a retrospective review.
Topics: Anemia; Australia; Blood Transfusion; Erythropoietin; Female; Hemorrhage; Humans; Jehovah's Witnesse | 2018 |
Trauma systems and emergency medical services: The missing link for tranexamic acid utilization in major trauma.
Topics: Emergency Medical Services; Hemorrhage; Humans; Patient Compliance; Tranexamic Acid; Trauma Centers | 2018 |
Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe hemorrhage.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Time-to-Treatment; Tranexamic Acid | 2018 |
Evaluation of tranexamic acid in trauma patients: A retrospective quantitative analysis.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; British Columbia; Female; Hemorrhage; Hospital Mo | 2019 |
Severely injured trauma patients with admission hyperfibrinolysis: Is there a role of tranexamic acid? Findings from the PROPPR trial.
Topics: Adult; Antifibrinolytic Agents; Female; Fibrinolysis; Hemorrhage; Hemostasis; Humans; Injury Severit | 2018 |
Dental extractions in patients with mild hemophilia A and hemophilia B and von Willebrand disease without clotting factor supplementation.
Topics: Adult; Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Dental Caries; Female; Hemop | 2018 |
Tranexamic acid administration is associated with an increased risk of posttraumatic venous thromboembolism.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Injury Severity Score | 2019 |
Use of tranexamic acid in trauma patients requiring massive transfusion protocol activation: an audit in a major trauma centre in New Zealand.
Topics: Adult; Antifibrinolytic Agents; Blood Component Transfusion; Female; Hemorrhage; Humans; Male; Medic | 2018 |
[Effects of Tranexamic Acid after Cardiopulmonary Bypass on the Outcomes of Patients Undergoing Cardiac Surgery].
Topics: Adult; Antifibrinolytic Agents; Cardiopulmonary Bypass; China; Hemorrhage; Humans; Retrospective Stu | 2018 |
A delicate balance: Bleeding versus thrombosis?
Topics: Aspirin; Coronary Artery Bypass; Hemorrhage; Humans; Thrombosis; Tranexamic Acid | 2019 |
Implementation of tranexamic acid for bleeding trauma patients: a longitudinal and cross-sectional study.
Topics: Adult; Antifibrinolytic Agents; Cross-Sectional Studies; England; Female; Hemorrhage; Humans; Longit | 2019 |
Tranexamic acid mediates proinflammatory and anti-inflammatory signaling via complement C5a regulation in a plasminogen activator-dependent manner.
Topics: Adult; Anti-Inflammatory Agents; Antifibrinolytic Agents; Blood Coagulation; Complement C5a; Female; | 2019 |
Towards patient-specific management of trauma hemorrhage: the effect of resuscitation therapy on parameters of thromboelastometry.
Topics: Adult; Antifibrinolytic Agents; Clinical Decision-Making; Decision Support Techniques; Erythrocyte T | 2019 |
Total Knee Arthroplasty Is Safe and Successful in Patients With Klippel-Trénaunay Syndrome.
Topics: Adult; Aged; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Hemorrhage; Humans; Klippel | 2019 |
Low endoscopy bleeding risk in patients with congenital bleeding disorders.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Coagulants; Endoscopy, Digestive Sy | 2019 |
Effects of modification of trauma bleeding management: A before and after study.
Topics: Adult; Antifibrinolytic Agents; Blood Transfusion; Coagulants; Controlled Before-After Studies; Eryt | 2019 |
Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?
Topics: Adult; Antifibrinolytic Agents; Biomarkers; Female; Fibrin Clot Lysis Time; Fibrin Fibrinogen Degrad | 2019 |
Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation.
Topics: Animals; DNA Damage; DNA, Mitochondrial; Endothelial Cells; Granulocytes; Hemorrhage; Humans; Mice; | 2019 |
Letter to the Editor: No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model.
Topics: Administration, Intravenous; Animals; Antifibrinolytic Agents; Hemorrhage; Infusions, Intraosseous; | 2019 |
Topical tranexamic acid inhibits fibrinolysis more effectively when formulated with self-propelling particles.
Topics: Administration, Topical; Animals; Antifibrinolytic Agents; Calcium Carbonate; Carbon Dioxide; Diseas | 2019 |
Inhaled TXA for cases of massive hemoptysis.
Topics: Antifibrinolytic Agents; Hemoptysis; Hemorrhage; Humans; Tissue Plasminogen Activator; Tranexamic Ac | 2020 |
Tranexamic acid in traumatic hemorrhage: Evidence argues for a prehospital administration.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Trauma Centers | 2020 |
Prehospital tranexamic acid shortens the interval to administration by half in Major Trauma Networks: a service evaluation.
Topics: Adult; Antifibrinolytic Agents; Female; Hemorrhage; Humans; London; Male; Middle Aged; Registries; R | 2019 |
Trauma-targeted delivery of tranexamic acid improves hemostasis and survival in rat liver hemorrhage model.
Topics: Animals; Antifibrinolytic Agents; Blood Platelets; Disease Models, Animal; Fibrinogen; Hemorrhage; H | 2019 |
Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process.
Topics: Antifibrinolytic Agents; Blood Transfusion; Child; Consensus; Delphi Technique; Hemorrhage; Humans; | 2019 |
Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process.
Topics: Antifibrinolytic Agents; Blood Transfusion; Child; Consensus; Delphi Technique; Hemorrhage; Humans; | 2019 |
Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process.
Topics: Antifibrinolytic Agents; Blood Transfusion; Child; Consensus; Delphi Technique; Hemorrhage; Humans; | 2019 |
Development of transfusion guidelines for injured children using a Modified Delphi Consensus Process.
Topics: Antifibrinolytic Agents; Blood Transfusion; Child; Consensus; Delphi Technique; Hemorrhage; Humans; | 2019 |
[Management of massive bleeding in 2013: seven questions and answers].
Topics: Acute Disease; Blood Component Transfusion; Combined Modality Therapy; Disease Management; Erythrocy | 2013 |
Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study.
Topics: Afghanistan; Antifibrinolytic Agents; Cohort Studies; Drug Therapy, Combination; Factor VIII; Female | 2013 |
PURLs: Trauma care--don't delay with TXA.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injuries | 2013 |
Tranexamic acid and trauma: current status and knowledge gaps with recommended research priorities.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injuries | 2013 |
The CRASH-2 trial was not about global scientific supremacy.
Topics: Antifibrinolytic Agents; Emergency Treatment; Hemorrhage; Humans; Multicenter Studies as Topic; Rand | 2013 |
Reducing trauma deaths in the UK.
Topics: Antifibrinolytic Agents; Clinical Protocols; Emergency Service, Hospital; Hemorrhage; Humans; Tranex | 2013 |
Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions.
Topics: Drug Design; Hemorrhage; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Prodrugs; Tranexa | 2013 |
Tranexamic acid in trauma: we need stronger global health policy.
Topics: Antifibrinolytic Agents; Global Health; Health Policy; Hemorrhage; Humans; Multicenter Studies as To | 2013 |
Tranexamic acid and thrombosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Female; Hematuria; Hemorrhage; Humans; Menorrhagia; R | 2013 |
Trauma and tranexamic acid.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Thrombosis; Tranexamic Acid; Woun | 2013 |
Clinical transfusion practice update: haemovigilance, complications, patient blood management and national standards.
Topics: Acute Lung Injury; Anticoagulants; Antifibrinolytic Agents; Australia; Blood Transfusion; Clinical P | 2013 |
Tranexamic acid reduced mortality in trauma patients who were bleeding or at risk for bleeding.
Topics: Antifibrinolytic Agents; Blood Transfusion; Female; Hemorrhage; Humans; Male; Thrombosis; Tranexamic | 2013 |
Tranexamic acid in the prehospital setting: Israel Defense Forces' initial experience.
Topics: Adult; Antifibrinolytic Agents; Clinical Protocols; Emergency Medical Services; Female; Hemorrhage; | 2014 |
Battlefield administration of tranexamic acid by combat troops: a feasibility analysis.
Topics: Antifibrinolytic Agents; Feasibility Studies; Hemorrhage; Humans; Military Medicine; Military Person | 2014 |
Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
Topics: Blood Coagulation; Factor XIII; Fibrinogen; Fibrinolysin; Fibrinolysis; Hemodilution; Hemorrhage; Hu | 2014 |
The effects of tranexamic acid and prothrombin complex concentrate on the coagulopathy of trauma: an in vitro analysis of the impact of severe acidosis.
Topics: Acidosis; Animals; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Coagulation Factors; | 2013 |
[Can local administration of tranexamic acid reduce aspirin-induced bleeding in off-pump coronary artery bypass grafting( CABG) ?].
Topics: Antifibrinolytic Agents; Aspirin; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Male | 2013 |
No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin.
Topics: Aged; Aprotinin; Blood Transfusion; Elasticity; Female; Fibrinolysis; Hemorrhage; Hemostatics; Human | 2014 |
Bronchoscopic intratumoral injection of tranexamic acid to prevent excessive bleeding during multiple forceps biopsies of lesions with a high risk of bleeding: a prospective case series.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Bronchoscopy; Epinephrine; Female; Hemorrhage; Humans; Injec | 2014 |
Tranexamic acid and trauma.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injur | 2014 |
Tranexamic acid and trauma.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injur | 2014 |
Tranexamic acid and trauma.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Hemorrhage; Humans; Tranexamic Acid; Wounds and Injur | 2014 |
Tranexamic acid for trauma: filling the 'GAP' in evidence.
Topics: Antifibrinolytic Agents; Evidence-Based Medicine; Hemorrhage; Humans; Multiple Trauma; Resuscitation | 2014 |
Tranexamic acid for trauma: filling the 'GAP' in evidence.
Topics: Antifibrinolytic Agents; Evidence-Based Medicine; Hemorrhage; Humans; Multiple Trauma; Resuscitation | 2014 |
Tranexamic acid for trauma: filling the 'GAP' in evidence.
Topics: Antifibrinolytic Agents; Evidence-Based Medicine; Hemorrhage; Humans; Multiple Trauma; Resuscitation | 2014 |
Tranexamic acid for trauma: filling the 'GAP' in evidence.
Topics: Antifibrinolytic Agents; Evidence-Based Medicine; Hemorrhage; Humans; Multiple Trauma; Resuscitation | 2014 |
Early tranexamic acid use in trauma haemorrhage: why do we give it and which patients benefit most?
Topics: Antifibrinolytic Agents; Disseminated Intravascular Coagulation; Fibrinogen; Hemorrhage; Humans; Tra | 2015 |
Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma.
Topics: Blood Component Transfusion; Chest Pain; Combined Modality Therapy; Disseminated Intravascular Coagu | 2014 |
What is the evidence for tranexamic acid in burns?
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Burns; Hemorrhage; Humans; Tranexamic Acid | 2014 |
Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Blood Coagul | 2015 |
Tranexamic acid at the point of injury: the Israeli combined civilian and military experience.
Topics: Adult; Antifibrinolytic Agents; Clinical Protocols; Emergency Medical Services; Female; Hemorrhage; | 2014 |
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Blood--the most important humour?
Topics: Blood Transfusion; Erythrocyte Transfusion; Hemorrhage; Humans; Tranexamic Acid | 2015 |
Perioperative solutions for rapid recovery joint arthroplasty: get ahead and stay ahead.
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement; Clinical Protocols; Fluid Therapy; Hemorrhage; H | 2015 |
Tranexamic acid for treatment of bleeding in hemophagocytic lymphohistiocytosis.
Topics: Adult; Antifibrinolytic Agents; Female; Fibrinogen; Hemorrhage; Humans; Lymphohistiocytosis, Hemopha | 2015 |
Prophylactic intraoperative tranexamic acid administration and postoperative blood loss after transapical aortic valve implantation.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Aortic Valve Stenosis; Drug Administration | 2015 |
Protocol guided bleeding management improves cardiac surgery patient outcomes.
Topics: Aged; Blood Coagulation Tests; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Erythrocyte Tran | 2015 |
Tranexamic Acid for Hyperfibrinolytic Hemorrhage During Conservative Management of Placenta Percreta.
Topics: Adult; Antifibrinolytic Agents; Female; Fibrinolysis; Hemorrhage; Humans; Placenta Accreta; Pregnanc | 2015 |
A practical guideline for the haematological management of major haemorrhage.
Topics: Antifibrinolytic Agents; Blood Transfusion; Clinical Audit; Disease Management; Hematologic Tests; H | 2015 |
Iatrogenic Endobronchial Bleeding: Speed Things Up or Cool It Down?
Topics: Biopsy; Bronchoscopy; Clopidogrel; Epinephrine; Hemorrhage; Humans; Iatrogenic Disease; Platelet Agg | 2015 |
Forum for debate: Safety of allogeneic blood transfusion alternatives in the surgical/critically ill patient.
Topics: Anemia; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Factors; Blood Transfusion; Clinical T | 2015 |
TXA in the USA. Tranexamic acid's potentially bright future relies on collaborative data.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Evidence-Based Medicine; Hemorrhage; Humans; Tr | 2015 |
Use of Tranexamic Acid in Bleeding Combat Casualties.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Military Personnel; Tranexamic Acid; Wounds and Injurie | 2015 |
Tranexamic acid in major trauma: implementation and evaluation across South West England.
Topics: Adult; Aged; Antifibrinolytic Agents; Emergency Medical Services; Emergency Service, Hospital; Engla | 2017 |
Time since injury is the major factor in preventing tranexamic acid use in the trauma setting: An observational cohort study from a major trauma centre in a middle-income country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Cohort Studies; Drug Administra | 2015 |
Direct oral anticoagulants and the bleeding patient.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antifibrinolytic Agents; Antithrombins | 2016 |
The Combat Medic Aid Bag: 2025. CoTCCC Top 10 Recommended Battlefield Trauma Care Research, Development, and Evaluation Priorities for 2015.
Topics: Analgesics; Antifibrinolytic Agents; Attitude of Health Personnel; Biomedical Research; Blood Transf | 2015 |
Tranexamic acid in the trauma patient.
Topics: Accidents, Traffic; Adult; Antifibrinolytic Agents; Emergency Nursing; Emergency Service, Hospital; | 2016 |
Tranexamic acid in the trauma patient.
Topics: Accidents, Traffic; Adult; Antifibrinolytic Agents; Emergency Nursing; Emergency Service, Hospital; | 2016 |
Tranexamic acid in the trauma patient.
Topics: Accidents, Traffic; Adult; Antifibrinolytic Agents; Emergency Nursing; Emergency Service, Hospital; | 2016 |
Tranexamic acid in the trauma patient.
Topics: Accidents, Traffic; Adult; Antifibrinolytic Agents; Emergency Nursing; Emergency Service, Hospital; | 2016 |
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2016 |
Fibrinolytic shutdown: fascinating theory but randomized controlled trial data are needed.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Injury Severity Score; Randomized Controlled Trials as | 2016 |
Coagulation factor concentrate-based therapy for remote damage control resuscitation (RDCR): a reasonable alternative?
Topics: Antifibrinolytic Agents; Blood Coagulation Factors; Emergency Medical Services; Hemorrhage; Humans; | 2016 |
Major transfusions remain frequent despite the generalized use of tranexamic acid: an audit of 3322 patients undergoing cardiac surgery.
Topics: Antifibrinolytic Agents; Aprotinin; Blood Transfusion; Cardiac Surgical Procedures; Databases, Factu | 2016 |
Self-Propelled Dressings Containing Thrombin and Tranexamic Acid Improve Short-Term Survival in a Swine Model of Lethal Junctional Hemorrhage.
Topics: Animals; Bandages; Disease Models, Animal; Female; Hemorrhage; Hemostatics; Models, Statistical; Swi | 2016 |
Tranexamic Acid Use in United States Trauma Centers: A National Survey.
Topics: Adult; Antifibrinolytic Agents; Female; Health Care Surveys; Hemorrhage; Humans; Male; Severity of I | 2016 |
Successful use of tranexamic acid in the management of haemophilic pseudotumour.
Topics: Abdomen; Aged; Animals; Antibodies, Neutralizing; Antifibrinolytic Agents; Coagulants; Cysts; Factor | 2016 |
EXAMINING TRANEXAMIC ACID.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Hemorrhage; Humans; Tranexamic Acid | 2016 |
Activated prothrombin complex concentrate in combination with tranexamic acid: a single centre experience for the treatment of mucosal bleeding and dental extraction in haemophilia patients with inhibitors.
Topics: Adult; Antibodies, Neutralizing; Antifibrinolytic Agents; Blood Coagulation Factors; Coagulants; Dos | 2016 |
Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial.
Topics: Antifibrinolytic Agents; Child, Preschool; Controlled Before-After Studies; Double-Blind Method; Fem | 2016 |
Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
Implementation of a Tranexamic Acid Protocol to Reduce Blood Loss During Cranial Vault Remodeling for Craniosynostosis.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Craniosynostoses; Hemorrhage; Humans; Infant; Postope | 2016 |
Response to Letter to the Editor on "Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid".
Topics: Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Trane | 2016 |
[Uncritical use of tranexamic acid in trauma patients : Do no further harm!]
Topics: Antifibrinolytic Agents; Emergency Medical Services; Evidence-Based Medicine; Hemorrhage; Humans; Tr | 2016 |
Tranexamic Acid Attenuates The Loss of Lung Barrier Function in a Rat Model of Polytrauma And Hemorrhage With Resuscitation.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Hemorrhage; Lung; Male; Multiple Trauma; Rats; R | 2017 |
Cochrane in CORR
Topics: Administration, Topical; Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid | 2017 |
The pre-hospital administration of tranexamic acid to patients with multiple injuries and its effects on rotational thrombelastometry: a prospective observational study in pre-hospital emergency medicine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Coagulation; Dose-Respons | 2016 |
Compatibility of Hydroxyethyl Starch and Tranexamic Acid for Battlefield Co-Administration.
Topics: Drug Therapy, Combination; Fluid Therapy; Hemorrhage; Humans; Hydroxyethyl Starch Derivatives; Trane | 2016 |
PT-VWD posing diagnostic and therapeutic challenges - small case series.
Topics: Adolescent; Child, Preschool; Deamino Arginine Vasopressin; Drug Therapy, Combination; Factor VIIa; | 2017 |
Combined effect of therapeutic strategies for bleeding injury on early survival, transfusion needs and correction of coagulopathy.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfus | 2017 |
Ticagrelor reversal:
Topics: Adenosine; Blood Coagulation; Blood Platelets; Dose-Response Relationship, Drug; Factor VIIa; Fibrin | 2017 |
[Tranexamic acid in the German emergency medical service : A national survey].
Topics: Antifibrinolytic Agents; Emergency Medical Services; Germany; Guideline Adherence; Guidelines as Top | 2017 |
Damage control resuscitation in patients with severe traumatic hemorrhage: A practice management guideline from the Eastern Association for the Surgery of Trauma.
Topics: Antifibrinolytic Agents; Blood Cell Count; Blood Transfusion; Factor VIIa; Hemorrhage; Humans; Recom | 2017 |
Effectiveness of early administration of tranexamic acid in patients with severe trauma.
Topics: Adult; Aged; Antifibrinolytic Agents; Blood Transfusion; Brain Injuries; Female; Hemorrhage; Humans; | 2017 |
Pregnancy and delivery in a woman with severe haemophilia A.
Topics: Adult; Factor VIII; Female; Hemophilia A; Hemorrhage; Humans; Pregnancy; Pregnancy Complications, He | 2017 |
Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis.
Topics: Adult; Antifibrinolytic Agents; Cardiomyopathy, Hypertrophic; Colectomy; Colostomy; Embolization, Th | 2008 |
Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci.
Topics: Animals; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Female; Fibrin; He | 2010 |
Managing stomal bleeds.
Topics: Antifibrinolytic Agents; Child; Hemorrhage; Humans; Surgical Stomas; Tranexamic Acid; Treatment Outc | 2009 |
Successful rotational thromboelastometry-guided treatment of traumatic haemorrhage, hyperfibrinolysis and coagulopathy.
Topics: Afibrinogenemia; Antifibrinolytic Agents; Fibrinogen; Fibrinolysis; Hemorrhage; Hemostasis; Humans; | 2010 |
A single centre experience in circumcision of haemophilia patients: Izmir protocol.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Child; Child, Preschool; Circumcision, Male; Factor I | 2010 |
Management of second-degree burn induced by dry ice in a Christmas disease patient.
Topics: Administration, Oral; Adult; Antifibrinolytic Agents; Bandages; Burns; Dry Ice; Factor IX; Hemophili | 2010 |
Antifibrinolytic therapy: new data and new concepts.
Topics: Antifibrinolytic Agents; Fibrinolysin; Hemorrhage; Hemostasis; Humans; Tranexamic Acid; Wounds and I | 2010 |
Dental surgery with minimal factor support in the inherited bleeding disorder population at the Alfred Hospital.
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders, Inherited; Blood Coagulation Factors; Cellulos | 2011 |
Tranexamic acid for trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Tranexamic Acid; | 2010 |
Tranexamic acid for trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Nervous System Diseases; Randomized Controlled Trials a | 2010 |
Tranexamic acid for trauma.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Selection Bias; | 2010 |
Engineering kunitz domain 1 (KD1) of human tissue factor pathway inhibitor-2 to selectively inhibit fibrinolysis: properties of KD1-L17R variant.
Topics: Amino Acid Substitution; Animals; Antifibrinolytic Agents; Aprotinin; Blood Coagulation Factors; Dis | 2011 |
Effect of consent rituals on mortality in emergency care research.
Topics: Antifibrinolytic Agents; Emergency Treatment; Hemorrhage; Humans; Informed Consent; Logistic Models; | 2011 |
Tranexamic acid for trauma.
Topics: Antifibrinolytic Agents; Emergency Medical Services; Emergency Service, Hospital; Hemorrhage; Humans | 2011 |
The use of fresh whole blood transfusions by the SOF medic for hemostatic resuscitation in the austere environment.
Topics: Blood Transfusion; Emergency Medical Services; Hemorrhage; Hemostatic Techniques; Hemostatics; Human | 2010 |
[Clinical trials in surgery - health care research of the future?].
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Forecasting; Germany; Health Services Research; H | 2011 |
[Hyperfibrinolysis as the cause of haemorrhage and increased mortality in trauma patients].
Topics: Antifibrinolytic Agents; Blood Coagulation Disorders; Blood Transfusion; Fibrinolysis; Hemorrhage; H | 2011 |
Thousands of lives could be saved using tranexamic acid for patients with bleeding trauma.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Review Literature as Topic; Tranexamic Ac | 2011 |
Bronchoscopic intratumoral injection of tranexamic acid: a new technique for control of biopsy-induced bleeding.
Topics: Adult; Biopsy; Bronchoscopy; Hemorrhage; Humans; Injections, Intralesional; Male; Methods; Middle Ag | 2011 |
Advances in trauma care.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Child; Child, Preschool; Emergency Medical Services; Hem | 2011 |
Consent in emergency care research.
Topics: Antifibrinolytic Agents; Biomedical Research; Emergency Service, Hospital; Hemorrhage; Humans; Infor | 2011 |
Early administration of tranexamic acid in trauma patients.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Time Factors; Tr | 2011 |
The effect of ε-aminocaproyl-S-benzyl-L-cysteine on the t-PA activity of human saliva.
Topics: Aminocaproates; Aminocaproic Acid; Animals; Antifibrinolytic Agents; Blood Coagulation; Cattle; Cyst | 2011 |
Tranexamic acid--a recipe for saving lives in traumatic bleeding.
Topics: Antifibrinolytic Agents; Female; Hemorrhage; Humans; Male; Menorrhagia; Randomized Controlled Trials | 2011 |
You can stop the bleeding.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Information Dissemination; Tranexamic Acid | 2011 |
CRASH-2 goes viral.
Topics: Adult; Antifibrinolytic Agents; Cost-Benefit Analysis; Hemorrhage; Humans; Information Dissemination | 2011 |
Tranexamic acid--a recipe for saving lives in traumatic bleeding.
Topics: Adult; Antifibrinolytic Agents; Drug Administration Schedule; Follow-Up Studies; Hemorrhage; Humans; | 2011 |
Tranexamic acid--a recipe for saving lives in traumatic bleeding.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Multiple Trauma; Randomized Controlled Trials as Topic; | 2011 |
Tranexamic acid for traumatic hemorrhage.
Topics: Antifibrinolytic Agents; Clinical Trials as Topic; Hemorrhage; Humans; Tranexamic Acid | 2012 |
Tranexamic acid: less bleeding and less thrombosis?
Topics: Antifibrinolytic Agents; Factor V; Factor VIII; Fibrinolysin; Hemorrhage; Humans; Plasminogen; Plate | 2012 |
Case report: use of topical tranexamic acid to stop localised bleeding.
Topics: Administration, Topical; Antifibrinolytic Agents; Hemophilia A; Hemorrhage; Humans; Male; Nipples; T | 2013 |
[Coagulation management of trauma patients with unstabile circulation : establishment of a hemoglobin-oriented standard operating procedure].
Topics: Aged; Algorithms; Anticoagulants; Blood Coagulation Tests; Critical Care; Crystalloid Solutions; Dea | 2012 |
Pattern of bleeding and response to therapy in Glanzmann thrombasthenia.
Topics: Antifibrinolytic Agents; Contraceptives, Oral; Factor VIIa; Female; Hemorrhage; Humans; Male; Platel | 2012 |
Tranexamic Acid: a recipe for saving lives in traumatic bleeding.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Tranexamic Acid | 2011 |
Administer tranexamic acid early to injured patients at risk of substantial bleeding.
Topics: Antifibrinolytic Agents; Early Medical Intervention; Hemorrhage; Humans; Risk Factors; Tranexamic Ac | 2012 |
Enhanced hemostatic performance of tranexamic acid-loaded chitosan/alginate composite microparticles.
Topics: Absorption; Alginates; Animals; Cell Death; Cell Shape; Chitosan; Disease Models, Animal; Female; Fi | 2012 |
A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
Topics: Factor XIII; Female; Fibrin; Fibrinogen; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Hemorrhage | 2013 |
Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia.
Topics: Adult; Antifibrinolytic Agents; Autoantibodies; Factor VIII; Hemophilia A; Hemorrhage; Humans; Male; | 2002 |
A splicing donor site point mutation in intron 6 of the plasmin inhibitor (alpha2 antiplasmin) gene with heterozygous deficiency and a bleeding tendency.
Topics: alpha-2-Antiplasmin; Family Health; Female; Hemorrhage; Heterozygote; Humans; Introns; Middle Aged; | 2003 |
Multifocal myoclonus secondary to tranexamic acid.
Topics: Antifibrinolytic Agents; Catheters, Indwelling; Hemorrhage; Humans; Male; Middle Aged; Myoclonus; Pe | 2003 |
Antifibrinolytic agents in traumatic hemorrhage: a large scale randomized controlled trial is needed.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Tranexamic Acid; | 2005 |
[Antihemorrhagic prophylaxis in low risk surgery in Bernard-Soulier syndrome].
Topics: Adult; Antifibrinolytic Agents; Bernard-Soulier Syndrome; Deamino Arginine Vasopressin; Female; Hemo | 2005 |
Tranexamic acid does not prevent rebleeding in an uncontrolled hemorrhage porcine model.
Topics: Animals; Antifibrinolytic Agents; Female; Fluid Therapy; Hemodynamics; Hemorrhage; Male; Secondary P | 2005 |
[CRASH-2: the Clinical Randomization of an Antifibrinolytic in Significant Haemorrhage trial].
Topics: Adult; Antifibrinolytic Agents; Child; Hemorrhage; Humans; Multicenter Studies as Topic; Patient Sel | 2005 |
[Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
Topics: Adult; Aminocaproic Acid; Antiphospholipid Syndrome; Aprotinin; Blood Coagulation Tests; Blood Loss, | 2006 |
Trial of drug for trauma patients includes victims of Iraqi violence.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Randomized Controlled Trials as Topic; Tranexamic Acid; | 2006 |
Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage.
Topics: Aminocaproic Acid; Animals; Antifibrinolytic Agents; Aprotinin; Deamino Arginine Vasopressin; Diseas | 2006 |
Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study.
Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Child, Preschool; Deamino Arginine Vasopressin | 2006 |
[The "Seville" Consensus Document on Alternatives to Allogenic Blood Transfusion. Sociedades españolas de Anestesiología (SEDAR), Medicina Intensiva (SEMICYUC), Hematología y Hemoterapia (AEHH), Transfusión sanguínea (SETS) Trombosis y Hemostasia (SETH)].
Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Blood Substitutes; Bloo | 2006 |
Tranexamic acid and uremic bleeding: evidence-based treatment recommendations.
Topics: Antifibrinolytic Agents; Hemorrhage; Humans; Tranexamic Acid; Uremia | 2007 |
The use of topical crushed tranexamic acid tablets to control bleeding after dental surgery and from skin ulcers in haemophilia.
Topics: Administration, Topical; Adolescent; Adult; Antifibrinolytic Agents; Dental Care for Chronically Ill | 2007 |
A bleeding tongue - acute presentation of fibrinolysis.
Topics: Adenocarcinoma; Aged; Antifibrinolytic Agents; Fibrinolysis; Hemorrhage; Humans; Male; Prostatic Neo | 2007 |
Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid.
Topics: Antifibrinolytic Agents; Drug Interactions; Fibrinolysis; Fibrinolytic Agents; Hemorrhage; Humans; I | 2008 |
[Coagulative changes in gynecologic surgery. Clinical and therapeutic evaluation].
Topics: Adult; Aged; Anesthesia; Aprotinin; Blood Coagulation Disorders; Disseminated Intravascular Coagulat | 1980 |
The value of activated coagulation time in monitoring heparin therapy during extracorporeal circulation.
Topics: Aged; Antithrombin III; Blood Coagulation Tests; Coronary Artery Bypass; Dose-Response Relationship, | 1984 |
Congenital deficiency of alpha 2-plasmin inhibitor in three sisters.
Topics: alpha-2-Antiplasmin; Blood Coagulation Tests; Blood Transfusion; Child, Preschool; Female; Fibrinoly | 1982 |
The use of frusemide and epsilon-amino-caproic-acid in transurethral prostatectomy. a review after 7 years.
Topics: Aged; Aminocaproates; Aminocaproic Acid; Furosemide; Hemorrhage; Humans; Male; Postoperative Complic | 1982 |
[Further notes on the topical use of tranexamic acid in the treatment of gynecological hemorrhage].
Topics: Adolescent; Adult; Aged; Cyclohexanecarboxylic Acids; Female; Hemorrhage; Humans; Metrorrhagia; Midd | 1980 |
Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Topics: Animals; Antidotes; Antifibrinolytic Agents; Aprotinin; Bacterial Proteins; Cricetinae; Fibrinolysis | 1995 |
The use of tranexamic acid in cardiac operations.
Topics: Aminocaproic Acid; Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative | 1994 |
Tranexamic acid after bypass: too late to help?
Topics: Cardiopulmonary Bypass; Coronary Artery Bypass; Hemorrhage; Humans; Postoperative Complications; Tra | 1994 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Treatment with tranexamic acid during pregnancy, and the risk of thrombo-embolic complications.
Topics: Abruptio Placentae; Case-Control Studies; Cesarean Section; Female; Hemorrhage; Humans; Incidence; P | 1993 |
Impact of medical treatment on the outcome of patients after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Antifibrinolytic Agents; Brain Ischemia; Female; Hemorrhage; Humans; Hydrocephalus; Int | 1998 |
Management of anticoagulation in patients with prosthetic heart valves undergoing oral and maxillofacial operations.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Heart Valve Prosthesis; Hemorrhage; H | 2000 |
Acute myocardial infarction after oral tranexamic acid treatment initiation.
Topics: Administration, Oral; Aged; Female; Hemorrhage; Humans; Myocardial Infarction; Tranexamic Acid | 2002 |
The effect of fibrinolytic inhibition in the resolution of experimental vitreous hemorrhage.
Topics: Absorption; Animals; Chemotaxis, Leukocyte; Cyclohexanecarboxylic Acids; Erythrocytes; Eye Diseases; | 1977 |
The value of tranexamic acid (cyklokapron) in the prevention of secondary bleeding, a complication of traumatic hyphaemia.
Topics: Acetazolamide; Adolescent; Adult; Aged; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Female | 1977 |
Medicated intrauterine devices to improve bleeding events.
Topics: Female; Hemorrhage; Humans; Intrauterine Devices; Intrauterine Devices, Copper; Intrauterine Devices | 1977 |
Traumatic hyphaema treated with the antifibrinolytic drug tranexamic acid.
Topics: Adolescent; Adult; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Eye Injuries; Female; Hemor | 1976 |
[Preventive use of AMCHA in tonsillectomies under general anesthesia. Clinical evaluation].
Topics: Adolescent; Adult; Anesthesia, General; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Drug E | 1976 |
Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia.
Topics: Adult; Disseminated Intravascular Coagulation; Female; Hemorrhage; Humans; Leukemia, Promyelocytic, | 1992 |
Tranexamic acid and rectal bleeding.
Topics: Drug Administration Schedule; Enema; Hemorrhage; Humans; Male; Middle Aged; Rectal Diseases; Tranexa | 1991 |
Prevention of severe bleeding by tranexamic acid in a patient with disseminated intravascular coagulation.
Topics: Aged; alpha-Macroglobulins; Aorta, Abdominal; Aortic Aneurysm; Cyclohexanecarboxylic Acids; Dissemin | 1990 |
Increased susceptibility of aged rats to haemorrhage and intravascular hypercoagulation following endotoxin administered in a generalized Shwartzman regime.
Topics: Aging; Animals; Depression, Chemical; Disease Susceptibility; Disseminated Intravascular Coagulation | 1991 |
Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.
Topics: Animals; Aspirin; Drug Combinations; Glycoproteins; Hemorrhage; Hemostasis; Plasminogen Inactivators | 1989 |
Retinal artery occlusion associated with tranexamic acid therapy.
Topics: Cyclohexanecarboxylic Acids; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Leukemia, Myelo | 1988 |
Tranexamic acid.
Topics: Cyclohexanecarboxylic Acids; Hemophilia A; Hemorrhage; Humans; Premedication; Prospective Studies; T | 1987 |